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The staggeringly large number of dengue virus (DENV) infections around the 
globe has led to increasing viral genetic diversity, some of which appears to 
be associated with greater epidemic potential. The underlying mechanisms of 
viral fitness in an epidemiological setting, however, remain poorly defined. 
We conducted in vitro studies and identified a determinant of fitness in a 
foreign dominant (PR-2B) DENV-2 clade, which emerged during the 1994 
epidemic in Puerto Rico and replaced an endemic (PR-1) DENV-2 clade. The 
PR-2B DENV-2 produced increased levels of subgenomic relative to genomic 
RNA during replication. The subgenomic RNA bound and inhibited de-
ubiquitylation of tripartite motif 25 (TRIM25), which is needed to activate its 
E3 ligase activity critical for sustained and amplified RIG-I induced type-I 
interferon expression. Our findings demonstrate a unique viral RNA-host 
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An Introduction to                                                                   
the role of viral                                                               
genetics in dengue 




1.1 Dengue Virus 
1.1.1 Virus Structure and genome organization 
Dengue virus (DENV) is a member of the genus Flavivirus within the 
family Flaviviridae (Lindenbach, 2007). Flaviviruses are enveloped, positive 
single-stranded RNA viruses that replicate in the cytoplasm of arthropods 
and infected mammalian cells (Lindenbach, 2007). This genus can be 
subdivided into three groups, namely (1) mosquito-borne (2) tick-borne and 
(3) viruses with no known vector (NKV) (Figure 1.1) (Charlier et al., 2004; 
Lindenbach, 2007). Many clinically important viruses such as the yellow 
fever virus (YFV), Japanese encephalitis virus (JEV), tick-borne encephalitis 
virus (TBEV) and the West Nile virus (WNV) belong to Flavivirus (Figure 1.1) 






Figure 1.1 Flaviviruses and medically important viruses within the genus                           
(A) Phylogenetic tree displaying the subgroups among Flavivirus. DENV: dengue virus; 
WNV: west nile virus; MVEV: murray valley encephalitis virus; JEV: japanese 
encephalitis virus; YFV: yellow fever virus; LIV: louping ill virus; TBEV: tick-borne 
encephalitis virus; MMLV: montana myotis leukoencephalitis virus; MODV: modoc virus 
(B) Clinical manifestations during infection. 
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Among the flaviviruses, DENV is one of the most prevalent causing an 
estimated 390 million infections annually and with over 3 billion people at 
risk (Figure 1.2) (Bhatt et al., 2013; Gubler, 2002). 
There are four serotypes of DENV (DENV-1, DENV-2, DENV-3, DENV-
4) that are immunologically distinct but antigenically related, 65-70% 
homology in amino acid sequence (Guzman et al., 2010). Despite these 
Figure 1.2 Global evidence consensus and burden of dengue in 2010                           
(A) National and subnational evidence on dengue. Red indicates complete presence 
through to green indicating complete absence. (B) Cartogram of annual number of 






differences, each serotype circulates in the same ecological niche and causes 
almost identical syndromes in humans (Halstead, 2008).  
The dengue virion comprises a spherical particle, 40-50nm in 
diameter and is composed of a single, positive-stranded RNA genome that is 
packaged by the virus capsid (C) protein and surrounded by an envelope 
(Figure 1.3) (Kuhn et al., 2002; Zhang et al., 2004).  
The envelope (E) 
protein consists of 180 
monomers organized into 90 
tightly packed dimers that lie 
flat on the surface of the viral 
membrane (Kuhn et al., 2002; 
Zhang et al., 2004). The ~ 11 
kb DENV genome consists of a 
single open reading frame 
(ORF) flanked by highly 
structured untranslated 
regions (UTRs) that is capped 
at the 5’end but lacks a polyA tail (Figure 1.4) (Guzman et al., 2010; Pastorino 
et al., 2010). The type 1 cap is a modified guanine nucleoside methylated at 
the N-7 and 2’-O positions identical to that of cellular messenger RNAs 
(mRNAs) (Saeedi and Geiss, 2013). The genome is translated to produce a 
Figure 1.3 Structure of the mature dengue virion 
arrangement of the envelope (E) protein subunits 
on the surface is shown. E proteins exist as 
homodimers arranged as 30 “rafts” organized into a 
herringbone pattern. Domains I, II and III of E 
proteins are coloured red, yellow and blue 
respectively. Fusion peptides are shown in green. 
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single polyprotein which is cleaved co- and post-translationally by viral and 
cellular proteases into three structural (C, membrane (M), E) and seven 
nonstructural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) proteins that are 
essential for viral RNA replication, virus assembly and modulation of the host 
cell responses (Figure 1.4) (Guzman et al., 2010; Pastorino et al., 2010). 
  
Figure 1.4 Flavivirus genome and polyprotein organization The single open reading 
frame (ORF) (~11kb) is depicted with the structural and non-structural protein coding regions 
highlighted in blue and green respectively. This ORF has a 5’cap and is flanked by the 5’and 
3’untranslated regions (UTRs). It encodes an immature polyprotein precursor that is co- and 
post- translationally cleaved into three structural proteins (C, M, E) and seven non-structural 
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5). Cleavage sites for cellular proteases, 





1.1.2 Lifecycle of dengue virus 
Dengue virus particles bind to a ubiquitous, low-affinity receptor on 
the cell surface and enter cells through receptor-mediated endocytosis. 
Although various mammalian cell receptors have been proposed including 
heparan sulfate (Chen et al., 1997), heat shock protein 90 (Valle et al., 2005), 
CD14 (Chen et al., 1999), C-type lectins CLEC5A (Chen et al., 2008b) and the 
mannose receptor (Miller et al., 2008), the best characterized interaction is 
between DENV and DC-specific intercellular adhesion molecule 3 (ICAM-3)-
grabbing nonintegrin (DC-SIGN) (Tassaneetrithep et al., 2003).  
Besides direct interaction with a cellular receptor, DENV has an 
alternative mechanism of entry into monocytes/macrophages. In the 
presence of dengue-specific antibodies, antibody opsonization of DENV 
results in the formation of immune complexes. These immune complexes can 
bind to Fcγ receptors (FcγR) on the surface of myeloid cells resulting in 
increased entry and infection via FcγR-mediated phagocytosis (Figure 1.5) 
(Chan et al., 2011; Chawla et al., 2013; Halstead and O'Rourke, 1977; van der 




Upon entry into cells, acidification of the late endosomes triggers 
trimerization of the E protein, inducing fusion of viral and cell endosomal 
membranes, thus allowing the viral nucleocapsid to uncoat (Kuhn et al., 
2002; Li et al., 2008; van der Schaar et al., 2008). The DENV genome is then 
released into cells and translated. Once the viral replication complex is 
synthesized by viral and co-opted host proteins, RNA synthesis begins in 
DENV-induced replication compartments within the endoplasmic reticulum 
(ER).  
A full-length complementary minus strand RNA, termed an antisense 
intermediate is first synthesized by the viral RNA-dependent RNA 
polymerase (RdRp). This RNA, acting as a replicative intermediate, is then 
used as a template for multiple rounds of positive sense genomic RNA 
(gRNA) synthesis. Subsequently, successive rounds of translation generate 
large quantities of viral proteins and immature virions assemble in the ER 
Figure 1.5 Antibody-dependant enhancement of dengue virus replication In the 
presence of heterotypic antibodies, either from previous infections or maternal 
transfer, the infecting dengue virus can be opsonized to form immune complexes. 
These immune complexes are able to engage Fcγ receptors (FcγR) facilitating 





with the prM acting as a scaffold to prevent premature virus fusion. These 
immature virions are then transported to the trans-Golgi network where 
premembrane (prM) is cleaved into pr and M by furin. Mature infectious 
particles are thus formed and egress cells via the host secretory pathway 
leading to new rounds of infection (Figure 1.6) (Fernandez-Garcia et al., 
2009; Mukhopadhyay et al., 2005; Pastorino et al., 2010).  
  
Figure 1.6 Lifecycle of dengue virus After binding to its receptor on target cells, 
dengue virus enters through receptor-mediated endocytosis. The acidic pH in the 
endosomal compartments causes a conformational change of the virus and viral 
fusion occurs. Once the nucleocapsid is released, uncoating follows and RNA is 
released into the cytoplasm where it undergoes the first round of translation. Viral and 
host proteins are involved in the formation of ER membrane-bound compartments 
wherein replication occurs. After several rounds of replication and translation, 
progeny virions are assembled in the ER and transported to Golgi where they are 
cleaved by furin to form mature particles. Mature viruses leave the cell by exocytosis. 
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1.1.3 Virus Transmission 
Dengue, an arthropod-borne virus, is spread to humans through a 
human-mosquito-human cycle of transmission. The virus is transmitted to 
humans by Aedes mosquitoes (Monath, 1994). Dengue is most widely 
transmitted by its main vector, Aedes aegypti. The Aedes albopictus mosquito 
and other Aedes species transmit dengue in specific geographical regions 
where they are found. For instance, Aedes polynesiensis plays an important 
role in dengue transmission in the Pacific islands (Rosen et al., 1954). Aedes 
aegypti, a highly domesticated mosquito is the principal vector of dengue 
because of its close contact with humans in urban areas as it breeds in 
domestic and peridomestic water containers (Gubler, 1998a; Platt et al., 
1997). In a single gonotrophic cycle, Aedes aegypti is known to feed on 
multiple human hosts for a blood meal.  
The secondary vector, Aedes albopictus, is also of increasing 
importance in dengue transmission and is responsible for endemic 
transmission of dengue in Asia and for epidemic spread in circumstances 
where A. aegypti is absent or in low density (Lambrechts et al., 2010). Since 
these mosquitoes originated from forests, a sylvatic cycle for dengue 
transmission has been documented in Africa (Diallo et al., 2003) and 
southeast Asia (Wolfe et al., 2001). However, the contribution of the sylvatic 
cycle of dengue transmission to human infection has only been dissected 
recently with studies showing that sylvatic DENV may have an equal or 
10 
 
greater potential to cause dengue as compared to established urban DENV 
genotypes (Vasilakis et al., 2010; Vasilakis et al., 2008). 
1.1.4. Clinical presentation and progression 
Typically, someone bitten by an infected mosquito may develop 
symptoms of acute dengue 3-14 days later. A range of clinical manifestations 
has been reported, ranging from mild flu-like illness to severe disease and 
death. Majority of the patients are diagnosed with dengue fever which 
presents as a self-limiting febrile illness. Most common signs and symptoms 
include high fever (>38°C), leukopenia and rash (Snow et al., 2014). 
Headache, retro-orbital pain, petechiae, myalgia, arthralgia, flushing of the 
face, anorexia, abdominal pain and nausea are some of the other symptoms. 
A very low percentage of patients experience nosebleed. Macular rash can be 
observed during fever defervescence and majority of the patients recover 
without complications about a week after disease onset (Simmons et al., 
2012).  
A small proportion of infected individuals may progress to more 
severe dengue. Around the time of fever defervescence some patients 
develop signs of thrombocytopenia (platelet count ≤ 100,000/mm3), 
hemorrhagic manifestations and enhanced vascular permeability with 
leakage of intravascular fluid (Gubler, 1998a). The fluid leakage through 
increased vascular permeability may lead to shock when a critical volume of 
plasma is lost into the extravascular space and cardiac output becomes 
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insufficient to maintain the necessary blood pressure. Prolonged shock may 
result in organ hypoperfusion leading to progressive organ impairment, 
metabolic acidosis and disseminated intravascular coagulation (Figure 1.7) 
(WHO, 2009). Without proper treatment, a stage of profound shock may set 
in, causing death within 12 to 36 hours after shock onset. It is thus important 
to detect patients progressing from non-severe to severe disease early as 
intravenous rehydration can reduce case fatality rates to less than 1% of 
severe cases (Simmons et al., 2012). 
Despite being a disease complex in its manifestations, clinical 
management of dengue is not difficult, inexpensive and highly effective 
provided timely appropriate interventions are provided. Treatment plans for 
Figure 1.7 World Health Organization (WHO) dengue case classification and 
levels of severity 
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dengue are provided by the latest WHO guidelines based on the severity of 
clinical manifestations (WHO, 2012; Wright and Pritt, 2012). 
Supportive care such as analgesics, acetaminophen, fluid replacement, 
and bed rest is usually sufficient for classic dengue cases. These patients can 
be successfully managed as outpatients. For patients with warning signs of 
severe dengue, hospitalization with sufficient fluid replacement, proactive 
treatment of hemorrhage and supportive medical care is recommended 
(WHO, 2012; Wills et al., 2005). Frequent and regular measurement of the 
patient’s hemocrit is crucial as a heightened hemocrit precedes plasma 
leakage, indicating potential hemorrhagic complications (WHO, 2009). 
Besides hematocrit, plasma leakage could also be monitored using ultra 
sonography of the gall bladder wall or pleural cavity. Another warning sign is 
when patients have moderate to severe thrombocytopenia (platelet count of 
below 100,000 cells per cubic millimeter) (Halstead, 2007; Lye et al., 2009; 
WHO, 2009). 
Although these clinical parameters can be monitored for development 
of severe dengue, timely intervention is not always possible as the clinical 
outcome of dengue infections is often unpredictable. Despite close 
monitoring, some cases have progressed to severe disease without any 
warning signs. Hence, prevention and control of dengue transmission may be 
a better prospect than case management in reducing the overall burden of 
dengue.   
13 
 
1.1.5 Prevention and control of dengue 
There is currently no licensed dengue vaccine or anti-viral drug 
available. To reduce morbidity rates, effective prevention of dengue 
transmission and thus vector control remains important (Eisen et al., 2009; 
Guzman and Kouri, 2002). Historically, prevention and control of dengue has 
relied on control of the main vector, Aedes aegypti. Unfortunately, most 
countries do not have intensive dengue preventative programs. There are 
multiple reasons for this, which include misguided public health policies, the 
lack of resources for mosquito control, lack of political will, and lack of 
research along with the global trend of unprecedented population growth, 
unplanned urbanization and globalization (Gubler and Clark, 1994).  
1.1.5.1 Vector control Programs 
The first vector control program was instituted in Central and South 
America by the Pan American Sanitory Board in the 1950s-1960s. Highly 
successful, it depended on a multifaceted approach which included 
surveillance, constant inspection, chemical control and community 
involvement (Schliessmann, 1967).  
Another instance of a vector control program being successful was in 
Cuba, where a national campaign to eradicate Aedes aegypti was started in 
1981. Intense insecticidal treatment along with source reduction brought the 
epidemic under control in about four months (Kouri et al., 1989). In 
Singapore, a successful reduction of Aedes aegypti from 16% to 2% was 
14 
 
observed with the initiation of a similar program in 1970 (Ooi et al., 2006). 
This was followed by a 15 year period of low dengue incidence.  
Despite the initial success of all the above programs, none of them 
were sustainable mainly due to the lack of long-term political and financial 
support. Other reasons such as over-reliance of chemical control and 
“passive” community participation also contributed to the non-sustainability 
of vector control (Gubler, 1989). A resurgence of dengue was even observed 
in Singapore probably due to lowered herd immunity (Goh, 1995), shift in 
virus transmission from domestic to non-domestic settings (Ooi et al., 2001) 
and change in surveillance emphasis of the program (Yew et al., 2009). Thus, 
vector control is ultimately unreliable as a method for dengue prevention 




1.1.5.2 Vaccines in clinical development  
Although much progress has been made in the development of a 
dengue vaccine, it has been considerably challenging as there is a need to 
immunize against all four DENV serotypes simultaneously. Moreover, to 
minimize the risk of vaccine-induced ADE (Figure 1.5) of dengue infection, it 
is necessary to develop tetravalent dengue vaccines that induce balanced 
immune responses to all four serotypes (Table 1.1) (Guzman and Harris, 
2014). Despite this difficulty, currently there are live attenuated viruses, 
inactivated viruses, recombinant proteins and DNA vaccines under 
development as dengue vaccine candidates (Table 1.1) (Guzman and Harris, 
2014; Thomas and Endy, 2011). 
  
Table 1.1 Candidate dengue vaccines 
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The Sanofi Pasteur ChimeriVax-DENV (CVD) vaccine, which has 
recently completed Phase III clinical trials, is the most advanced vaccine 
candidate to date. A chimeric vaccine, it consists of the structural genes (prM 
and E) from all four DENV serotypes inserted into the backbone of the yellow 
fever virus 17D vaccine strain (Guirakhoo et al., 2001). Results from the 
phase I and II trials have shown the vaccine to be safe and immunogenic 
(Dayan et al., 2013a; Dayan et al., 2013b; Guy et al., 2010; Guy et al., 2008; 
Sabchareon et al., 2012). The recent phase III trials in Southeast Asia 
demonstrated the clinical efficacy of this vaccine to be 59% in preventing 
acute dengue caused by any of the four serotypes (Capeding et al., 2014). 
Similar trends have also been observed in the (Guzman and Vazquez, 2010; 
Halstead, 1974) phase III trial in Latin America with the vaccine being 60.8% 
efficacious against dengue fever and severe dengue as compared to the 
placebo group (Villar et al., 2014). However, serotype-specific efficacy varies 
significantly, with DENV4 and DENV2 having the highest and lowest efficacy, 
respectively (Capeding et al., 2014; Sabchareon et al., 2012; Villar et al., 
2014). Overall, the trials have shown collectively that this vaccine has a good 
safety profile although the efficacy in preventing disease is less than ideal 
(Capeding et al., 2014).  
The low efficacy of the CVD vaccine for DENV-2 as seen in the phase II 
and III trials poses several questions. Firstly, it suggests that the neutralizing 
antibody titers might be insufficient for protection against that specific strain 
of DENV-2 (Mullard, 2014). Alternatively, the plaque reduction neutralization 
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test (PRNT), used as an immune correlate to predict dengue infection 
outcome might not be an accurate measure because of the discrepancy with 
trial results. Furthermore, other vital immune correlates of protection might 
have been ignored. For instance, recent evidence has suggested a protective 
role for CD8+ T cells response in dengue infection (Yauch et al., 2009). The 
specificity of this response was mapped to epitopes on the DENV 
nonstructural proteins. Since the CVD vaccine is based on a yellow fever virus 
backbone, it lacks the epitopes required to induce cell-mediated immunity 
during an infection.  
Yet another major limitation of this vaccine is the requirement of an 
extended dosing schedule of 3 doses at intervals of 6 months. This could 
potentially lead to major compliance issues or problems related to ADE in 
endemic areas as the waning immunity over such an extended interval might 
cause severe dengue. Therefore, it is highly recommended that further 
studies be conducted to assess the long-term effects of this vaccine and to 
completely prove its clinical effectiveness and the robustness of its 
immunogenicity (da Costa et al., 2014).  
Other vaccines in development include the live attenuated vaccine 
(LAV), TV003 by the National Institutes of Health (Whitehead et al., 2003) 
and DENVax produced by CDC-Inviragen (Osorio et al., 2011), now a part of 
Takeda. TV003 is a tetravalent formulation comprising of DENV-1Δ30, DENV-
2/4Δ30, DENV-3Δ30/31 and DENV4Δ30. Except for DENV-2/4Δ30 that has a 
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recombinant genome consisting of DENV-2 structural genes inserted into an 
attenuated DENV-4 backbone, the remaining serotypes are attenuated by a 
30-nucleotide deletion in the 3’UTR. A single dose of this LAV induced a 
trivalent or better neutralizing antibody response in 75-90% of vaccinees 
(Durbin et al., 2013). Based on the promising phase I trial results, this 
vaccine is currently undergoing a phase II trial. Similarly, DENVax has also 
entered phase II trials (Osorio et al., 2011). The genomic backbone of 
DENVax consists of a DENV-2 strain (16681-PDK53) serially passaged in 
primary dog kidney cells. The DENV-2 prM and E genes were substituted 
with those from DENV-1, DENV-3 and DENV-4 to form chimeras which 
formulated the rest of this tetravalent vaccine. 
Despite considerable progress made in dengue vaccine development, 
much still remains to be understood about protective immune responses 
against DENV (Webster et al., 2009). The lack of an ideal animal model for 
DENV infection or a well-characterized human infection model also means 
that the study of DENV pathogenesis is limited. Thus, an improved 
understanding of disease pathogenesis and immune protection will greatly 




1.2 Disease Pathogenesis 
1.2.1. Factors contributing to dengue pathogenesis 
The pathogenesis of severe dengue disease is highly complex and 
multifactorial. Unfortunately, the lack of a good animal model hampers the 
study of dengue pathogenesis. However, it remains crucial to attain a better 
understanding of the underlying mechanisms leading to severe disease for 
the development of prognostic markers, novel diagnostics, therapeutics and a 
safe vaccine. High viremia has been shown by several studies to be directly 
correlated with severe dengue disease (Libraty et al., 2002; Vaughn et al., 
2000; Wang et al., 2003). However, there are two main bodies of thought as 
to what might cause an increase in viral load. These are: (1) Secondary 
infection or immune enhancement (Halstead et al., 1970) (2) Viral virulence 
(Gubler, 1998a). These theories are not mutually exclusive and could be 
equally valid as shown by multiple clinical and epidemiological observations. 
This section aims to highlight the complex interplay of host immunity and 
viral factors in dengue pathogenesis. 
1.2.1.1 Role of secondary infection in severe dengue pathogenesis 
The assumption that neutralizing or non-neutralizing antibodies 
control, eliminate and protect against viral infection holds true in most 
infection models. Nonetheless, a detrimental role for virus specific antibodies 
has been described for dengue where the subsequent infection of preimmune 
individuals to a different DENV serotype would exacerbate rather than 
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mitigate dengue disease due to the presence of enhancing concentrations of 
antibodies. This phenomenon is termed antibody-dependant enhancement 
(ADE).  
After a primary DENV infection, immunoglobulin M (IgM) antibodies 
are first generated and decline to undetectable levels over the following 2-3 
months (Guzman et al., 2010). Towards the end of the first week of illness, 
immunoglobulin G (IgG) antibodies are generated. Majority of these 
antibodies act against NS1, E and prM proteins (de Alwis et al., 2011). Anti-E 
antibodies are protective and produced at levels sufficient for efficient 
neutralization against all four DENV serotypes during early convalescence 
after acute infection (Sabin, 1952; Zompi et al., 2012). Subsequently, 
antibody levels decline and only serotype-specific antibodies retain the 
capability to protect the host from re-infection (Guzman and Vazquez, 2010; 
Halstead, 1974). 
When antibody levels decline to sub-neutralizing levels, infection with 
a heterologous DENV serotype can result in more severe disease. Both sub-
neutralizing and cross reactive antibodies can opsonize DENV to enhance 
infection through entry via Fc gamma receptors (FcγR) (Figure 1.8) 
(Halstead and O'Rourke, 1977). However, infection enhancement is peculiar 
as cross-linking of FcγRs induces type I interferon-stimulated gene 
expression which would create an unfavourable intracellular environment 
for DENV replication (Dhodapkar et al., 2007). To resolve this question, a 
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study recently showed that antibody-opsonized DENV co-ligates leukocyte 
Ig-like receptor-B1 (LILRB1) to inhibit FcγR signaling for ISG expression 
  
Figure 1.8 Antibody-dependant Enhancement Dengue virus infects by attachment 
to the cell surface followed by engulfment through endocytosis. The virus rearranges 
its coat proteins to bind to the endosome, releasing its genome into the cytoplasm 
where replication and release of new progeny virions occur. (1) The infected cell 
triggers an immune response. (2) T cells are recruited and release pro-inflammatory 
cytokines and antibodies. (3) Virus specific antibodies bind and cover the virus, 
leading to (4) clearance of the virus by immune cells. (5) Upon infection with a 
second serotype, memory B cells created during the first infection get activated (6), 
releasing antibodies to the first serotype. (7) These are less effective to binding to the  
second serotype but allow efficient uptake into mononuclear cells through entry via 
Fc receptors. (8) This leads to enhanced replication in macrophages and monocytes 




through spleen tyrosine kinase (Syk) dephosphorylation (Chan et al., 2014). 
Therefore, ADE not only facilitates viral entry process, but also modulates 
innate and adaptive intracellular antiviral mechanisms, resulting in 
unrestricted DENV replication. Signaling from the immunoreceptor tyrosine 
inhibitory motif of LILRB1 may also modify other processes in the cell for 
enhanced DENV infection. Further work will need to be carried out to 
identify these modified processes. 
The abovementioned study is consistent with the concept labeled 
“intrinsic ADE” (Halstead et al., 2010). “Intrinsic ADE” suggests that besides 
providing an alternative and perhaps a more efficient mode of entry into 
monocytes, FcγR signaling also modifies the antiviral immune mechanisms to 
create an intracellular environment favorable for enhanced replication and 
infection (Halstead et al., 2010). Indeed, DENV infection via ADE caused 
suppression of IL-12, IFNγ production and the Jak/STAT signaling pathway 
(Chareonsirisuthigul et al., 2007).  
Prior infection thus, through ADE, could potentially cause an 
enhanced viral load in mononuclear cells in patients. Infected mononuclear 
cells also produce and secrete vasoactive mediators that increase vascular 
permeability, causing severe dengue disease. Indeed, studies have shown 
that plasma leakage, the hallmark of severe disease generally occurs at or 
near defervesence, suggesting that disease pathogenesis is primarily 




Epidemiologically, the role of secondary infection in severe dengue 
has been described. Sera from mothers whose infants developed severe 
dengue upon a primary infection, contained sub-neutralizing levels of 
dengue-specific antibodies, suggesting that maternal transfer of antibodies to 
the infants had enhanced the disease outcome (Kliks et al., 1988). Likewise, 
65% of Vietnamese infants that experienced severe dengue had sub-
neutralizing levels of maternally transferred dengue-specific antibodies 
(Simmons et al., 2007). Another study showed an approximately 15-80 fold 
increase in risk of hemorrhagic manifestations upon secondary infection 
with another serotype (Thein et al., 1997). A prospective study in 
Yogyakarta, Indonesia on dengue in young children showed that all the 
children who had to be hospitalized for severe disease had secondary 
infection (Graham et al., 1999). In Rayong, the biggest risk factor for severe 
clinical outcome was secondary infection with DENV-2 (Sangkawibha et al., 
1984).  
Nonetheless, not all severe dengue cases are caused by secondary 
infection alone and not all secondary infections lead to severe dengue disease 
outcome (Watts et al., 1999). A prospective study on primarily DENV-3 
infections in infants showed no significant association between levels of 
maternal antibodies at disease onset and the development of severe disease 
(Libraty et al., 2009). Moreover, a severe dengue outbreak occurred in Niue 
in 1972 where many children died of severe disease {Barnes and Rosen, 
1974 #424}. Since Niue had been free of dengue for the preceding 25 years, it 
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is highly unlikely that secondary infection resulted in severe disease, thus 
suggesting that other factors such as differential virulence of DENV strains 
may also contribute to disease pathogenesis (Barnes and Rosen, 1974; 
Rosen, 1977)  
1.2.1.2 Viral virulence contributes to pathogenesis 
Support for the differential virulence of DENV strains began as early 
as the 1950s with Sabin’s experimental infections of human volunteers 
(Sabin, 1952). Subcutaneous inoculation of the Hawaii DENV strain into 
subjects resulted in more severe disease as compared to inoculation with the 
New Guinea strain, proving the existence of “multiple immunological types” 
of dengue, as noted by Sabin.  
Based on nucleotide variations, the four DENV serotypes can be 
further subdivided into many genotypes and according to the viral virulence 
hypothesis, some DENV strains are responsible for more severe disease 
(Figure 1.9) (Holmes and Burch, 2000). The selection of more virulent 
dengue strains occurs in nature and analysis of DENV genomes has shown 
that dengue virus is continually evolving even during epidemics (Chen et al., 
Figure 1.9 Processes that led to an increase in DENV genetic diversity 
and two likely consequences 
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2008a; Rico-Hesse, 1990; Rodriguez-Roche et al., 2005).  
In the Western Hemisphere, although dengue was circulating prior to 
1981, the first outbreak of severe disease only occurred in 1981 when the 
American genotype DENV-2 was displaced by the more virulent Southeast 
Asian DENV-2 genotype (Cologna et al., 2005; Rico-Hesse et al., 1997). In 
Cuba, towards the end of the 1981 DENV-2 epidemic, the severity of disease 
and case fatality rates increased, suggesting that the circulating DENV-2 
might have become more virulent (Kouri et al., 1987). This was observed 
again during the 1997 Cuban epidemic (Guzman et al., 2000). Similarly, 
during the 1992 dengue epidemic in Australia, the number of cases with 
spontaneous hemorrhagic manifestations increased as the epidemic 
progressed, thus implying that the virus might have evolved due to selection 
pressure to become more virulent (Streatfield et al., 1993). Collectively, these 
epidemiological studies show that viral genetics contributes to dengue 
disease pathogenesis. 
In addition, in vitro studies that examined the attenuation of viral 
strains for vaccine production have suggested that viral genetic differences 
can lead to variations in DENV infectivity and/or virulence (Brault et al., 
2011; Hanley et al., 2004; Kelly et al., 2011). In a comparison of live 
attenuated DENV-2 viral strain PDK-50 and its parent strain, thirteen 
attenuating amino acid mutations were identified in prM, E, NS1, NS2A, 
NS2B, NS4B genes and 5’UTR (Kelly et al., 2011). Another study investigated 
the genetic basis for the impaired replication of a vaccine candidate and 
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found substitutions in NS1, NS3 and 5’UTR responsible (Brault et al., 2011). 
Furthermore, attenuating mutations introduced into the 3’UTR of a dengue 
vaccine candidate resulted in decreased replication in rhesus monkeys 
(Hanley et al., 2004). Thus, DENV can be attenuated by mutations in its 
genome which suggests that genetic mutations could also conversely increase 
its virulence.  
In mice, a single nucleotide substitution in the E protein gene resulted 
in increased neurovirulence (Sanchez and Ruiz, 1996). Mutations engineered 
into the 5’UTR of a DENV-2 infectious clone also showed differences in 
replication and variability in neurovirulence in mice (Sirigulpanit et al., 
2007). Yet another study looking into mouse-adapted DENV-4 strains, 
identified the E protein to be an important determinant of mouse 
neurovirulence with mutations in this region significantly changing the 
DENV-4 phenotype (Kawano et al., 1993). Collectively, these aforementioned 
studies suggest that a small number of genetic changes in the DENV genome 
can lead to significant phenotypic differences, including increased 
replication, viremia and disease severity.  
In an attempt to directly study viral factors contributing to severe 
disease, dengue viral RNA sequences were isolated from patients with 
dengue fever and severe dengue, sequenced and compared (Leitmeyer et al., 
1999). Results showed multiple amino acid changes in the proteins along 
with several sequence variations in both the 5’ and 3’ noncoding regions. 
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Although suggestive, this data is not compelling as not all variations were 
conserved among the viruses in both the dengue fever and severe dengue 
groups. Furthermore, host genetics may have played a role as these viruses 
were isolated from patients living in two different locales: Thailand and 
Americas. 
Hence, disease outcome cannot always be attributed to DENV 
sequence variations. For instance, in Singapore, a major outbreak took place 
in 2005, during which both DENV-1 and DENV-3 were co-circulating and 
genomic analysis confirmed that there was no connection between viral 
sequences and disease outcome (Schreiber et al., 2009). Rather, this study 
pointed out that ecological or immunological factors were the main 
determinants of the epidemic. Likewise, there may be other secondary 
factors such as age, host genetics contributing to disease pathogenesis as 
well (Watts et al., 1999). 
In summary, increased viral replication caused by both secondary 
infection or virus virulence will lead to a higher antigenic stimulation of host 
cells. This will result in greater levels of pro-inflammatory immune responses 
in the host which then leads to more severe dengue disease outcome 
(Devignot et al., 2010). The next section will thus explore the immune 




1.2.2 Immune responses to dengue infection  
Being a human disease that has no known animal reservoirs, dengue 
virus has developed sophisticated mechanisms to evade human immune 
responses, especially innate antiviral immunity. This section focuses on 
mechanisms of innate antiviral responses against dengue and how the virus 





Figure 1.10 Type I interferon signal pathway and evasion strategies of flaviviruses 
(A) Pattern recognition receptors (PRR) (RIG-I and TLR3/7) sense flavivirus dsRNA and 
ssRNA structures. These receptors activate their adaptor molecules initiating signaling 
cascades that activate IRF3, IRF7, and NF-κB, leading to IFN-α/β gene transcription. 
Mechanisms of evasion at this stage include: a delay in recognition of viral RNA by 
PRRs; impairment of RIG-I signaling by high mannose carbohydrates on the structural 
E protein; attenuation of TLR3 signaling by the NS1 protein; and reduction in IFN-β 
gene transcription by NS2A protein. (B) Activation of JAK/STAT pathway by binding of 
type I IFN to the IFN-α/β receptor (IFNAR). This results in generation, phosphorylation, 
and assembly of the trimeric ISGF3 transcription factor complex, which consists of a 
STAT1-STAT2 heterodimer and IRF9. This is followed by nuclear translocation of this 
complex and binding to IFN-stimulated response elements (ISREs). The production of 
ISGs is induced. The evasion mechanisms of flaviviruses consist of: blockade of 
phosphorylation of Tyk2 and Jak1 by NS5; reduction in STAT2 gene and protein 
expression by NS5; inhibition of STAT signaling by non-structural proteins; down-
regulation of the IFNAR through virus-induced redistribution of cellular cholesterol and 





1.2.2.1  Host innate immune response against dengue 
The host cell’s first line of defense starts with innate immune 
recognition of dengue viral RNA by pattern recognition receptors (PRRs). 
PRRs important for RNA viruses include toll-like receptors (TLRs), 
particularly TLR-3, TLR-7, TLR-8, intracellular sensors such as the DExE/H 
box and RNA helicases such as retinoic acid-inducible gene (RIG-I) and 
melanoma differentiation-associated protein 5 (MDA5) (Green et al., 2014) 
After endosomal acidification, one of the TLRs, involved in dengue 
viral recognition, TLR-3, recognizes DENV RNA and induces strong IL-8 and 
interferon α/β responses (Lee et al., 2012a; Tsai et al., 2009). This results in 
phosphorylation of TIR-domain-containing adapter-inducing interferon β 
(TRIF). Following phosphorylation, TRIF interacts with both TNF-receptor-
associated factors TRAF3 and TRAF6. Interaction of TRAF3 with TANK 
binding kinase 1 and Ik kinase 1(Ikk1) cause interferon regulatory factor 
(IRF)-3 phosphorylation while TRAF6 signals through association with TAK1, 
leading to activation of activator protein 1 (AP-1), initiation of Ikk1/Ikk2 
dephosphorylation of IkB and finally NFkB (nuclear factor kappa-light-chain-
enhancer of activated B cells) activation. Production of IFNs, interferon 
stimulation genes (ISGs) and chemokines is then induced following nuclear 
translocation of IRF3, AP-1, and NFkB. Administration of TLR-3 and TLR-
7/TLR-8 agonists resulted in significantly decreased viral replication along 
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with increased production of pro-inflammatory chemokines, thus revealing a 
protective role for TLRs during dengue infection (Sariol et al., 2011).  
In conjunction with TLRs, RNA helicases such as RIG-I and MDA5 
sense the intracellular viral RNA during infection and are induced leading to 
IFN-β production (Loo et al., 2008; Nasirudeen et al., 2011). Both RIG-I and 
MDA5 signal through the mitochondrial antiviral signaling protein (MAVS) 
present on the mitochondria which interacts with the stimulator of 
interferon genes (STING). Upon activation, mitochondrial antiviral signaling 
protein (MAVS) oligomerizes and attracts many ubiquitin E3 ligases such as 
TRAF3 and TRAF6 which activate intracellular signaling cascade that results 
in the transcription and production of interferon (IFN) α/β.  
Interferons promote the intracellular antiviral responses and initiate 
the adaptive immune responses throughout the course of dengue infection. 
When secreted by infected cells, IFN-α/β triggers warning signals to adjacent 
cells that an infection is in progress and acts as an autocrine or paracrine 
induction of cellular antiviral responses. IFN-α/β binds to the IFN-α/β 
receptor (IFNAR), activating the JAK/STAT pathway via phosphorylation of 
the adaptor molecules tyrosine kinase 2 (TYK2) and janus kinase 1 (JAK1) 
(Darnell et al., 1994; Velazquez et al., 1992). This results in the 
phosphorylation and dimerization of various signal transducer and activator 
of transcription (STAT) molecules. In response to IFNAR activation, the 
interferon stimulating gene factor 3 complex (STAT1, STAT2, IRF9) is one 
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important signaling complex formed that migrates to the nucleus and binds 
to IFN-stimulated response elements located in the promoter region of IFN 
stimulated genes (ISG). This binding induces the production of multiple 
antiviral proteins including interferon-induced transmembrane (IFITM) 
proteins, viperin, ISG20, double-stranded RNA activated protein kinase R 
(PKR) and pro-inflammatory cytokines (Platanias, 2005). All these ISGs are 
known to restrict dengue infection by either preventing viral entry or 
replication (Chan et al., 2012; Jiang et al., 2010). In addition, IFNAR signaling 
induces alternative signaling cascades, such as the mitogen-activated protein 
kinase p38 cascade and the phosphatidylinositol 3 kinase cascade that lead 
to production of pro-inflammatory cytokines and chemokines. 
Thus, interferons have been demonstrated to be highly effective 
against DENV infection (Diamond et al., 2000; Johnson and Roehrig, 1999). In 
response, DENV has developed many ways to manipulate the cellular 
antiviral responses and directly inhibit cellular signaling cascades.  
1.2.2.2 Subversion of innate immune responses by dengue 
As interferons are such strong inhibitors of dengue infection, DENV 
has evolved several strategies to attenuate the induction of IFN and its 
effector responses (Morrison et al., 2012). Dengue virus is able to inhibit IFN 
at various steps of the signaling cascade. Such a multifaceted approach is 
likely important to ensure that if one evasion strategy fails, yet another can 
aid in downregulation of IFN during dengue infection. This review shall focus 
33 
 
on the role of dengue coding and noncoding regions in subversion of IFN 
response during infection. 
1.2.2.2.1 Role of dengue coding regions 
The coding regions of the dengue genome are translated to produce 
viral proteins, essential for the various stages of DENV lifecycle and as 
numerous studies have shown, important for the inhibition of innate immune 
responses during infection (Figure 1.11) (Green et al., 2014).  
Firstly, DENV non-structural proteins can act directly as IFN 
antagonists on distinct components of the signaling cascade. Flaviviral NS1 
can mediate the inhibition of TLR3-dependant responses during infection 
(Wilson et al., 2008). A transmembrane receptor, TLR3 interacts with an 
Figure 1.11 Dengue virus interference with IFN-α/β signaling The DENV non-
structural proteins impede IFN-α/β signaling in infected cells. (A) NS2A, NS4A and 
NS4B complex together to prevent STAT1 phosphorylation, nuclear translocation and 
transcriptional activation of ISGs. (B) DENV NS5 binds and degrades human STAT2, 
targeting it toward the proteasomal degradation pathway. This prevents the formation 
of the STAT1/STAT2 heterodimer and its transcriptional ISG induction. 
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adaptor molecule to induce activation of kinases, phosphorylation and 
nuclear translocation of IRF3. Its signaling leads to activation of transcription 
factors such as NF-κB and subsequent IFN-β promoter transcriptional 
activation. In West Nile virus infection, NS1 was found to inhibit TLR3 
induced transcriptional activation of promoters by preventing nuclear 
translocation of IRF3, thus interfering with the type 1 interferon pathway 
and TLR3-dependent establishment of an antiviral state in cells. 
Recently, three independant reports have also shown that the 
enzymatically active DENV NS2B/3 protease abrogates the IFN production in 
a species-specific manner by directly cleaving the STING protein (Aguirre et 
al., 2012; Rodriguez-Madoz et al., 2010; Yu et al., 2012). A key adapter 
protein in the type 1 interferon pathway, STING induces interferon 
production when cells are infected with pathogens through TANK-binding 
kinase (TBK-1) phosphorylation and subsequent activation of transcription 
factors IRF3/7 and NFκB. The cleavage site of STING was mapped to the 
NS2B/NS3 protease, thus identifying one other mechanism of how dengue 
subverts the host innate immunity (Aguirre et al., 2012; Yu et al., 2012). 
In addition, NS2B, NS4A and NS4B are able to block the nuclear 
localization of STAT1 and transcriptional activation of the IFN promoters 
leading to inhibition of IFN signaling and hence downregulation of ISG 
expression (Grant et al., 2011; Munoz-Jordan et al., 2005; Munoz-Jordan et 
al., 2003). Interestingly, proper proteolytic processing of NS4A/4B is 
required for this anti-interferon function (Munoz-Jordan et al., 2005). 
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Even if ISG expression were to occur, DENV is still able to overcome 
some of their effects. One mechanism of subversion is through the 2′-
O methylation of the viral mRNA cap structure by the dengue NS5 protein 
(Daffis et al., 2010; Dong et al., 2012). Since cellular messenger RNA (mRNAs) 
are similarly methylated at the 2'-O positions of the 5' guanosine cap, by 
“camouflaging” as host mRNA, dengue RNA avoids MDA5 recognition and 
host restriction via interferon induced proteins with tetratricopeptide 
repeats (IFIT)-1 dependent and IFIT1-independent mechanisms (Daffis et al., 
2010; Dong et al., 2012).  
In addition, dengue NS5 has also been shown to bind and reduce the 
expression of STAT-2 protein (Ashour et al., 2009; Mazzon et al., 2009). Upon 
binding of IFN to IFN receptors on cell surfaces, STAT2 gets phosphorylated, 
activating the IFN signaling pathway leading to cells attaining an antiviral 
state to prevent viral replication. Thus, STAT2 plays an important role in IFN 
signaling. However, dengue antagonizes STAT2 by the binding of 
proteolytically processed mature NS5 (Ashour et al., 2009). This binding 
subsequently results in STAT2 degradation via the proteosomal pathway. 
Hence, NS5 is a potent and specific antagonist of the Type 1 IFN pathway. 
Interestingly, although NS5 alone can bind and inhibit phosphorylation of 
STAT2, its degradation is induced only when all nonstructural proteins are 




1.2.2.2.2 Role of dengue noncoding regions - sfRNA  
More recently, the 3’UTR of the DENV and other flaviviral genomes 
has been shown to play a critical role in regulating the host immune 
responses through the production of an abundant, highly structured 
noncoding RNA species of 0.3-0.7 kb in length termed subgenomic flavivirus 
RNA (sfRNA) (Roby et al., 2014). Remarkably, sfRNA is detected in 
abundance in cytoplasm of infected cells, not packaged into virions and is 
highly conserved among all members of the genus Flavivirus but not the 
family Flaviviridae (Pijlman et al., 2008). This suggests that it plays a vital 
and conserved role in flaviviral infections.  
Interestingly, the start of sfRNA remains remarkably conserved even 
amongst different flaviviruses and corresponds to stemloop SL-II (or its 
equivalent structure) at the 5’end of the 3’UTR (Figure 1.12) (Chapman et al., 
2014a; Funk et al., 2010; Pijlman et al., 2008). The formation of sfRNA is 
vastly dependent on the presence of conserved pseudoknot structures and 
does not require viral proteins nor viral replication. In 2010, two groups 
presented a model in which sfRNA is generated by the incomplete 
degradation of uncapped viral genomes by the cellular 5’-3’ exonuclease 
XRN1 which cannot progress through the pseudoknot structures in SL-II 
(Funk et al., 2010; Silva et al., 2010). For DENV-2 however, the pseudoknot in 
SL-II does not appear necessary for sfRNA production but conserved 
residues within the SL-II stem may play an analogous role by forming XRN1 





Figure 1.12 The 3'UTR structure of west nile virus and conservation of 
SL-II within the genus Flavivirus (A) Schematic representation of the 3'UTR 
demonstrating the arrangement of stemloops (SL) and pseudoknots (PK) and 
the sfRNA start site. (B) Schematic representation showing the predicted 
conservation of the SL-II/PK1-like RNA structure within the 3'UTR of divergent 





The proportion of sfRNA is greater than viral genomes in both 
infected mammalian and mosquito cells with ratios ranging from 10:1. sfRNA 
could thus play a critical role in regulating the flaviviral life cycle (Fan et al., 
2011; Funk et al., 2010; Lin et al., 2004; Liu et al., 2010; Pijlman et al., 2008; 
Silva et al., 2010). Surprisingly, functional studies using mutants showed that 
viral replication is not abrogated when sfRNA is not produced (Funk et al., 
2010; Liu et al., 2014; Pijlman et al., 2008; Silva et al., 2010). Although there 
was a delay in replication, viruses deficient in sfRNA could still reach peak 
titers as compared to wild type viruses. Consistent with this finding, when 
sfRNA formation was compromised, there was no effect on translation, RNA 
synthesis or packaging of reporter constructs (Pijlman et al., 2008). However, 
presence of sfRNA is absolutely vital to viral cytopathogenicity suggesting 
that sfRNA is critical for virus-host interactions (Liu et al., 2014; Pijlman et 
al., 2008; Silva et al., 2010). 
Although sfRNA was first observed in Murray Valley encephalitis 
(Urosevic et al., 1997), Japanese encephalitis (Lin et al., 2004) and West Nile 
viruses (Scherbik et al., 2006), the mechanism of sfRNA generation and its 
importance in pathogenicity remained highly elusive till recent years. Since 
then, it has been shown to play a multifaceted role in modulating the host 
antiviral response, although many underlying mechanisms remain 





Functions of sfRNA that have been described include: regulation of 
RNAi pathway, modulation of interferon pathway and inhibition of RNA 
decay. 
  
Figure 1.13 Cellular functions of noncoding sfRNA Several cellular targets and 
characterized functions for the various sfRNAs (indicated in blue) have been 
summarized. RNA interference (RNAi) and interferon (IFN) pathways are insect and 




1.2.2.2.2.1 Inhibition of cellular RNA decay 
The biological process of mRNA turnover occurs in cytoplasmic 
structures known as processing bodies (PBs). Given their canonical role in 
mRNA decay, PB machinery is hypothesized to have potent antiviral activity 
against viral RNA genomes. Antagonizing PB-associated functions is thus a 
strategy employed by many viruses to evade cellular defences (Lloyd, 2012). 
Likewise, flaviviral sfRNA has been shown to interact with XRN1, increasing 
the overall messenger RNA (mRNA) stability within the host cell (Moon et al., 
2012). This is possible as XRN1 remains associated with sfRNA after stalling 
at the 3’UTR RNA structures. This results in an accumulation of uncapped 
RNA transcripts in infected cells. On the other hand, this accumulation of 
partial RNAs is not noticed in cells infected with a kunjin virus (KUNV) 
mutant that is unable to produce sfRNA (Moon et al., 2012). Although the 
reason behind this inhibition is not clearly elucidated as yet, it is suggested 
that disruption of mRNA homeostasis by preventing XRN1 function might 
impair cellular functions to benefit the virus.  
1.2.2.2.2.2 Perturbing the RNAi pathway 
The inhibition of gene expression by RNA molecules is known as RNA 
interference (RNAi). Typically, the target mRNA molecules get destroyed in 
this process. Two types of small RNA molecule, microRNA (miRNA) and small 
interfering RNA (siRNA) are central to RNA interference. Both RNAs can be 
produced by the same pathway after which their precursors are processed 
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by endonucleases such as Dicer before being loaded into the RNA-induced 
silencing complex (RISC). In flavivirus-infected cells, RNAi mediated silencing 
of genes is impaired and expression of DENV and WNV sfRNAs inhibit DICER 
cleavage of double stranded RNA by directly binding to and saturating the 
RNAse (Pijlman, 2014; Schnettler et al., 2012). Given that RNAi has direct and 
broad antiviral activity in arthropod cells, the suppression of RNAi pathway 
by sfRNA could be a host-specific evasion of innate immunity in mosquito 
cells (Bidet and Garcia-Blanco, 2014).  
1.2.2.2.2.3 Interference with IFN-mediated innate immune responses 
The antagonism of the innate immune response is one of the better 
characterized functions of sfRNA. sfRNA has been implicated in the evasion 
of IFN-α/β pathway in DENV (Bidet et al., 2014), KUNV (Schuessler et al., 
2012) and JEV (Chang et al., 2013).  
During JEV infection, sfRNA inhibited IFN production by interfering 
with the phosphorylation, activation and nuclear translocation of IRF3 
(Chang et al., 2013). Without sfRNA production, KUNV mutants were 
inhibited in IFN-competent cell lines and mice. These mutants were 
especially sensitive to exogenous IFN suggesting that KUNV sfRNA likely 
impairs ISG expression or function (Schuessler et al., 2012). In both cases, 
however, the actual mechanism of action was not fully determined.  
In DENV-infected cells, it was recently reported that sfRNA sequesters 
three multifunctional RNA binding proteins (G3BP1, G3BP2 and CAPRIN1) 
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required for translation of ISG mRNAs (Bidet et al., 2014). This led to 
inhibition of ISG expression and renders the infected cells unable to mount 
an efficient antiviral state. This is the first mechanism proposed at the 
molecular level for the interaction between sfRNA and RNA binding proteins 
to impede host immune response. What is remarkable is that this mechanism 
is not conserved between flaviviruses or even between DENV-2 and DENV-3. 
This finding proposes that specific mechanism of action of sfRNA for viral 
evasion of the IFN response may diverge widely between related viruses and 
even strains (Diamond, 2009; Schoggins et al., 2011; Umareddy et al., 2008). 
Thus, it appears likely that different sfRNAs may target various host factors 
to perturb multiple stages of the IFN pathway using a sfRNA as a common 





Figure 1.14 Model depicting diverse strategies for sfRNA-mediated viral evasion of 
the IFN response Model proposes that rapidly evolving sequences in the sfRNA permit 
different viruses to sequestrate various types of host proteins (X, Y and Z). Binding to 
host proteins inhibits their activity, resulting in antagonism of the IFN response at different 
stages. 
 
To summarize, DENV has many tactical approaches to inhibit the host’s 
innate immune response which may impact the adaptive immune response 





1.3.1 Dengue is an emerging disease 
Over the last five decades, global dengue incidence has grown 
precipitously throughout the tropical and subtropical world, endangering 
an estimated 3 billion people – over 40% of the world’s population (Figure 
1.15) (Bhatt et al., 2013; Guzman et al., 2010; Simmons et al., 2012). 
Where only 9 countries had experienced severe dengue epidemics before 
1970, the disease is now endemic in more than 100 countries in Africa, 
South-east Asia, Eastern Mediterranean, the Americas and Western Pacific 
(WHO, 2007)  
 
This spread of dengue across the tropics and subtropics is mainly due 
to an increased geographical distribution of the virus and its mosquito vector 
from demographical change, unprecedented and uncontrolled urbanization, 
inadequate domestic water supplies, increased international travel and trade 
Figure 1.15 Global dengue risk Risk status was determined based on combined 
reports from the World Health Organization, the Centers for Disease Control and 




(Gubler, 2001, 2004; Gubler and Meltzer, 1999; Rigau-Perez et al., 1998). 
This convergence of factors has resulted in an increase in the number of 
reported cases.  
Based on World Health Organization reports, dengue cases have 
exceeded 1.2 million in 2008 and over 2.3 million in 2010 (Figure 1.16) 
(WHO, 2014). In 2013, 2.35 million cases were reported in Americas alone 
and this number continues in an upward trend. Furthermore, these reported 
cases are likely to underestimate the true burden of disease. A recent report 
using cartographic approaches estimated an intimidating figure of 390 
million dengue infections each year (Figure 1.2)(Bhatt et al., 2013; WHO, 
2014). Another recent report showed that India alone has an estimated 5.8 
million dengue cases per year, a stark contrast to the reported 20, 500 cases 
after adjusting for under-reporting (Shepard et al., 2014). 
 
 
Figure 1.16 Average number of reported dengue cases Average  
numbers of dengue and severe dengue cases reported annually to 




Besides increasing incidence of dengue cases in contrast with 
observations made 30 years ago, more places are also in recent years 
reporting the co-circulation of all four dengue virus serotypes (DENV-1-4) at 
any given time (Figure 1.17) (Mackenzie et al., 2004). Such endemicity for all 
four serotypes, or hyperendemicity, contributes to increased risk of 
secondary infection and the increased risk of emergence of new and perhaps 
fitter strains (Gubler and Trent, 1993). All these factors culminate in 
increased incidence of severe disease and epidemic dengue.  




1.3.2 Problems caused by dengue as an emerging disease 
The public health and economic impact of dengue is greatly 
underestimated because of limited surveillance data and gross under-
reporting either due to the insensitivity of clinical diagnosis in regions 
without sufficient laboratory support. Despite this, severe dengue disease 
has now emerged as a major cause of hospitalizations and deaths globally. 
The number of severe cases reported between 1981 and 1995 was four 
times higher than that of the previous 30 years (Gubler, 1998b). 
Approximately 500,000 people with severe dengue require 
hospitalization every year, a considerable proportion of whom are 
children and about 2.5% of those affected die (Gubler, 2002). 
Furthermore, dengue brings a costly burden with a 2009 estimate 
reporting that 700 000 disability-adjusted life years (DALYs) are lost to 
dengue globally each year (Hotez et al., 2009; Meltzer et al., 1998).  The 
main burden of this mortality and morbidity lie with children in most 
dengue endemic countries, thus placing dengue among the most 
significant diseases of children worldwide (Guzman et al., 2002; 
Hammond et al., 2005) 
Dengue also causes substantial economic loss. The economic cost 
for dengue is an average of US$41.5 million per year based on distribution 
of costs in Singapore from 2000-2009 (Carrasco et al., 2011). A review of 
all nations in Americas estimated an aggregate annual cost of US $2.1 
billion for dengue, excluding costs pertaining to dengue prevention 
48 
 
(Shepard et al., 2011). Indirect or “productivity” losses amounted to 60% 
of this cost. Yet another study revealed an annual economic burden of US 
$950 million among 12 nations in South East Asia, with ~52% of these 
costs amounting from productivity losses (Shepard et al., 2013). Thus, the 
extensive impact of dengue has ranked it as the most important mosquito-




1.3.3 Interplay of host and viral factors in dengue epidemics 
In the absence of a licensed vaccine, antiviral therapy or sustainable 
preventative measures, the geographic distribution of DENV has increased 
over the last 40 years causing frequent cyclical epidemics. Although the 
emergence of epidemic dengue is complex and multifactorial, including 
urbanization, globalization and lack of mosquito control, this section shall 
provide deeper insights into the complex dynamics between immunological 
determinants (namely, serotype switch) and viral genetics in the context of 
dengue epidemics.  
1.3.3.1 Serotype switch linked to dengue epidemics 
Herd immunity proposes that when the majority of a population are 
immune or less susceptible to a disease, such as dengue, the chains of 
infection are disrupted with less susceptible individuals getting infected. 
Since DENV infection is serotype-specific, this means that introduction of 
new serotypes into a population would lead to dengue epidemics. 
Furthermore, if a population has been previously exposed to one serotype of 
DENV, heterologous antibodies could enhance virus replication. This would 
lead to higher viremia in infected individuals that would increase virus 
transmission to mosquitoes and hence, expansion of epidemics. 
Therefore, previously it was widely thought that a serotype switch 
was responsible for most dengue epidemics in endemic countries, because of 
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lowered herd immunity to the new serotype and the likelihood of enhanced 
dengue infection. This was evident in Cuba, where DENV-1 caused a 
nationwide epidemic of dengue fever in 1977 and introduction of DENV-2 in 
1982 resulted in a massive epidemic of severe dengue disease (Kouri et al., 
1989). Similarly in 2001-2002, upon introduction of DENV-3, there was 
another major epidemic in Cuba (Alvarez et al., 2006). In Martinique, four 
outbreaks occurred between 2001 and 2010, all of which were characterized 
by the predominance of a new serotype replacing a previous serotype: 
DENV-3 in 2001, DENV-4 in 2005, DENV-2 in 2007, DENV-1 and DENV-4 in 
2010 (Thomas et al., 2014). In French Polynesia, after almost a decade of 
DENV-1 circulation, the introduction of DENV-4 resulted in an epidemic in 
2009 (Cao-Lormeau et al., 2011). Likewise, in Iquitos, Peru, the introduction 
of DENV-3 in 2001 resulted in replacement of the co-circulating DENV-1 and 
DENV-2, subsequently causing an epidemic. Subsequently, DENV-3 was 
displaced by DENV-4 in 2008 resulting in another major outbreak (Stoddard 
et al., 2014). 
A shift in dominant serotypes from DENV-2 to DENV-3 in 1987 and 
DENV-4 to DENV-3 in 1995 also resulted in severe outbreaks in Bangkok, 
Thailand (Nisalak et al., 2003). In Singapore, serotype switch also played a 
role in dengue epidemiology. A major outbreak in 2005 occurred when the 
predominant DENV-2 serotype was suddenly displaced by DENV-1 (Koh et 
al., 2008). Interestingly, despite the population having been exposed to 
DENV-2 previously which should have increased herd immunity to DENV-2, 
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another DENV-2 outbreak occurred in 2007. Upon further probing, it was 
discovered that a change in DENV-2 viral genotype accompanied this 2007 
epidemic (Lee et al., 2010). Therefore, serotype switch alone cannot explain 
the resurgence of many epidemics and viral genetics play an undeniable role 




1.3.3.2 Virus genetics linked to recent epidemics 
Several studies have reported the association between the emergence 
of novel dengue genotypes and the onset of epidemics (Bennett et al., 2006; 
Kanakaratne et al., 2009; Liang et al., 2013; Messer et al., 2003; OhAinle et al., 
2011; Steel et al., 2010; Vu et al., 2010). This is evident in Puerto Rico, a 
densely populated island in the Americas where the first recorded dengue 
epidemic occurred in 1915 (Brathwaite Dick et al., 2012). Dengue was first 
identified in 1969 and DENV-2 persisted for 8 years prior to 1994 (Figure 
1.18) (Brathwaite Dick et al., 2012; McElroy et al., 2011). 
In 1994 a novel DENV-2 genotype emerged in Puerto Rico and 
triggered an island-wide outbreak (Bennett et al., 2006). This outbreak was 
the largest Puerto Rican dengue epidemic on record in terms of 
hospitalizations and deaths at the time (Rigau-Perez et al., 2001). A total of 
24,700 cases were detected with at least 23% of the patients showing 
hemorrhagic manifestations and 19% hospitalized. 40 deaths were reported. 
Up till the DENV-4 epidemic in 1998 and the 2007 DENV-3/DENV-2 
epidemic, the 1994 epidemic produced the most hospitalizations, severe 
disease cases and deaths in Puerto Rico (Bennett et al., 2003; Tomashek et 
al., 2012). Disease severity also remained unchanged throughout the entire 
year. Lowered herd immunity could not be attributed as the cause of this 
outbreak since DENV-2 had been circulating in Puerto Rico prior to the 
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 epidemic. Partial genome sequencing of the structural genes later revealed 
that three distinct DENV-2 lineages were circulating during this epidemic: 
the endemic lineage introduced to Puerto Rico in 1984 and two foreign 
lineages that appeared for the first time on the island in 1994 (Figure 1.19) 
(Bennett et al., 2006).  
 
  
Figure 1.18 Historic Overview of dengue in Puerto Rico, 1986-2007 (A) Number of 
dengue cases per year, reported to Centers for Disease Control and Prevention’s 
Dengue Branch. (B) Percentage of each serotype identified relative to the total positive 






Figure 1.19 Maximum-likelihood (ML) phylogenetic tree of DENV-2 sequences in Puerto 
Rico and other countries. Analysis was based on published sequences of the structural 
genes (capsid, membrane and envelope). All samples are coded by location, number and year 
of isolation: Australia (AUS), Bolivia (BOL), Brazil (BRA), Burkino Faso (BurF), China (CHI), 
Colombia (COL), Costa Rica (CR), Ecuador (EC), El Salvador (ES), Honduras (HON), 
Jamaica (JAM), Malaysia (MAL, sylvatic), Martinique (MAR), Mexico (MEX), New Guinea 
(NewG C), Peru, Philippines (PHI), Puerto Rico, (PR), Seychelles (SEY), Sri Lanka (SrL), 
Surinam (SUR), Taiwan (TAI), Thailand (THD), Trinidad (TRI), Uganda (UGA), Venezuela 
(VEN), Vietnam (VIET), Barbados (BAR), Dominica (DOM), Dominican Republic (DR) and St 
Vincent (STV). Colour coding of branches shows the year of sample isolation for PR 
sequences with foreign isolates coloured black. Bootstrap-support values appear above and 
below nodes, respectively. Unambiguous amino acid changes in the structural genes are 
indicated along the major lineages, highlighted with black bars and labeled with amino acid 




One of these foreign DENV-2 lineages includes only 4 divergent 
isolates from 1994 to 1998, suggesting that it never became established in 
Puerto Rico. The other foreign lineage rapidly became dominant and 
persisted through 2001 (Bennett et al., 2006). The appearance of this 
dominant foreign lineage and the concomitant dengue epidemic of 1994 
strongly suggest that this particular lineage possessed greater fitness than 
the endemic strain of DENV-2 that had been in circulation on the island. 
Similar introduction or evolution of new viral genotypes or subtypes 
resulting in epidemic dengue has been reported elsewhere.  
 In Sri Lanka, DENV-3 was responsible for the first dengue hemorrhagic 
fever outbreak in that country’s history in 1989 despite the fact that this 
serotype had been in circulation since at least 1981. That outbreak was 
associated with a lineage change in the endemic genotype of DENV-3 (Messer 
et al., 2003). Abrupt increases in reported dengue cases in 1989 and 2000 
were again observed in Sri Lanka, and this coincided with emergence of new 
clades of DENV-3 (Kanakaratne et al., 2009). Notably, DENV-3 isolates from 
mild and severe disease outbreaks fell into genetically distinct groups, thus 
suggesting a role for viral genetics in severe dengue disease. 
 In Nicaragua, a sudden increase in dengue disease severity was detected 
across DENV-2 epidemic seasons. This was found to coincide with a clade 
replacement event where the endemic Asian/American DENV-2 NI-1 was 
replaced by a new virus clade NI-2B. In vitro studies showed that NI-2B 
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viruses had increased fitness in human and mosquito cells, thus supporting 
the emergence of a fitter virus (Figure 1.14) (OhAinle et al., 2011).  
 In the Pacific islands, the American genotype DENV-2 was circulating 
since 1971, causing epidemics of varying intensity and clinical severity. 
However, upon reaching Tonga in 1973, near-silent transmission was 
observed for more than a year. Whole genome sequencing and phylogenetic 
analysis revealed that a clade change had occurred with the Tonga viruses 
being genetically distinct, thus coinciding with decreased disease severity, 
viremia levels and epidemic potential (Gubler et al., 1978; Steel et al., 2010)  
 Genotype replacement events in Vietnam, Thailand and Cambodia also 
occurred resulting in a complete replacement of the dominant 
Asian/American lineage viruses by Asian I viruses (Vu et al., 2010). In vitro 
studies showed little difference in infectivity of mosquitoes but significantly 
higher plasma viremia levels were observed in patients infected with Asian I 
lineage viruses. The latter could have resulted in greater likelihood of 
mosquito infection upon taking blood meal from dengue patients. In Canton, 
China, DENV-3 was introduced in 2009 after almost 30 years since its 
previous circulation (Liang et al., 2013). However, a larger outbreak only 
occurred in 2010. Epidemiological and phylogenetic analyses showed that 
the outbreak in 2010 was caused by a different strain of DENV-3.  
 Collectively, the abovementioned epidemiological studies reveal the 
association between DENV strains and epidemic emergence. Despite these 
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associations, however, little is known about the underlying mechanisms 




1.4 What is the molecular basis for dengue epidemics - Gaps in 
knowledge 
The literature review has elaborated on the contribution of viral 
factors to severe dengue pathogenesis and increased epidemic potential, 
otherwise referred to as epidemiological fitness throughout this text. Indeed, 
epidemiological fitness is a term coined in this study to indicate the ability of 
a virus to propagate itself in a natural human-mosquito-human transmission. 
Epidemiological fitness thus encompasses several factors, including virus 
replication rate and the ability to evade host immune responses. For 
instance, a virus that replicates rapidly in vitro may not necessarily be 
epidemiologically fitter as it is unable to suppress host immune responses.  
Although molecular studies have shown that genetic differences in 
DENV can result in increased replication, viremia and hence more efficient 
transmission to mosquitoes, there remains a lack of knowledge into how 
these genetic differences can mechanistically result in epidemics at a 
molecular level. On the other hand, despite the strong association between 
emergence of new viral phylogenetic clades and epidemic dengue reported in 
several locations globally, epidemiological studies are unable to provide 
mechanistic explanations for how genetic differences alter epidemiological 
fitness of DENV. Combining epidemiologic studies with molecular 
investigations could thus be highly informative not only on the virus origin 
but also as a predictor of its epidemic potential.  
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This thesis thus attempts to bridge these gaps in knowledge by studying 
DENV-2 isolates from the 1994 Puerto Rican epidemic. The main aims are:- 
(1) To define the regions of the DENV-2 genome that could contribute 
towards greater epidemiological fitness. 
(2) To determine the molecular mechanism that contributes to 
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HuH-7, C6/36, Vero and BHK-21 cells were purchased from the 
American Type Culture Collection (ATCC, USA) and cultured according to 
ATCC recommendations.  
Harvesting and culture of primary monocytes was carried out in 
collaboration with Eugenia Ong and approved by the National University of 
Singapore Institutional Review Board (NUS IRB reference code 12-160). 
Venous blood was collected from the principal investigator in BD sodium 
heparin vacutainers (Biomed Diagnostics, Singapore). Then the blood was 
diluted with 2 volumes of 0.5% bovine serum albumin (BSA, Sigma-Aldrich, 
USA) in phosphate buffered solution (PBS, 1st Base, Singapore) (0.5% 
PBS/BSA). Diluted blood was layered carefully onto Ficoll-hypaque (GE 
healthcare, Singapore) and centrifuged at 750g, without brakes. After 
centrifugation, interphase cells that contain the peripheral blood 
mononuclear cells (PBMC) were aspirated and transferred to a clean tube, 
after which the PMBC were washed thrice with 0.5% PBS/BSA and 
resuspended in growth medium (RPMI-1640 supplemented with 10% fetal 
bovine serum, 100U/ml penicillin and 100µg/ml streptomycin). Cells were 
then counted and seeded onto T25 tissue culture flasks (NUNC, Bio 
Laboratories, Singapore) at 1x107 cells per flask. They were incubated at 
37°C, 5% CO2 for 2.5 hours to allow the monocytes to adhere to the flask 
surface. After this incubation, adhered cells were washed 5 times with PBS to 
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remove the non-adherent cells, and replenished with fresh growth medium. 
This was followed by an overnight incubation at 37°C, 5% CO2 to allow the 
PBMC to recover before use in experiments. 
2.2 Viruses  
The DENV-2 infected patient sera used in this study were gifts from 
the Dengue Branch of the Centers for Disease Control and Prevention, Puerto 
Rico. These patient sera were obtained during the 1994 DENV-2 epidemic in 
Puerto Rico. Low-passage stocks of virus isolates were generated by 
inoculating acute patient sera onto C6/36 cells as previously described 
(Christenbury et al., 2010). These virus stocks were propagated in the C6/36 
cell line and harvested 7 days post-infection following filtration. All viral 
isolates included in this study were passaged less than 5 times. Viruses were 
confirmed to be DENV-2 by an immunofluorescence assay, aliquoted and 
stored at −80 °C until use.  
2.3 Plaque assay.  
BHK-21 cells were seeded in 24-well plates (NUNC, Bio Laboratories, 
Singapore) overnight. The next day, serial dilutions (10-fold) of the virus 
were added to the confluent cells and incubated for 1 hour at 37oC. Following 
incubation, the media was aspirated and replaced with 0.8% methyl-
cellulose in maintenance medium (RPMI-1640, 2% FCS, 25mM HEPES, 
penicillin and streptomycin). Then, the cells were incubated at 37˚C for 5 
days and fixed with 20% formaldehyde at room temperature for 20 min. 
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After fixing, cells were washed with water, and 1ml of 1% crystal violet was 
added for 20 min. The plates were washed, dried and the plaque forming 
units per ml (pfu/ml) calculated. 
2.4 Infections 
HuH-7 cells were seeded onto 24-well plates at a dilution of 2x105 
cells per well overnight. When they reached ~80% confluency the next day, 
they were counted for an estimate of cell numbers. Viruses were then diluted 
in maintenance medium (1xDMEM, 2% FCS).accordingly to achieve a suitable 
multiplicity of infection (MOI), after which they were added onto the cells 
and incubated for 1 hour at 37oC. After the incubation, cells were washed 
with 1xPBS and maintenance medium was added. Infected cells were 
incubated at 37oC and subsequently harvested at various time-points. All 
HuH-7 infections were performed at a MOI of 1 for 24 hours unless otherwise 
indicated. After infection, the supernatant was harvested for plaque assay 
while RNA was extracted from infected cells for quantitative real-time PCR 
(qRT-PCR). Infection of Vero cells was performed exactly as described above. 
For primary monocytes, infection was performed at MOI 10 with an 
enhancing concentration of humanized 3H5 monoclonal antibody 
(0.391µg/ml) to permit efficient uptake of the viruses, as previously 
described (Chan et al., 2014). Infectivity was measured using qRT-PCR on 
RNA from infected cells at 24 hpi and plaque assay on supernatant harvested 
at 72 hpi. 
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2.5  Sequence and structure analysis  
The complete coding and non-coding regions of the clinical isolates 
were sequenced previously (Christenbury et al., 2010). The maximum 
likelihood phylogenetic tree was constructed using MEGA6 (Tamura et al., 
2013) with the GTR+Γ4 model of nucleotide substitution from an alignment 
of 158 open reading frame DENV-2 sequences from Puerto Rico and 
neighboring countries. Neighbor-joining trees with a maximum likelihood 
optimized nucleotide model were generated using PAUP for full genomes of 
the 39 Puerto Rican isolates and 154 Nicaraguan isolates (Swofford, 1993). 
Statistical support for the topology of all the trees was determined by 1000 
bootstrap replications. Individual gene trees were generated with the same 
method described above. Topological congruence of the gene trees with the 
genome tree was determined by the Shimodaira-Hasegawa and the Kashino-
Hasegawa likelihood based tests (Kishino and Hasegawa, 1989; Shimodaira 
and Hasegawa, 1999). To construct the secondary structures of the 3’UTR, 
the chemical probing model proposed by Chapman et al, 2014 was used 
(Chapman et al., 2014a). Since the substitutions in the Nicaraguan clade 
replacement event were found to be a covariation of a base pairing, the 
UNAFold webserver was used to estimate the impact of this covariation on 




2.6 Quantification of RNA  
Total RNA from infected cells was extracted using Trizol (Invitrogen, 
Life Technologies, USA) or the RNeasy kit (Qiagen, Germany) as per 
manufacturer’s protocols. Superscript III reverse transcriptase and random 
hexamers (Invitrogen, Life Technologies, USA) were used in the reverse 
transcription reactions to generate cDNA according to manufacturer’s 
protocol. Quantitative real-time PCR (qRT-PCR) was performed on 2µl of 
cDNA using the iQ™ SYBR Green Supermix Kit (Bio-Rad, USA) according to 
the manufacturer's instructions. All PCR reactions were set up in triplicates 
and normalized against GAPDH mRNA levels (GAPDH primers: GAPDH-
F/GAPDH-R). 
Quantification of gRNA and sfRNA levels was performed as previously 
described (Bidet et al., 2014). Briefly, one primer (QG-For) anneals upstream 
of the stop codon, recognizing on the gRNA while the second primer (QGSF-
For) anneals on the 3’UTR, downstream from the start of sfRNA, thus 
amplifying both gRNA and sfRNA. The reverse primer (QGSF-Rev) which 
anneals downstream of the dumbbell 2 structure is kept consistent in both 
instances, leading to PCR products of lengths 309bp and 184bp respectively. 
Reactions were carried out in the Roche Lightcycler® 480 (Roche 
Diagnostics, USA) machine with the following conditions: 95°C for 5 min, 
followed by 45 cycles of 95°C for 10 sec, 55°C for 5 sec and 72°C for 10 sec. 
For every reaction, the molar amount of template, n(G) and n(GSF) was 
calculated using a standard curve generated from serial dilutions of in-vitro 
66 
 
transcribed, full length pDENrep-FH (DENV-2 replicon) RNA. gRNA levels 
corresponded to the n(G) molar amounts while sfRNA was calculated by 
subtracting n(GSF)-n(G). Ratios of sfRNA:gRNA were determined by dividing 
the levels of sfRNA with gRNA. Quantification of intracellular viral RNA levels 
was carried out as detailed above, using a different primer set (LYL-F/ LYL-
R) as previously published (Lai et al., 2007). This pair of primers bind within 
the 3’UTR, amplifying both gRNA and sfRNA. Primer sequences are shown in 
the table below (Table 2.1). 
Primers used to detect the IFN-β and NFκB expression levels were 
obtained from OriGene. Cycling conditions for the quantification of immune 
genes: 95°C for 5 min, followed by 45 cycles of 95°C for 5 sec, 53°C for 10 sec 
and 72°C for 10 sec. Each reaction was accompanied by a matching reaction 
quantifying GAPDH mRNA levels for normalization. Results were expressed 
as fold change in target gene over untreated control cells, normalized to the 
GAPDH mRNA using this formula: Fold change = 2-d(dct).  
Table 2.1 List of primers used for qRT-PCR 











2.7 Northern hybridization 
HuH-7 cells were infected with MOI 10 of DENV-2 and RNA harvested 
24 hpi using Trizol (Invitrogen, Life Technologies, USA). Uninfected cells 
were used as control. Northern hybridizations were then performed as 
previously described (Pijlman et al., 2008) with slight modifications. Briefly, 
10µg of purified RNA was denatured in a formamide buffer and run on a 1% 
formaldehyde-agarose gel at 80V for ~ 105 min. After that, the gel was 
soaked in autoclaved water thrice for 15 min each, denatured in 50mM NaOH 
for 20 min, neutralized in 100mM Tris-HCL (ph 7.0-7.5) for 20 min and 
finally soaked in 10x SSC for 15 min. Transfer of the RNA from the gel onto 
the Hybond-N+ membrane (Amersham, GE Healthcare Lifesciences, USA) was 
then carried out overnight with 20x SSC buffer. Following the overnight 
transfer, the membrane was rinsed in 10x SSC after which RNA on the 
membrane was crosslinked using the CL-1000 UV crosslinker (UVP, USA).  
Radioactive RNA probes were next prepared using the MAXIscript® 
T7 kit (Ambion, Life Technologies, USA), as per manufacturer’s instructions. 
PCR products were first generated from uninfected HuH-7 cells using beta-
actin primers (NB_ACTIN_F: 5’-
CTAGAAGCTTTAATACGACTCACTATAGGGTGACCCATGCCCACCATCAC-3’ and 
NB_ACTIN_R: 5’-CTAGGCTAGCATAGAGCACAGAGCCTCGCCTTT-3’) and from a 







PfuUltra II HS fusion polymerase (Agilent Technologies, USA) was used for 
PCR reactions. Then, 1µg of purified 3’UTR and beta-actin PCR products were 
in-vitro transcribed with 5μl α32P dUTP. Reactions were stopped with 1µl 
0.5M EDTA and labeled RNA probes were purified with mini Quick Spin RNA 
columns (Roche Life Science, USA). Incorporation was measured with a 
Geiger counter. Denaturation of the labeled probes was carried out at 95°C 
for 5 min followed by snap cooling on ice. Probes were then centrifuged 
briefly before addition to the membrane.  
Overnight hybridization of probes to the membrane was performed in 
ULTRAhyb® Ultrasensitive Hybridization (Ambion, Life Technologies, USA) 
at 43°C. After hybridization, the following washes were done in the 
respective order: 6xSSC/0.1% SDS buffer at room temperature for 15 min (3 
times); 6xSSC/0.1% SDS buffer at 43°C for 15 min (1 time); 0.1xSSC/0.1% 
SDS buffer at room temperature for 15 min. The background of the 
membrane was consistently checked with a Geiger counter between washes 
to ensure that radioactivity is not too high. Finally, the membrane was 
wrapped in cling film, exposed on a phosphorscreen for about 3 hours up to 
overnight (depending on signal strength) and signals were quantified using a 
Typhoon phosphorimager (Amersham, GE Healthcare Lifesciences, USA). 
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Intensity of the bands was calculated using ImageJ software (National 
Institutes of Health, USA). 
2.8 siRNAs 
The siRNAs used for knockdown experiments were obtained from 
Singapore Applied Biologics (SABio, Singapore). 100nM siRNA was 
transfected into HuH-7 cells seeded onto 24-well plates using DharmaFect2 
(Dharmacon, GE Healthcare Lifesciences, USA) according to manufacturer’s 
instructions 48 hours prior to infection. AllStars negative control siRNA 
(Qiagen, USA) was used as the control siRNA (siC). The siRNAs for IRF3 
knockdown target three different sequences in IRF3 RNA (IRF3-01: 5’-
GCAAAGAAGGGUUGCGUUU-3’; IRF3-03: 5’-AUGCACAGCAGGAGGAUUU-3’ 
and IRF3-04: 5’-GGGAAGAGUGGGAGUUCGA-3’). Knockdown efficiency was 
determined by Western blot using anti-IRF3 antibody (1:3000) (Cell 
Signaling Technology, USA). 
2.9 Western blot 
Cells were trypsinized, washed twice in 1xPBS and resuspended in lysis 
buffer (50µl lysis buffer for up to 2x105 cells) containing 1% NP-40, 150mM 
NaCl, and 50mM Tris, pH 8.0 in the presence of protease and phosphatase 
inhibitors (Sigma-Aldrich, USA). After centrifugation, the cell lysates were 
exposed to 1x loading buffer and separated by SDS-PAGE. After transfer to 
polyvinylidene fluoride (PVDF) (Merck Millipore, USA), IRF3 and GAPDH 
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proteins were detected with anti-rabbit IRF3 antibody (1:3000) (Cell 
Signaling Technology, USA) and anti-mouse GAPDH antibody (1:3000) 
(Abcam, UK) respectively. Addition of appropriate HRP-conjugated 
antibodies (Dako, Agilent Technologies, USA) followed and bands were 
visualized using enhanced chemiluminescence (ECL) (Amersham, GE 
Healthcare Lifesciences, USA) for development. 
2.10 Constructs 
The DENV-2 reporter replicon system (pDENrep-FH) has been 
described previously and was a gift from Eva Harris (Holden et al., 2006). 
This replicon has the backbone of the Thai 16681 DENV-2 strain (U87411.1) 
and contains Renilla luciferase and a T7 promoter region. Point mutations 
were made to create the other replicons (pDENrep-FH/PR1, pDENrep-
FH/PR2B/28nt, pDENrep-FH/PR2B/117nt and pDENrep-FH/PR2B) using 
the Quikchange site-directed mutagenesis kit (Stratagene, Agilent 
Technologies, USA) as per manufacturer’s instructions. A Firefly luciferase 
containing construct pTNT-Ffluc was used as the normalization control.  
2.11 In vitro transcription  
All DENV replicon DNA templates were generated by XbaI digestion of 
the corresponding plasmids, followed by phenol-chloroform extraction and 
ethanol precipitation. The T7 RiboMax large-scale RNA production system 
(Promega, USA) and m7G(5')ppp(5')A RNA Cap Structure Analog (New 
England Biolabs, USA) were used to generate capped RNA by in vitro 
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transcription with the modifications to the manufacturer’s protocol as 
previously detailed (Friebe and Harris, 2010). Briefly, a 20µl mastermix was 
set up as follows: 5x buffer (4µl), rGTP (1.5µl) rCTP (1.5µl), rUTP (1.5µl), 
rATP (0.3µl), A cap (6µl), T7 enzyme (2µl), RNAsin Ribonuclease inhibitor 
(1µl) (Promega, USA), 1µg linearized DNA and RNAse-free water. After 
30min incubation at 37°C, another 0.72µl of rATP was added to each 
reaction. Reactions were then left to incubate overnight at 37°C. After in-
vitro transcription, each reaction is incubated with 1 µl RNase-Free DNase at 
37°C for 15min. RNA is then purified using the RNeasy kit (Qiagen, Germany) 
as per manufacturer’s protocols before electroporation. 
2.12 Electroporation and dual-luciferase assay 
Briefly, HuH-7 cells were trypsinized and washed thrice with cold, 
sterile PBS after which they were counted and resuspended to 1×107 
cells/ml in cold Opti-MEM (Invitrogen, Life Technologies, USA). 800µl of the 
cell suspension was aliquoted into each 4mm electroporation cuvette (Bio-
Rad, USA) followed by addition of 10µg of purified replicon RNA and 1 µg of 
pTNT-Ffluc. After one pulse at 950μF and 250V with a Gene Pulser II system 
(Bio-Rad, USA), cells were incubated at room temperature for 10 min. Cells 
were gently transferred from each cuvette to 11.2ml of pre-warmed media 
and 500 µl of this final mixture was aliquoted into each well (sufficient for a 
24-well plate). Cells were harvested at various time-points using the passive 
lysis buffer (Promega, USA) and luciferase activity was measured using the 
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Dual Luciferase Reporter Assay system (Promega, USA) according to 
manufacturer’s instructions. 
2.13 sfRNA transfections 
DENV-2 3′UTR templates were PCR amplified from PR-2B viral cDNA 
to add a T7 promoter immediately upstream of the DENV-2 stop codon and 
in vitro transcribed using the Megascript T7 transcription kit (Life 
technologies, USA). A size-matched control RNA was similarly prepared from 
the pGEM-T vector (Promega, USA). Primers used for the amplification of 
DENV-2 3’UTR templates are T7 D2 3UTR For (5’-
TAATACGACTCACTATAGGGAAGAGATTCAGA-3’) and D2 3UTR Rev (5’AGA 
ACC TGT TGA TTC AAC AGC ACC3’). For the amplification of the size-matched 
control RNA, pGEM Non For (5’-
CTAGGGATCCTAATACGACTCACTATAGGGCGAATT-3’) and pGEM Non Rev 
(5’-CTAGGGATCCGTTCTTTCCTGCGTTATCCCCTGA-3’) were used. 
The RNAs were decapped by a 45 min tobacco acid pyrophosphatase 
(Epicentre, Illumina, USA) treatment at 37°C, purified using the RNeasy kit 
(Qiagen, Germany) and subjected to heat denaturation followed by cooling to 
form secondary structures. All RNAs were quantified spectrophotometrically 
and agarose gel electrophoresis was used to verify their integrity before use. 
500ng of the RNAs was either co-electroporated with pDENrep-FH or 
transfected into HuH-7 cells at 90% confluency pre-seeded on 24-well plates 
along with polyinosinic-polycytidylic acid (PolyIC) (1g/l per well) to 
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stimulate the RIG-I pathway using Lipofectamine RNAiMax (Life 
Technologies, USA) as per manufacturer’s instructions.  
2.14 RNA-protein interactions 
2.14.1 SILAC-qMS 
Viral RNA was extracted from virus supernatants of PR-1 and PR-2B 
viruses utilizing the QIAamp viral RNA mini kit (Qiagen, Germany). Then, 
cDNA was made with the Superscript III reverse transcriptase and random 
hexamers (Invitrogen, Life Technologies, USA). Short DENV-2 PCR products 
comprising of the proximal end of the 3’UTR (SL-II to SL-IV) were next 
prepared from the viral cDNA using AW005-PR-FOR (5’ CGG GTA TGT GCG 
TCT GGA TCC TAT RGG AAG AGG AAG AGG CMG G 3’) and AW135R (5’ TTG 
TTG CTG CGA TTT GTA AGG G 3’). Similarly, a size-matched control PCR 
product was constructed from a plasmid containing the DENV-2 NS2A open 
reading frame as reported before (Ward et al., 2011). Tobramycin aptamers 
were then incorporated into the partial UTRs including the control and the 
Megascript T7 transcription kit (Life technologies, USA) was utilized to 
produce the RNAs.  
Meanwhile, stable isotope labeling by amino acids in cell culture 
(SILAC) was carried out to obtain labeled (i.e. light, medium, heavy) HuH-7 
cell lysates (Mann, 2006; Ong et al., 2002). The prepared RNAs were bound to 
a tobramycin matrix, incubated with SILAC-labeled cell lysates, washed and 
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eluted using excess tobramycin (Ward et al., 2011; Ward et al., 2014). Eluates 
were finally analyzed by quantitative mass spectrometry (qMS) at the 
Quantitative Proteomics group, Institute of Molecular and Cell Biology, 
Singapore. In order to identify the proteins involved in innate immunity, the 
list of proteins from the MS data was loaded into GO term finder. 32 out of 
1199 proteins were represented in the GO term "innate response 
process"(Boyle et al., 2004).  
2.14.2 RNA-immunoprecipitations 
Viral infections were performed at MOI 5 on HuH-7 cells pre-seeded 
onto T175 cell culture flasks. At 24 hpi, RNA-immunoprecipitations (RIP) 
were carried out using the MAGNA-RIP kit (Merck Millipore, USA) following 
manufacturer's recommendations. Briefly, infected cells were lysed with the 
RIP lysis buffer (Merck Millipore, USA). In the meantime, 5µg of the anti-
TRIM25 (BD Biosciences, USA) or anti-MAVS (Abcam, UK) were incubated 
with the magnetic beads (Merck Millipore, USA) at room temperature for 30 
min to form beads-antibody complexes alongside with the respective isotype 
control antibodies (Abcam, UK).  
After washing, the beads-antibody complexes were resuspended in 
RIP immunoprecipitation buffer (Merck Millipore, USA) and cell lysates were 
added to these complexes. After resuspending, 50µl each of the final mixture 
was removed for subsequent qRT-PCR and western blot analysis. This was 
labeled as “Input”. The mixture was then incubated overnight at 4°C. The 
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next morning, 50µl of the mixture (labeled “Sup”) was removed for western 
blot analysis. The remaining bead suspension was washed at least six times, 
pelleted and resuspended into a total volume of 500µl. From this final 
mixture, described as “Pellet”, 250µl was resuspended in RLT buffer (RNeasy 
kit, QIAGEN, Germany) for qRT-PCR and the remaining 250µl stored for 
western blot analysis. The levels of RNA in RIP were determined by qRT-PCR 
and normalized to GAPDH mRNA levels, control mouse IgG (TRIM25) and 
rabbit IgG (MAVS) RIP levels following this formula: Fold enrichment = 2-
ddCt where ddCT= ((CTRNA,IP-CTGAPDH,IP)-(CTRNA,controlIP-CTGAPDH,controlIP)) 
2.15 Co-immunoprecipitation and immunoblot analysis 
Transfected or infected HuH-7 cells were trypsinized, washed twice in 
1xPBS and resuspended in lysis buffer (50µl lysis buffer for up to 2x105 cells) 
containing 0.1% NP-40, 150mM NaCl, and 50mM Tris, pH 8.0 in the presence 
of protease and phosphatase inhibitors (Sigma-Aldrich, USA). Cells were left 
on ice to allow lysis for at least 1 hour, after which they were spun down at 
maximum speed in the pre-cooled centrifuge for 10 min. Cell lysate was 
removed without disturbing the pelleted debris and separated into tubes for 
the subsequent immunoprecipitations.  
5ug of anti-mouse TRIM25 (BD Biosciences, USA) or anti-rabbit RIG-I 
(Alexis, Enzo Life Sciences, USA) antibody was incubated with the cell lysates 
overnight at 4°C. Each antibody was paired with its respective isotype 
control antibodies (Abcam, UK). Protein A agarose beads (Thermo Scientific, 
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USA) were washed with immunoprecipitation buffer (25mM Tris, 150mM 
NaCl, pH 7.2) and incubated with lysate for 2.5 hours at 4°C. After washing, 
proteins were eluted with SDS-PAGE loading buffer and respective proteins 
were detected. Primary antibodies used were: anti-TRIM25 (1:5000) (BD 
Biosciences, USA), anti-MAVS (1:1000) (Abcam, UK), anti-ubiquitin (1:1000) 
(P4D1, Santa Cruz Biotechnology, USA) and anti-RIG-I (1:1000) (Alexis, Enzo 
Life Sciences, USA). Appropriate HRP-conjugated antibodies (Dako, Agilent 
Technologies, USA) were used as secondary antibodies and bands were 
visualized using ECL (Amersham, GE Healthcare Lifesciences, USA) for 
chemiluminescence development. 
2.16 Statistical analysis 
All results are presented as mean ± SD of at least 3 independent 
experiments, unless otherwise indicated. Data were analyzed using two-
tailed unpaired Student's t-test or ANOVA and considered significant if 
p<0.05 (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001). All calculations were 
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3.1.1 Comparative analysis of the 1994 Puerto Rican DENV-2 isolates 
To gain insights into how genetic variation of DENV could modulate 
the outcomes in an epidemic, we examined a DENV serotype 2 (DENV-2) 
clade replacement event in Puerto Rico that coincided with an island-wide 
epidemic in 1994 (Bennett et al., 2006; Rigau-Perez et al., 2001). This 
epidemic was the largest on record, with the highest reported numbers of 
hospitalization (2004), severe dengue cases (139) and deaths (40) in Puerto 
Rico until 1998 (Bennett et al., 2006; McElroy et al., 2011). Using complete 
coding sequences of clinical isolates obtained during the epidemic and other 
DENV-2 GenBank sequences from Puerto Rico and neighbouring countries, 
we built a maximum likelihood phylogenetic tree (Figure 3.1). The maximum 
likelihood phylogenetic tree is a statistically established simple model that 
supposes the least evolutionary change to explain the observed data. Thus, 
this method searches for the tree with the highest probability to interpret the 
1994 clade replacement event. Results showed that three distinct clades (PR-
1, PR-2A and PR-2B) within the American/Asian genotype were circulating in 
Puerto Rico in 1994, which is concordant with previous analysis using partial 
genome sequences (Figure. 3.1) (Bennett et al., 2006). Clade PR-1 was 
regularly isolated from clinical cases from 1986 to 1995. It is thus referred to 
as “endemic” throughout this study since it has been prevalent in Puerto Rico 
prior to the 1994 epidemic. The second clade PR-2 contains viruses isolated 
beginning in 1994 and can be subdivided into PR-2A, which persisted at low 
levels till 1998 and PR-2B. The PR-2B viruses arose in 1994 at the onset of 
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the epidemic, replacing the PR-1 clade to become the dominant DENV-2 clade 





Figure 3.1 Whole genome phylogenetic tree of DENV-2 clinical isolates from Puerto Rico and 
neighboring countries Black dots indicate viruses used in this study. Data from Esteban Finol. 
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In order to assess the parts of the DENV genome in which the 
nucleotide substitutions could be responsible for the separation of the Puerto 
Rican isolates into two clades, the Shimodaira-Hasegawa (SH) test was 
performed (Buckley et al., 2001). The SH test is a widely used method that 
corrects for the fact that the parameters for the substitution process and the 
branch lengths in a maximum likelihood tree are estimated. Hence, it is a 
completely unbiased comparison of tree topology of maximum likelihood 
trees. Using this method, the topology of the full genome phylogenetic tree 
was compared with that of each tree constructed from different regions of 
the DENV genome.  
This analysis identified variations in NS1, NS3, NS5 and the 3’UTR as 
potentially critical to how the viruses segregated into PR-1 versus PR-2B 
clades (Figure 3.2). The SH test on the other regions of the genome showed 
statistically significant differences compared to the whole genome tree 
indicating that sequence differences in these parts of the genome are unlikely 







Figure 3.2 Phylogenetic trees of the whole genome, 3’UTR, NS1, NS3 and NS5 
regions of Puerto Rican clinical isolates used in this study Isolates from PR-1 
lineage are marked in black while isolates from the PR-2B lineage are in blue. The p-
values generated by the SH test are shown below each tree in brackets. This test statistic 
is the score difference between the Maximum Likelihood tree (full genome phylogenetic 
tree) and every other tree compared. Comparison with NS1, NS3, NS5 regions and the 
3’UTR yield p-values that are not significant, indicating that they are good explanations of 





Figure 3.3 Phylogenetic trees of the other genetic regions of Puerto Rican clinical 
isolates used in this study Isolates belonging to the PR-1 lineage are marked in black 
color while the isolates from the PR-2B lineage are highlighted in blue. The p-values 
generated by the SH test are shown below each tree in brackets. This test statistic is the 
score difference between the Maximum Likelihood tree (full genome phylogenetic tree) 
and every other tree compared. From the SH test scores, these regions are significantly 
different from the whole genome tree (Figure 3.2) indicating that they are not likely to lead 




To complement the SH test findings, we also aligned the complete 
genome sequences and identified both amino acid and nucleotide 
substitutions occurring in at least 25 % of the isolates from each clade 
(Figures 3.2 and 3.3). Variant residues identified were omitted from analysis 
to reduce noise resulting from stochastic effects. Using these criteria, we 
observed a total of 17 non-synonymous amino acid changes throughout the 
DENV-2 genome of PR-2B isolates as compared to PR-1 as well as 2 
nucleotide differences in the 5’UTR and 3 nucleotide differences in the 
variable region of the 3’UTR (Table 3.1).  
The results from Table 3.1 were then combined with the data from the 
SH test to identify the substitutions that were critical in the PR-1 and PR-2B 
segregation. These were in NS1, NS3, NS5 and 3’UTR (Table 3.1). There were 
2 amino acid changes in NS1 and NS3 while NS5 had a total of 6 amino acid 
substitutions. Within the 3’UTR, all PR-2B isolates had guanine and adenine 
at positions 10301 and 10331, respectively (Table 3.1). Twelve out of 
thirteen PR-2B isolates had cytosine at position 10389 (Table 3.1). In 
contrast, all PR-1 lineage viruses had adenine and guanine at positions 10301 
and 10331, respectively, while 92.3% of viruses studied had thymine at 
position10389 (Table 3.1). 
Collectively, these findings suggest that genetic differences in NS1, 
NS3, NS5 regions and the 3’UTR may have conferred greater epidemiological 




Table 3.1 Amino acid and nucleotide substitutions present in at 
least 25%of the PR-2B viruses. 
%: Percentages of viruses over total number of isolates in each clade 
bearing the substitutions. Regions identified by the SH test to be 
responsible for the segregation of PR-1 and PR-2B into two separate 
clades are highlighted in blue. Substitutions in these regions are likely 
to be significant for our study. 
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3.1.2 Viral isolates from the PR-2B clade produce less viral RNA and 
infectious particles at 24 hours p.i. but higher relative amounts of sfRNA  
Besides interacting with the viral RNA genome to form the replication 
complex, DENV NS1, NS3 and NS5 are known to downregulate the innate 
immune response (Ye et al., 2013). More recently, the 3’UTR of the DENV and 
other flaviviral genomes have also been shown to play a critical role in 
regulating the interferon response through the production of subgenomic 
flavivirus RNA (sfRNA) (Bidet et al., 2014; Schuessler et al., 2012). 
Pseudoknot structures in the 3’UTR are essential in sfRNA production as they 
prevent complete degradation of DENV RNA by the cellular XRN1 (Chapman 
et al., 2014b).  
To determine if the substitutions in PR-2B viruses might affect the 
structure and pseudoknot formation in the 3’UTR, we next constructed the 
3’UTR structure for the PR-1 viruses using a newly proposed model 
(Chapman et al., 2014a). Structural analysis showed that the first A-to-G 
substitution preceded stemloop (SL)-II and was positioned on a linear 
stretch of RNA (Figure 3.4). The other two 3’UTR substitutions found in PR-
2B isolates mapped to SL-II and SL-IV respectively (Figure 3.4). Remarkably, 
the G-to-A substitution at position 10331 was on the exact site where 
pseudoknot pk1 is predicted to form while the third substitution was on a 
side loop of SL-IV (Figure 3.4). Since two of the 3’UTR substitutions found in 
PR-2B isolates map to stemloops where pseudoknots are likely to form, we 
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tested for a possible role for sfRNA in modulating fitness in our viruses. 











































































































































































To measure viral fitness in vitro, we performed DENV infection assays 
in human hepatoma (HuH-7) cells. Cells were infected with each isolate for 
24 hours at a multiplicity of infection (MOI) of 0.1. After which, the culture 
supernatants were titrated by plaque assay and intracellular RNA levels were 
measured by quantitative RT-PCR (qRT-PCR), using a previously described 
method (Bidet et al., 2014). 
We expected PR-2B isolates to replicate more efficiently than PR-1 
viruses that they replaced in Puerto Rico. However, plaque assays performed 
on BHK-21 cells with culture supernatants at 24 hours post-infection (hpi) 
showed that the PR-1 viruses produced more viral progenies than the PR-2B 
viruses (Figure 3.5A). Likewise, DENV genomic RNA (gRNA) levels were 
significantly higher in cells infected with PR-1 compared to PR-2B viruses, a 
trend consistent with plaque titers (Figure. 3.5B). The degree of difference in 
sfRNA levels between PR-1 and PR-2B viruses was smaller although 
statistically significant (Figure 3.5C), resulting in PR-2B viruses having much 
higher sfRNA:gRNA ratios compared to PR-1 viruses (Figure 3.5D). 
Collectively, these findings suggest that PR-2B viruses produce at least 100 
fold more sfRNA relative to gRNA during replication. 
To validate the qRT-PCR findings, we used another published method 
to measure intracellular viral RNA levels (Lai et al., 2007). Results showed 
that the differences in the DENV genome copies between PR-1 and PR2B 
viruses diminished to below statistically significant levels (Figure 3.5E). This 
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was interesting and confirmed our findings that PR-2B viruses produce more 
sfRNA:gRNA as compared to PR-1, as this qPCR assay targeted the 3’UTR 





Figure 3.5 DENV infection assays in human hepatoma (HuH-7) cells 
Black boxes indicate the PR-1 viruses and blue boxes indicate the PR-2B 
isolates. (A) Plaque titers of PR-1 and PR-2B DENV-2 viruses at 24 hpi in 
HuH-7 cells infected at an MOI of 0.1. (B) PR-1 and PR-2B DENV-2 genomic 
RNA (gRNA) in infected HuH-7 cells (MOI = 0.1), 24 hpi. (C) PR-1 and PR-
2B DENV-2 sfRNA in infected HuH-7 cells (MOI = 0.1), 24 hpi. (D) Ratio of 
sfRNA:gRNA in HuH-7 cells infected with PR-1 and PR-2B viruses at MOI 
0.1, 24 hpi.(E) Quantification of DENV RNA in infected cells (MOI O.1, 24 







To further confirm that PR-2B isolates are indeed producing more 
sfRNA to gRNA, northern blot was performed on two isolates, one from each 
clade. Infection was carried out on HuH-7 cells at MOI 10 in triplicates and 
RNA was purified using Trizol reagent, before being subjected to northern 
hybridization. Quantification of the band intensity using ImageJ software 
yielded lower sfRNA:gRNA ratios which could be due to multiple reasons: 
Differences in assay type, MOI of infection, cell quantity, probe (radioactive 
probe versus Sybr green in qRT-PCR) etc. However, results attained were 
similar to qRT-PCR with the PR-2B virus producing a higher sfRNA:gRNA 
ratio as compared to the PR-1 virus (Figure 3.6). Collectively, these findings 
suggest that PR-2B viruses produce more sfRNA relative to gRNA during 
replication. 
  






Figure 3.6 Northern blot showing gRNA and sfRNA amounts HuH-7 cells were 
infected with one clinical isolate from each clade (MOI 10) at 24 hpi. Beta-actin was 
used as the background control. Experiments were repeated thrice and graph depicts 




3.1.3 Increased sfRNA:gRNA in Nicaraguan DENV-2  
Increased production of sfRNA relative to gRNA in an epidemic clade 
of viruses is not unique to the PR-2B viruses from Puerto Rico. Another 
DENV-2 clade replacement event was previously reported in Nicaragua that 
resulted in increased disease severity and hospitalization (OhAinle et al., 
2011).  
We applied the SH test to the full genome of these clinical isolates and 
similarly identified variations in NS1, NS5 and the 3’UTR that differentiate 
the viruses into clades NI-1 (endemic) and NI-2B (epidemic) (Figure 3.7). 
Comparison of the full genome tree with other regions of the genome 
resulted in p-values that were significant, confirming that they are not likely 
to have caused the NI-1 and NI-2B segregation seen in the full genome 
phylogenetic tree (Figure 3.8). 
Upon structural analysis of the 3’UTR, the first substitution was 
located before the start of SL-II, thus not likely to induce any conformational 
change in 3’UTR structure. In this case, the other two 3’UTR substitutions 
occur in SL-IV and predict that clade NI-2B SL-IV would be energetically 
more stable (Figure 3.9). The minimal free energy required for the SL-IV 






Figure 3.7 Phylogenetic trees of the whole genome, 3’UTR, NS1 and NS5 
regions of Nicaraguan DENV-2 isolates Major Nicaraguan clades are 
highlighted (black: Nicaraguan isolates from 2000-2001; purple: NI-1; green: NI-
2A; blue: NI-2B). NI-1 was the endemic clade while NI-2B was the epidemic clade 
that rapidly came into dominance replacing NI-1. NI-2A, similar to PR-2A, 
appeared to be an intermediate clade with very few viral isolates belonging to it. 
The p-values generated by the SH test are shown below each tree in brackets. 
This test statistic is the score difference between the Maximum Likelihood tree (full 
genome phylogenetic tree) and every other tree compared. Comparison with NS1, 
NS5 regions and the 3’UTR yield p-values that are not significant, indicating that 
they are good explanations of the dataset, which separates the viruses into NI-1 





Figure 3.8 Phylogenetic trees of the other genetic regions of Nicaraguan DENV-2 
isolates Major Nicaraguan clades are highlighted (black: Nicaraguan isolates from 2000-
2001; purple: NI-1; green: NI-2A; blue: NI-2B). The p-values generated by the SH test are 
shown below each tree in brackets. This test statistic is the score difference between the 
Maximum Likelihood tree (full genome phylogenetic tree) and every other tree compared. 
Comparison with 5’UTR, Capsid, prM (premembrane), Env (envelope), NS2A, NS2B, 
NS3, NS4A, and NS4B regions yield p-values that are significant, indicating that they are 
different from the full genome tree that separates the viruses into NI-1 and NI-2B clades. 









































































































































































































Analysis of the sfRNA:gRNA ratios indicated that 3 out of the 4 NI-2B 
viruses had a 3-4 fold higher sfRNA:gRNA ratio compared to the endemic NI-
1 viruses that they replaced in 2005-07 (Figure 3.10). Collectively, these data 
suggest that the increased production of sfRNA relative to gRNA levels may 















Figure 3.10 Quantification of sfRNA:gRNA ratios in HuH-7 
cells at 48 hpi with clinical isolates from Nicaragua NI-1, 
DENV-2 Asian-American genotype present in Managua, 
Nicaragua, through 2005. NI-2B: Clade that replaced NI-1, 





PR-2B DENV-2 replication 
is associated with  
reduced expression  
of IFN-β relative  
to PR-1 DENV-2. 




3.2.1 sfRNA suppresses type I interferon expression for greater 
replication rates in the later stages of infection  
The greater production of sfRNA relative to gRNA may confer 
selective advantage to PR-2B, leading to greater epidemiological fitness, by 
subverting the host innate immune responses through mechanisms that have 
yet to be fully defined (Bidet et al., 2014; Schuessler et al., 2012). Thus, we 
next compared the replication kinetics of selected PR-1 and PR-2B viruses at 
24 and 96 hpi and their effect on interferon expression. While the plaque 
titers of PR-2B isolates were significantly lower at 24 hpi, they grew at a 
faster rate than PR-1 viruses between 24 and 96 hpi such that no difference 
in viral titers was observed at 96 hpi (Figure 3.11). Interestingly, expression 
of interferon-beta (IFN-β) was significantly lower in HuH-7 cells infected 
with PR-2B compared with PR-1 DENV isolates throughout the course of 
infection (Figure 3.12), suggesting that the higher sfRNA:gRNA ratio 








Figure 3.11 Plaque titers following infection of HuH-7 cells with selected viruses 
from each clade at 24 and 96 hpi Lines in black depict the PR-1 viruses and the blue 








Figure 3.12 Expression levels of IFN-β in infected HuH-7 cells at various 
time-points p.i. Quantitative real-time PCR was used to detect expression 
levels of IFN-β, normalized to GAPDH. Black lines depict PR-1 isolates and blue 
lines indicate PR-2B viruses. 
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The trends observed in infection of HuH-7 cells were replicated in 
primary monocytes, which are target cells for DENV in humans. Infection 
with PR-2B isolates, using antibody-enhanced condition that is associated 
with greater risk of severe dengue, produced less gRNA (Figure 3.13A) and 
greater sfRNA:gRNA ratios (Figure 3.13B) compared to PR-1 viruses at 24 
hpi. Likewise, at 72 hpi, the plaque titers of PR-1 and PR-2B isolates were 
similar suggesting that PR-2B viruses caught up with PR-1 despite 
significantly lower gRNA levels at 24 hpi (Figure 3.13C). 
Similar to infection in HuH-7 cells, IFN-β expression in primary 
monocytes was reduced following infection with PR-2B as compared to PR-1 







Figure 3.13 Infection assays with selected viruses in primary monocytes (A) 
Quantification of DENV-2 gRNA at 24 hpi. Infection was carried out with selected PR-1 
and PR-2B DENV-2 viruses opsonized with enhancing concentrations of humanized 
3H5 monoclonal antibodies (B) Quantification of sfRNA:gRNA ratios in primary 
monocytes, 24 hpi. (C) Plaque titers from supernatant of infected primary monocytes 
at 72 hpi. (D) IFN-β expression in primary monocytes at 24 hpi. Data obtained in 





3.2.2 Replication of PR-1 viruses is rescued more significantly in IFN-
β deficient systems as compared to PR-2B  
The reduced IFN- expression in both HuH-7 and primary 
monocytes when infected with PR-2B compared to PR-1 viruses suggests 
that the higher sfRNA levels produced by PR-2B viruses downregulated 
the signaling that leads to type-I IFN expression. To test that possibility, 
we knocked down the expression of IRF3, which activates the 
transcription of IFN-β in response to viral infection. Indeed, silencing of 
IRF3 resulted in significantly increased replication of PR-1 but not PR-2B 
viruses (Figure 3.14A), suggesting that sfRNA from PR-2B acted upstream 
of IRF3 to downregulate IFN expression.  
To test this possibility further, infection assays were performed on 
African green monkey (Vero) cells. Both the IFN-α (Diaz et al., 1988) and 
IFN-β (Mosca and Pitha, 1986) genes are deleted in Vero cells, making 
them type-I interferon deficient. As such, infection of Vero cells would 
likely lead to a significant increase in replication for PR-1 viruses as 
compared to PR-2B since PR-2B viruses already have a mechanism that is 
able to downregulate interferon expression efficiently. 
As expected, an increase in plaque titers was noted for all viruses 
as they can replicate more efficiently in the absence of interferon. 
However, PR-1 DENV-2 produced significantly higher plaque titers at 96 
hpi in IFN-deficient Vero cells as compared to PR-2B viruses (Figure 
3.14B). These findings collectively suggest that PR-2B produce higher 
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sfRNA:gRNA ratios to suppress type-I IFN expression during replication 






Figure 3.14 Infection of IFN-deficient systems by PR-1 and PR-2B viruses (A) IRF3 
knockdown. Plaque titers of supernatant quantified at 24 hpi with selected viruses from 
each clade. Western blot was performed with antibodies against GAPDH and IRF3, 
respectively, to confirm knockdown. Sizes of respective proteins are as indicated. (B) 
Infection of Vero cells with selected isolates from both lineages. Plaque titers obtained 









Subgenomic flavivirus  
RNA attenuates Type I  
interferon antiviral  
response for increased 
replication. 
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3.3.1 Residues in the 3’UTR affect sfRNA levels and DENV replication  
Given the observed association between increased sfRNA:gRNA 
ratios and reduced IFN-β expression, we examined if the three nucleotide 
substitutions in the 3’UTR could functionally account for the increased 
sfRNA:gRNA ratios. To eliminate the possible contributions of the 
variations in NS1, NS3 and NS5, we performed mutagenesis studies using 
a previously characterized DENV-2 replicon reporter, pDENrep-FH 
(Holden et al., 2006) This reporter was originally derived from the DENV-
2 Thai 16681 viral isolate and has the structural genes replaced with 
Renilla luciferase.  
The nucleotides at the 3 positions of interest were substituted to 
match either the PR-1 or PR-2B viruses (Figure 3.15). At 72 hours post-
electroporation, replicons with residues found in the PR-2B clade (i.e. 
pDENrep-FH/PR2B/28nt, pDENrep-FH/PR2B/117nt and pDENrep-
FH/PR2B) produced less gRNA but higher ratios of sfRNA:gRNA 
compared to pDENrep-FH/PR1 which bears the PR-1 residues (Figure 
3.15A). Likewise, replicons with PR-2B residues also showed reduced 
replication rate as indicated by the luciferase activity (Figure 3.15B). 
These findings indicate that substitutions in these 3 nucleotide positions 
can account for the observed differences in sfRNA:gRNA ratios in PR-1 
and PR-2B viruses. They also suggest that DENV-2 is particularly sensitive 
to variations in this genomic location and that alterations in the sequence 
can directly influence the amount of gRNA and sfRNA produced by a 





Figure 3.15 Electroporation of HuH-7 cells with mutants bearing relevant residues (A) 
Quantification of gRNA levels and sfRNA:gRNA ratios in HuH-7 cells, 72 hours post-
electroporation with replicons bearing nucleotide residues representative of PR-1 or PR-2B 
DENV-2. Bars show the gRNA levels (left axis); while lines show sfRNA:gRNA ratios (right 
axis). (B) Luciferase reporter activity for the original replicon (pDENrep-FH) and mutated 
replicons at various time-points post-electroporation. Determination of firefly luciferase (FLuc) 






3.3.2 Subgenomic flavivirus RNA downregulates IFN-β gene 
expression 
To test whether sfRNA plays a functional role in modulating IFN-β 
expression, we co-transfected in vitro-transcribed PR-2B sfRNA or a size-
matched RNA control with pDENrep-FH into HuH-7 cells. As compared to 
NFB expression where no difference was seen, IFN-β expression was 
significantly reduced with sfRNA co-transfection at 72 hours post-
electroporation (Figure 3.16A). Correspondingly, pDENrep-FH replication 
was significantly increased with sfRNA co-transfection compared to co-
transfection with control RNA (Figure 3.16B).  
To investigate if sfRNA is able to downregulate IFN expression 
upon stimulation of the RIG-I signaling pathway, we co-transfected sfRNA 
or size-matched control RNA with polyinosinic-polycytidylic acid (polyIC). 
PolyIC, a ligand of RIG-I, is able to induce interferon response after 
transfection into cells, thus simulating infection with a RNA virus. 
Transfection efficiency was first tested and qRT-PCR confirmed that there 
was no difference in levels of sfRNA or CtrlRNA when transfected with 
polyIC (Figure 3.17A). Experimental data confirmed that transfection with 
polyIC induced expression of IFN-β in HuH-7 cells (Figure 3.17B). Upon 
co-transfection with sfRNA, a significantly reduced IFN-β expression was 
observed but no such reduction was seen in the presence of CtrlRNA 
(Figure 3.17B). Taken collectively, these data indicate that sfRNA 





Figure 3.16 Electroporation of sfRNA with DENV-2 replicon (A) Quantification 
of IFN-β and NFkB expression using qRT-PCR at 72 hours post-electroporation 
with either pDENrep-FH + sfRNA or pDENrep-FH + CtrlRNA. (B) Luciferase 
reporter activity (RLuc) for pDENrep-FH + sfRNA and pDENrep-FH + CtrlRNA at 
various time-points post-electroporation. Determination of firefly luciferase levels 








Figure 3.17 Co-transfection of sfRNA and PolyIC into HuH-7 cells (A) 
Validation of transfection efficiency upon transfection with sfRNA or size 
matched RNA control (Ctrl RNA) using qRT-PCR, 24 hours post-transfection 
with polyIC. Results show that there is no significant difference in transfection 
efficiency between the two RNAs (B) Quantification of IFN-β expression in 
HuH-7 cells transfected with PolyIC and sfRNA or CtrlRNA using qRT-PCR at 
24 hours post-transfection. Annotations as depicted: No PolyIC (with 
transfection reagent but no PolyIC), PolyIC (only PolyIC), Poly IC + sfRNA 
(with in vitro-transcribed sfRNA and PolyIC), PolyIC + Ctrl RNA (with size-









Subgenomic flavivirus  
RNA binds TRIM25  
to inhibit TRIM25 
de-ubiquitylation. 
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3.4.1 Mass spectrometry identified TRIM25 as a RNA-binding protein 
that binds better to PR-2B sfRNA than PR-1 sfRNA 
The suppression of IFN-β expression is likely to be due to specific 
sfRNA-protein interactions. We thus used stable isotope labeling by 
amino acids in cell culture followed by quantitative mass spectrometry 
(SILAC-qMS) to identify host proteins that bind preferentially to the 
proximal end of the 3’UTR (SL-II to SL-IV) of PR-1 or PR-2B viruses (Ward 
et al., 2014). Briefly, a tobramycin RNA aptamer was incorporated into 
RNAs containing the partial 3’UTRs (PR-1 or PR-2B) or a size-matched 
control cloned from the DENV-2 NS2A open reading frame (Ctrl) (Ward et 
al., 2011). RNA was bound to a tobramycin matrix, incubated with SILAC-
labeled cell lysates, washed and eluted using excess tobramycin. Eluates 
were then sent to the Quantitative Proteomics Laboratory, Institute of 
Molecular and Cellular Biology, Singapore for qMS analysis, thus allowing 
a direct comparison of proteins bound to the PR-1 3’UTR, PR-2B 3’UTR or 
control RNA.  
A total of 1199 proteins were detected, a majority of which were 
non-specific background binders that were pulled down with both control 
RNA and the 3’UTRs. To further analyse these results, the student t-test 
was performed on three replicate experiments to prioritize candidate 
binding partners. This was followed by multiple sampling correction 
using the Benjamini-Hochberg method (FDR). Upon analysis, 198 proteins 
were found to be enriched (at least 1.5 fold change) with DENV 3’UTR 
compared to control RNA indicating that they are interacting partners of 
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DENV 3’UTR (Appendix, Figure 3.18). Both volcano plots depict the 
specific interactome of PR-1 (Figure 3.18A) and PR-2B (Figure 3.18B) 
RNAs as compared to control RNA, thus only the significantly enriched 
proteins (with positive log2 fold change and p-value < 0.05) are 
important. Of note, in comparison to PR-1, more interacting partners of 
PR-2B were evident based on the filtering criteria (Figure 3.18). 
Notably, several of these proteins are known intermediates in the 
signaling pathway regulating type-I IFN expression (Figure 3.18C). Of 
these, the tripartite motif containing 25 (TRIM25) and mitochondrial 
antiviral signaling (MAVS) proteins were striking (Figure 3.18). Both 
proteins were significantly enriched in the presence of PR-2B 3’UTR as 
compared to PR-1. In addition, both TRIM25 and MAVS function directly 
upstream and downstream respectively of the viral RNA sensor, RIG-I, to 
regulate type I IFN expression, and are directly involved in host antiviral 





Figure 3.18 Plots derived from mass spectrometry showing the distribution 
of select RNA binding proteins Volcano plots displaying proteins enriched with 
partial 3’UTRs (sequence ranging from the start  of SL-II to the end of SL-IV) of 
PR-1 (A) or PR-2B (B) clades as compared to control RNA. Red dots represent 
significantly enriched proteins (with positive log2 fold changes). The 4 labeled 
proteins (TRIM25, MAVS, Mitogen-Activated Protein Kinase 1 - MAPK1, 
Peroxiredoxin 3 - PRDX3) were highlighted from our data to be involved in IFN-β 
signaling. Annotations as depicted: M/L (PR-1 3’UTR divided by control), H/L 
(PR-2B 3’UTR divided by control). (C) Dot plot highlighting the 32 proteins 
selected by the GO term finder to be involved in type I interferon response. 
Annotations as depicted: M/L (PR-1 3’UTR divided by control), H/L (PR-2B 3’UTR 
divided by control). Green dots show proteins with H/L and M/L ratios lower than 
1.5 (i.e. not significantly enriched). Purple dots show proteins with H/L and M/L 
ratios higher than 1.5 (i.e. significantly enriched in presence of both 3’UTRs) and 
the blue dots show proteins with H/L ratio higher than 1.5 but M/L ratio lower than 
1.5 (i.e. significantly enriched with PR-2B 3’UTR as compared to PR-1 3’UTR). 






To validate our SILAC-qMS findings for both TRIM25 and MAVS, 
we first immunoprecipitated TRIM25 or MAVS from cells infected with 
PR-2B virus or PR-1 virus and quantified the sfRNA and gRNA bound to 
either of these proteins. Significantly higher levels of sfRNA compared to 
gRNA were detected with TRIM25 immunoprecipitation as compared to 
immunoprecipitation using isotype IgG controls, with the difference being 
more pronounced when PR-2B DENV was used (Figure 3.19). On the 
other hand immunoprecipitation of MAVS from either DENV-2 infection 
did not enrich for either sfRNA or gRNA (Figure 3.20). This led us to focus 






Figure 3.19 Validation of TRIM25 binding by RNA-immunoprecipitation 
(RIP) RIP was performed on HuH-7 cells 24 hpi with 2 viruses, one from each 
clade (MOI 5). Infected cells were subjected to TRIM25 or anti-mouse IgG 
control pull-down followed by immunoblotting with TRIM25 to confirm efficacy of 
pull-down. Input: Cell lysate before RIP; Sup: Supernatant following incubation 
of antibody-coated beads with cell lysate; Pellet: Final product after washing. 
The two bar charts show qRT-PCR results measuring fold enrichment of sfRNA 







Figure 3.20 RNA-immunoprecipitation of MAVS RIP was performed as 
described above but pull-down was performed with MAVS or anti-rabbit IgG 
control. Input: Cell lysate before RIP; Sup: Supernatant following incubation of 
antibody-coated beads with cell lysate; Pellet: Final product after washing. The 
two bar charts show qRT-PCR results measuring fold enrichment of sfRNA 
and gRNA upon pull-down with MAVS. 
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3.4.2 PR-2B 3’UTR binds to TRIM25 more stably than PR-1, 
preventing its de-ubiquitylation 
TRIM25 is an E3 ligase that polyubiquitylates RIG-I for sustained 
and amplified signal transduction (Gack et al., 2007). TRIM25 is stabilized 
via de-ubiquitylation by the ubiquitin-specific peptidase 15 (USP15) 
(Pauli et al., 2014). To examine if sfRNA interferes with these processes, 
we immunoprecipitated TRIM25 from DENV-2 infected cell lysates and 
probed for ubiquitin. Results showed a band identical in size to TRIM25 
(about 71kDa) in lysates infected with either PR-1 or PR-2B virus (Figure 
3.21). This suggests the possibility that sfRNA interferes with the de-






Figure 3.21 Immunoprecipitation of TRIM25 upon viral infection Lysates 
from HuH-7 cells infected with 2 viruses, one from each clade (MOI 5). 
Infected cells were subjected to TRIM25 or anti-mouse IgG control pull-down 
followed by immunoblotting with TRIM25 and ubiquitin (UB). Input: Cell lysate 
before RIP; Sup: Supernatant following incubation of antibody-coated beads 





To confirm this possibility, we transfected HuH-7 cells with sfRNA 
or size-matched control RNA and immunoprecipitated RIG-I from the cell 
lysates. We next immunoblotted for TRIM25 and ubiquitin. Results 
showed that sfRNA did not prevent TRIM25 from binding RIG-I (Figure 
3.22). However, TRIM25 co-immunoprecipitated with RIG-I remained 
ubiquitylated as indicated by a specific band identical in size to TRIM25 
on the anti-ubiquitin immunoblot upon transfection of PR-2B but not PR-
1 sfRNA (Figure 3.22). This finding indicates that PR-2B sfRNA interferes 
with the de-ubiquitylation and hence activation of the enzymatic function 


















Figure 3.22 Immunoprecipitation of RIG-I after transfection of 
cells with sfRNA HuH-7 cell lysates, after transfection with PR-1 
sfRNA, PR-2B sfRNA or size-matched RNA control were subjected to 
RIG-I pull-down followed by immunoblotting with RIG-I, TRIM25 and 









4.1 Summary of findings 
The global and intense transmission of dengue virus (DENV) has 
led to increasing genetic diversity of this virus, some of which appear to 
be associated with epidemic dengue. However, the underlying mechanism 
of viral fitness in a natural epidemiological setting remains poorly 
defined. Here we conducted in vitro studies using low passage clinical 
isolates to identify a determinant of fitness in a foreign dominant DENV-2 
PR-2B clade, which emerged during the 1994 epidemic and replaced the 
endemic DENV-2 PR-1 clade in Puerto Rico. The PR-2B DENV-2 produced 
increased levels of sfRNA during replication to bind and inhibit de-
ubiquitylation of TRIM25, which is needed to activate its E3 ligase 
activity. The E3 ligase activity is critical for sustained and amplified RIG-I 
signaling. Without which, type-I interferon expression becomes 
attenuated. Our findings demonstrate a unique viral RNA-host protein 
interaction to evade the innate immune response for epidemiological 
fitness.  
  Until this study, the epidemic potential of dengue has mainly been 
attributed to two factors: host resistance due to a lowered herd immunity 
and viral genetics. The former explanation has been widely studied and 
reviewed elsewhere (Alvarez et al., 2006; Halstead et al., 2010; Halstead 
and O'Rourke, 1977; Kouri et al., 1989; Vaughn et al., 2000) although the 
mechanisms remain to be fully understood. The latter explanation is now 
backed by several epidemiological observations (Lee et al., 2012b; Messer 
et al., 2003; OhAinle et al., 2011; Steel et al., 2010; Vu et al., 2010) 
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although none of these studies provided a mechanistic explanation for 
how viral genomic variations gave rise to epidemiologically fitter virus.  
 Indeed, viral genetics plays an important role in the epidemiological 
fitness of many viruses. Genomic analysis of the Ebola viruses isolated in 
the 2014 outbreak, which is largest outbreak to date, showed a rapid 
accumulation of genetic variation in the viruses that could have resulted 
in increased transmission (Gire et al., 2014). During the 2009 influenza A 
outbreak, the H1NI virus was shown to have significant pandemic 
potential based on its high transmissibility (Glinsky, 2010). Clinical, 
epidemiological and genomic analysis further confirmed that the 
increased disease severity was associated with novel mutations in 
hemagglutinin gene of the virus (Glinsky, 2010).  
 That genomic factors can give rise to epidemiologically fitter virus 
suggests that viral surveillance programs could incorporate viral genome 
sequence data into its activities. Indeed, this suggestion has been made 
previously (Ooi and Gubler, 2009; Ooi, 2007). Genomic surveillance of 
DENV could aid early warning of impending epidemics to trigger earlier 
responses. Without which, most public health responses to epidemics are 
often “too little too late” (Gubler, 2001, 2011). However, not all genetic 
changes can result in dengue epidemics. Successful genomic surveillance 
must thus depend on a mechanistic understanding of which sequence 
variations are functionally important and how these give rise to 
epidemiologically fitter virus. Elucidating the underlying mechanisms 
behind genetic variations that occur in the constantly evolving DENV 
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could thus be useful for predicting epidemic emergence. This was the 
motivation of this thesis. 
The following discussion will first highlight the novel mechanism 
by which sfRNA modulates interferon expression through TRIM25 de-
ubiquitylation. Finally, the role of 3’UTR in flaviviral pathogenesis and 
other DENV epidemics where sfRNA might have contributed to the 
increased epidemiological fitness will be discussed.  
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4.2 sfRNA-mediated de-ubiquitylation of TRIM25 leads to 
increased DENV epidemiological fitness 
To our knowledge, this is the first report that provides a 
mechanism for increased DENV fitness and its epidemic potential. This is 
also the first finding that reports TRIM25 as an RNA binding protein.  
TRIM25 belongs to the tripartite motif (TRIM) protein family 
which is involved in various cellular processes such as antiviral defence 
and cell proliferation (Nisole et al., 2005). TRIM25 consists of a RING 
domain at the N-terminus followed by a B-box domain, a coiled-coil 
domain and a SPRY domain at the C-terminus (Nisole et al., 2005). The 
RING domain is a specialized zinc finger of 40-60 residues and appears to 
be mainly involved in protein-protein interactions. Interestingly the RING 
domains in most TRIM proteins, including TRIM25, have E3 ubiquitin 
(UB) ligase activity (Joazeiro and Weissman, 2000). 
E3 ubiquitin ligases are proteins that are primarily responsible for 
granting specificity to ubiquitin conjugation (Joazeiro and Weissman, 
2000). They recruit the E2 ubiquitin-conjugating enzyme, recognize the 
specific substrate and assist or directly catalyze the ubiquitin transfer 
from E2 to the protein substrate. Ubiquitylation is a potent targeting 
signal for protein degradation and as such, E3 ubiquitin ligases are of 
profound importance in cell biology and regulate diverse cellular 
processes such as cell trafficking and DNA repair. Indeed the E3 ligase 
activity of TRIM25 is required to elicit host antiviral innate immunity in 
mammalian cells (Gack et al., 2007). 
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In 2007, Gack et al showed that the SPRY domain of TRIM25 
interacts with the caspase recruitment (CARD) domain at the N-terminus 
to deliver Lys63-linked UB moiety to RIG-I (Gack et al., 2007). This 
induces robust ubiquitylation of RIG-I which results in a marked increase 
in its downstream signaling activity. Both RIG-I and MDA5 are cytosolic 
receptors for viral RNA. Upon viral RNA recognition, RIG-I interacts with a 
mitochondrial protein, MAVS to trigger downstream signal transduction.  
Briefly, activation of MAVS results its massive polymerization that 
recruits several TRAF proteins (Liu et al., 2013). The TRAF proteins then 
promote ubiquitylation that recruits NFκB essential modulator (NEMO) 
protein to the MAVS signaling complex which in turn, triggers the 
cytosolic kinases, IκB kinase (IKK) and TBK-1 (Liu et al., 2013). IKK and 
TBK-1 activate the transcription factors NFκB and IRF3 respectively, 
leading to the MAVS-mediated induction of Type I interferon (Liu et al., 
2013). Hence, through its interaction with RIG-I which stimulates 
downstream MAVS signaling, TRIM25 is critical for IFN-β production and 
antiviral activity after an RNA virus infection (Gack et al., 2007).  
More recently, the ubiquitin specific protease 15 (USP15) has been 
identified as a critical regulator of TRIM25 and RIG-I mediated antiviral 
immune response (Pauli et al., 2014). Since the Lys48-linked 
ubiquitylation of TRIM25 stimulates its proteosomal degradation, USP15 
de-ubiquitylates TRIM25. De-ubiquitylation of TRIM25 is therefore 
essential in preventing its degradation, leading to its stabilization which 
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ultimately promotes the RIG-I signaling pathway and leads to IFN-β 
production.  
That TRIM25 is the target of sfRNA is highly interesting as 
influenza virus also targets this important amplifier of RIG-I signaling 
(Gack et al., 2009). In the latter case, however, TRIM25 inhibition is 
mediated by protein-protein interaction through the influenza-encoded 
NS1 protein. Namely, a newly identified domain in the influenza NS1 
protein interacts with the coiled-coil domain of TRIM25 blocking its 
multimerization and RIG-I CARD ubiquitylation. Our findings reveal that 
subgenomic flavivirus RNA (sfRNA), a highly structured non coding RNA 
generated by members of the Flavivirus genus, interacts with TRIM25. Not 
only does this finding emphasize the vital role of TRIM25 in modulating 
viral infections, but it shows that reducing sustained and amplified IFN 
expression could be important to many viruses, as IFN renders uninfected 
cells resistant to viral infection.  
  Based on our findings, we propose a model to explain the 1994 
dengue outbreak in Puerto Rico that coincided with the emergence of PR-
2B viruses (Figure 4.1). The initial results showing lower replication of 
PR-2B viruses were unexpected and seemed incongruent to us initially, 
given the epidemiological outcome. Subsequent investigations revealed 
that these viruses “sacrifice” their gRNA for sfRNA to evade the innate 
immune response to achieve greater replication efficiency at the later 
stages of infection. The higher sfRNA:gRNA ratios could represent a 
“double whammy”: greater levels of sfRNA result in increased inhibition 
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of TRIM25 while reduced gRNA result in lower stimulation of RIG-
I/MDA5 RNA sensors. Reduced IFN response in the early stages of 
infection would ensure availability of susceptible cells for spread of the 
virus in a human host to reach viremia levels sufficient to infect mosquito 
vectors for further transmission. This is probably why the PR-2B viruses 






Figure 4.1 Proposed model depicting how sfRNA inhibits RIG-I signaling for 
amplified and sustained type I interferon response (A) Upon recognition of 
viral RNA, RIG-I recruits MAVS and starts a downstream signaling cascade that 
leads to IFN production. However, RIG-I needs to be ubiquitylated by TRIM25 
before it can facilitate IFN production and TRIM25 has to be de-ubitquitylated by 
USP15 before it can ubiquitylate RIG-I. (B) When PR-2B viruses infect cells, the 
increased amounts of sfRNA:gRNA produced and the 3’UTR substitutions in the 
sfRNA cause a more stable interaction of sfRNA with TRIM25. This prevents 
TRIM25 from de-ubiquitylation. TRIM25 is thus unable to ubiquitylate RIG-I, 
resulting in a reduced IFN response. PR-2B viruses are then able to replicate 
more efficiently over time and the infection can spread more easily as cells cannot 
attain an antiviral state. This likely leads to increased viremia in infected 




4.3 Role of 3’ noncoding RNA – Key to DENV pathogenesis? 
 The 3’ noncoding region, although deemed essential for replication 
and translation, has been largely ignored in flavivirus pathogenesis until 
recently when Khromykh’s laboratory and colleagues delved into the 
study of sfRNA (Alvarez et al., 2005; Friebe and Harris, 2010; Pijlman et 
al., 2008). Interestingly, findings indicate that sfRNA represents a pan-
flaviviral strategy employed to antagonize the host innate immune 
response. Indeed, sfRNA likely contributes to viral pathogenesis by acting 
on various pathways (Bidet and Garcia-Blanco, 2014; Roby et al., 2014). 
 Consistent with our present study, Schuessler et al. had reported that 
sfRNA contributes to viral evasion of the type I interferon response upon 
infection with another flavivirus, West Nile virus (Schuessler et al., 2012). 
However, in their study, the mechanism by which sfRNA acts to down-
regulate the type I interferon response was not determined. Another 
study had recently reported on the downregulation of interferon through 
profound inhibition of ISG translation by dengue sfRNA (Bidet et al., 
2014). Thus, sfRNA might target IFN through multiple mechanisms, 
highlighting the importance of IFN as a potent antiviral during DENV 
infection.  
 One interesting question that arises is: Is the phenotype observed 
due to the amounts of sfRNA produced by the PR-2B viruses or 




4.3.1 Amount of sfRNA produced 
Initial experiments indicated that the amounts of sfRNA:gRNA in 
infected cells played an undeniably important role in downregulating IFN 
(Figure 3.5). Production of sfRNA is determined by the pseudoknot 
formation in the 3’UTR (Chapman et al., 2014a; Chapman et al., 2014b). 
There are 3 nucleotide substitutions present on the 3’UTR of the PR-2B 
viruses (Figure 3.4): One was on the linear RNA before SL-II; the second 
substitution was in fact, on the site of the predicted pseudoknot formation 
and the last substitution was on the side loop of SL-IV. Based on the 
proximity of these residues to the site of pseudoknot formation on the 
3’UTR of the PR-2B viruses, it is possible that these residues may affect 
the pseudoknot strength or folding. If the pseudoknot is stronger, it will 
prevent complete degradation of the gRNA resulting in increased amounts 
of sfRNA. Likewise, if the folding is affected, the structures formed in the 
3’UTR might be less or more stable leading to less or more sfRNA 
formation respectively.  
Interestingly, the third substitution resided on SL-IV of the PR-2B 
3’UTR structure. That substitutions on SL-IV were also observed in 
Nicaraguan DENV-2 NI-2B clade of viruses (Figure 3.9) strengthens the 
likelihood that nucleotide sequences in this region also influence viral 
fitness through their ability to affect sfRNA levels. Similar observations 
have also been made for the related West Nile virus where it was shown 
that when the SL-II structure on 3’UTR is deleted, the secondary 
structures SL-IV and dumbbell 1 (DB1) downstream of SL-II were able to 
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prevent further degradation of gRNA leading to production of sfRNAs 
(Funk et al., 2010). Thus, we deem it likely that SL-IV of DENV-2 might be 
involved in some molecular interactions which might be modulating 
sfRNA levels although detailed structural studies are required to confirm 
this.  
4.3.2 Sequence of sfRNA produced 
A second possibility is that the sequence of the sfRNA may 
determine its interaction with target proteins and consequently its effect 
on host immune pathways. This was suggested by the mass spectrometry 
results that showed an increased enrichment of TRIM25 with PR-2B 
3’UTR as compared to PR-1 (Figure 3.20). Thus, PR-2B sfRNA binds to 
TRIM25 more stably than PR-1, indicating that the sequence of sfRNA 
produced by PR-2B plays a significant role in its modulation of the IFN 
response. Sequence variations in 3’UTR could lead to differential binding 
to other host RNA-binding proteins apart from TRIM25 which would then 
modify various pathways in cells (Refer to Appendix).  
 Indeed, sequence variations in the 3’UTR can directly lead to 
modifications to either the secondary structures (Chapman et al., 2014b) 
or binding affinities of individual residues. Such modifications can alter 
long-range viral RNA-RNA, viral RNA-viral protein and viral RNA-host 
RNA-binding protein interactions that regulate critical steps in DENV 
lifecycle. For instance, the nucleotide substitution on position 10389 of 
PR-2B is located on the side loop of SL-IV (Figure 3.4), where free 
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hydroxyl groups could potentially form hydrogen bonds with amino acids 
of interacting proteins. 
To conclude, it appears that both the amounts and sequences of 
sfRNA play a central role in its role during DENV infection although 
further testing is required to establish this idea. Collectively, our results 
demonstrate that the 3’UTR is important in flavivirus infections and 
cannot be ignored in interplay of viral genetics, pathogenesis and 
epidemiological fitness.  
4.4 Experimental limitations and alternative explanations 
Although this work addressed the question of epidemiological 
fitness of DENV-2 viruses as adequately as possible in vitro, it is 
regardless an in vitro system and not ideal. As these isolates were 
collected through passive virologic surveillance, no clinical data was 
collected systematically, which meant that we could not determine if 
sequence changes were associated with disease outcome as well. 
Likewise, the lack of an immunocompetent animal model that mimics 
systemic DENV infection in humans, meant that there was no ideal in vivo 
system that could be used to study if the pathogenesis processes were 
also different with isolates from each of these clades. The closest that we 
came to an “in vivo” system was the use of primary human monocytes 
isolated fresh from peripheral blood; monocytes are primary targets of 
DENV infection. However, while the findings from primary monocytes 
does shed light on the intracellular mechanisms that operate during 
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infection, it does not provide any indication on how the intercellular 
response may operate to cause disease.  
With regards to experimental setup, we utilized the DENV-2 
replicon to study replication. However, it is to be noted that this DENV-2 
replicon has a Thai 16681 DENV-2 backbone and is not of the same 
sequence as the Puerto Rican viruses. Although it could be used to study 
individual point mutations in the 3’UTR, it would have been better to 
either use a replicon with the same sequence as the PR viruses or 
construct infectious clones based on the PR-1 and PR-2B viruses. 
Furthermore, the main drawback of the replicon system is that only one 
round of replication could be studied as the replicon does not contain the 
structural genes that allow packaging, release and re-infection of cells. 
Hence we could not correlate the later timepoints of viral infection with 
the results from the replicon assay. On the other hand, with infectious 
clones, one could even swap the 3’UTRs and perform experiments to 
better correlate with the viral infection assay. 
The study of dengue epidemiological fitness would also benefit 
from understanding the how these viruses behave in the mosquito vector. 
This is a limitation of this study. It would be interesting to determine if 
sfRNA:gRNA levels play similar immunomodulatory roles in mosquitoes. 
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4.5 Future directions 
4.5.1 Role of 3’UTR in DENV epidemiological fitness – Further 
investigation warranted  
 The substitutions on 3’UTR leading to increased epidemiological 
fitness is unlikely to be unique to the 1994 DENV2 outbreak in Puerto 
Rico. Although the mechanism behind the increased sfRNA levels (Figure 
3.10) in the Nicaraguan isolates might be different from our findings, the 
fact that 3’UTR suggests that this region of the genome is important for 
epidemiological fitness. Besides the 1994 dengue outbreak in Puerto Rico, 
which is the focus of this thesis, there are other epidemiological studies 
that reported clade changes in DENV (Bennett et al., 2006; Messer et al., 
2003; OhAinle et al., 2011; Steel et al., 2010; Vu et al., 2010). In future, it 
would be riveting to perform similar experiments with viruses from these 
outbreaks to check if substitutions in the 3’UTR might have affected the 
viral epidemiological fitness (Bennett et al., 2006; Messer et al., 2003; 
OhAinle et al., 2011; Steel et al., 2010; Vu et al., 2010). 
 Historically, many DENV phylogenetic analyses conducted have 
largely excluded the non-coding 3’UTR sequences (Weaver and Vasilakis, 
2009). Our findings indicate that DENV genome sequence must include 
the 3’UTR as it could determine the epidemic potential of DENV. 
Determination of the conserved and dynamic regions of the 3’UTR during 




4.5.2 Deeper insights on the contribution of sfRNA to viral 
pathogenesis  
 What we found with regards to the mechanism behind sfRNA-
mediated de-ubiquitylation of TRIM25 is but the tip of the iceberg. In 
future, it would be critical to shed light on the following aspects: What 
determines the specificity of TRIM25 binding? Which domain of TRIM25 
does sfRNA bind? Which structures or residues on sfRNA are involved in 
this interaction? Does USP15 play an active role in the sfRNA-TRIM25 
interaction? Is MAVS involved in this binding? 
 Apart from the interaction with TRIM25, other RNA-binding proteins 
could also interact with sfRNA that determines the phenotype of the virus. 
These proteins may be involved in alternative sfRNA-mediated proviral 
interactions which could affect various immune pathways or cellular 
processes. Alternatively, the different sfRNAs from the other DENV 
serotypes and flaviviruses may contribute in various ways to virus-host 
interactions upon infection. Studying the interactome of sfRNA could thus 
shed light on important determinants of DENV pathogenesis. 
 Elucidating the fine details behind these interactions will be crucial in 
the future consideration of vaccine design. Upon understanding how 
sfRNA contributes to DENV pathogenesis, appropriate alterations could 
be made to various residues in the 3’UTR to attenuate a vaccine 




In conclusion, our study demonstrates a novel mechanism of 
sfRNA-mediated IFN downregulation through the de-ubiquitylation of an 
E3 ligase, TRIM25. The higher sfRNA:gRNA ratios produced in the early 
phase of PR-2B infection could represent a “one-two punch” against the 
host response: greater levels of sfRNA inhibit TRIM25, while reduced 
gRNA results in lower stimulation of RIG-I/MDA5 RNA sensors. Reducing 
IFN responses in the early stages of infection would ensure that the virus 
is able to spread to neighbouring cells more effectively allowing them to 
reach viremia levels sufficient to infect mosquito vectors for further 
transmission. Meanwhile, the PR-2B isolates are also likely to result in 
greater disease pathogenesis because of the higher viremia and sfRNA 
levels in infected cells. Thus, the more efficient transmission of PR-2B 
viruses as well as the greater dengue pathogenesis upon PR-2B infection 
might have contributed to the DENV-2 epidemic in Puerto Rico when this 
clade emerged in 1994.  
This study also demonstrates that by combining epidemiologic 
studies with molecular investigations, viral phylogenetic information 
could be informative not only on the virus origin but also potentially as a 
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1. Cell culture medium 
1.1 Fetal bovine serum (FBS) 
Heat-inactivate at 56°C for 30mins  
Aliquot into 50ml Falcon tubes.  
Store at -20°C till further use. 
 
1.2 C6/36 growth medium, 500ml 
5ml of Penicillin/Streptomycin (100x liquid, Gibco) 
40ml FBS 
Top up to 500ml with Leibovitz’s L-15 medium (Gibco) and filter-sterilize 
 
1.3 C6/36 maintenance medium, 500ml 
5ml of Penicillin/Streptomycin (100X liquid, Gibco) 
10ml FBS 
Top up to 500ml with Leibovitz’s L-15 medium (Gibco) and filter-sterilize 
 
1.4 HuH-7 growth medium, 500ml 
Add 40ml FBS. 
Top up to 500ml with Dulbecco’s modified eagle’s medium, DMEM (High 
glucose, Sodium pyruvate) (Gibco) and filter-sterilize 
 
1.5 HuH-7 growth medium, 500ml 
Add 10ml FBS. 
Top up to 500ml with Dulbecco’s modified eagle’s medium, DMEM (High 
glucose, Sodium pyruvate) (Gibco) and filter-sterilize 
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1.6 BHK-21 growth medium, 500ml 
5ml of L-glutamine (200nM, Gibco) 
5ml of sodium pyruvate (100mM, Gibco) 
5ml of Penicillin/Streptomycin (100X liquid, Gibco) 
50ml FBS 
Top up to 500ml with RPMI-1640 (Gibco) and filter-sterilize 
 
1.7 BHK-21 maintenance medium, 500ml 
5ml of L-glutamine (200nM, Gibco) 
5ml of sodium pyruvate (100mM, Gibco) 
5ml of Penicillin/Streptomycin (100X liquid, Gibco) 
10ml FBS 
Top up to 500ml with RPMI-1640 (Gibco) and filter-sterilize 
 
1.8 Vero growth medium, 500ml 
5ml of sodium pyruvate (100mM, Gibco) 
5ml of Non-essential amino acids (10mM, Gibco) 
50ml FBS 
Top up to 500ml with Medium-199 (Gibco) and filter-sterilize 
 
1.5 Vero maintenance medium, 500ml 
5ml of sodium pyruvate (100mM, Gibco) 
5ml of Non-essential amino acids (10mM, Gibco) 
10ml FBS 
Top up to 500ml with Medium-199 (Gibco) and filter-sterilize  
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2. Plaque assay 
2.1  0.8% methycellulose overlay 
(A) 2 x RPMI 
Dissolve RPMI-1640 powder (Gibco) in 500ml deionized water 
10ml sodium bicarbonate (7.5%, Gibco) 




(B) 1.6% carboxy-methyl cellulose (CMC) 
Dissolve 8g of CMC (Calbiochem) in deionized water 
Autoclave-sterilize at 121°C, 20min 
 
Add 1 part of 2X RPMI (A) to 1 part of 1.6% CMC (B) in 50ml Falcon tubes. 
Shake vigorously to mix. Store at 4°C. 
 
2.2  0.5% crystal violet in 25% formaldehyde 
5g crystal violet (Sigma) 
676ml 37% Formaldehyde 




3. Northern Hybridization 
3.1 10x MOPS buffer 
200 mM MOPS (Sigma) 
10mM sodium acetate  
10mM EDTA 
Ensure that the pH is 7.0 and store in a dark bottle. 
 
3.2 1% formaldehyde-agarose gel 
(A) Solution A 
1.5g agarose 
100ml DEPC-water 
Microwave until agarose is completely dissolved and incubate in a 55°C 
waterbath for 15min. 
 
(B) Solution B 
15ml 10x MOPS buffer 
24.3ml formaldehyde  
10.7ml DEPC-water 
 
Mix (B) with (A) and pour the mixture into a gel cast. 
 
3.3 Formamide buffer 
10ml formamide  
3.5ml formaldehyde  
2ml 10x MOPS buffer  
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3.4 Electrophoresis buffer 
100ml 10x MOPS buffer 
80ml formaldehyde  
820ml DEPC-water  
 
4. Western blot 
4.1 Lysis buffer for western blot 
4.383g sodium chloride 
5ml Nonidet-P40 buffer 
3.03g Tris 
Dissolve in 500ml with milli-Q water 
Adjust to pH 8.0 
Protease and phosphastase inhibitors (Sigma) added fresh at 1:100 
 
4.2 Lysis buffer for co-immunoprecipitation 
4.383g sodium chloride 
0.5ml Nonidet-P40 buffer 
3.03g Tris 
Dissolve in 500ml with milli-Q water 
Adjust to pH 8.0 





4.3 Immunoprecipitation buffer  
1.51g Tris 
4.383g sodium chloride 
Dissolve in 500ml with milli-Q water 
Adjust to pH 7.2 
 
4.4 10x SDS running buffer 
288g glycine 
60.4g Tris base 
20g SDS 
Dissolve in 2 liters with de-ionized water 
To use, dilute 1 in 10 to use at 1x SDS running buffer 
 









5.1 LIGHT media, K0R0 
500µl K0 (Sigma, L8662) 
500µL R0 (Sigma, A8094) 
50ml dialyzed FBS (Thermo, Research Instruments, Singapore) 
5ml of Penicillin/Streptomycin (100x liquid, Gibco) 
SILAC-DMEM (Thermo, Research Instruments, Singapore) 
Filter sterilize before use 
 
5.2 MEDIUM media, K4R6 
500µl K4 (Cambridge Isotope Laboratories, DLM-2640) 
500µL R6 (Cambridge Isotope Laboratories, CLM-2247) 
50ml dialyzed FBS (Thermo, Research Instruments, Singapore) 
5ml of Penicillin/Streptomycin (100x liquid, Gibco) 
SILAC-DMEM (Thermo, Research Instruments, Singapore) 
Filter sterilize before use 
 
5.3 HEAVY media, K8R10 
500µl K8 (Cambridge Isotope Laboratories, CNLM-291) 
500µL R10 (Cambridge Isotope Laboratories, CNLM-539) 
50ml dialyzed FBS (Thermo, Research Instruments, Singapore) 
5ml of Penicillin/Streptomycin (100x liquid, Gibco) 
SILAC-DMEM (Thermo, Research Instruments, Singapore) 
Filter sterilize before use
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Mass spectrometry results. List of RNA binding proteins identified after pull-down with DENV-2 3’UTR (SL-II to SL-IV section) as 
compared to control RNA. Gene names are indicated. L2, L4 and L6 are normalized readings from three separate experiments. Annotations as 




































CAPRIN1 0.765 0.766 0.764 -0.387 0.000 1.396 1.229 0.636 0.041 0.917 1.154 1.093 1.004 0.113 0.193 
PRKRA 0.802 0.795 0.799 -0.325 0.000 1.017 0.950 1.054 0.009 0.860 1.239 1.161 1.236 0.277 0.012 
SHMT2 1.145 1.141 1.139 0.191 0.000 1.408 1.497 1.687 0.610 0.015 1.287 1.292 1.333 0.383 0.002 
RPS11 0.896 0.897 0.892 -0.159 0.000 0.950 0.950 0.983 -0.057 0.072 1.060 0.996 1.021 0.036 0.303 
HARS 1.287 1.303 1.287 0.370 0.000 1.234 1.246 1.298 0.333 0.004 0.980 0.893 0.990 -0.069 0.285 
PDLIM1 1.503 1.473 1.503 0.578 0.000 1.870 1.656 1.847 0.839 0.004 1.108 1.120 1.141 0.167 0.006 
RARS 1.108 1.100 1.104 0.143 0.000 1.437 1.396 1.467 0.519 0.002 1.228 1.274 1.302 0.342 0.005 
AP3S1 0.758 0.762 0.747 -0.404 0.000 0.765 0.753 0.787 -0.381 0.002 0.845 0.927 0.897 -0.170 0.050 
RPL28 0.897 0.893 0.900 -0.157 0.000 1.119 0.965 1.081 0.074 0.370 1.249 1.066 1.101 0.184 0.119 
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RBMS1 2.404 2.505 2.345 1.273 0.000 0.947 1.043 0.974 -0.018 0.702 0.288 0.414 0.390 -1.475 0.012 
OTUD6B 0.832 0.821 0.832 -0.271 0.001 0.992 0.837 0.862 -0.160 0.168 1.019 1.073 1.017 0.051 0.179 
PRMT1 1.772 1.859 1.794 0.854 0.001 2.011 2.159 2.023 1.045 0.001 1.039 1.118 1.069 0.104 0.079 
RPL3 0.902 0.906 0.898 -0.149 0.001 1.184 1.208 1.472 0.358 0.070 1.371 1.385 1.379 0.463 0.000 
RDX 0.707 0.684 0.700 -0.521 0.001 0.648 0.585 0.651 -0.674 0.006 0.892 0.888 0.932 -0.146 0.023 
GLDC 1.279 1.306 1.277 0.364 0.001 1.510 1.375 1.468 0.536 0.006 1.082 1.067 1.148 0.136 0.053 
ESYT1 1.277 1.294 1.310 0.371 0.001 0.785 1.221 0.734 -0.169 0.540 0.578 0.670 0.519 -0.772 0.019 
ABCE1 0.943 0.946 0.941 -0.084 0.001 1.223 1.201 1.122 0.240 0.024 1.297 1.259 1.144 0.301 0.031 
EIF3E 0.924 0.925 0.931 -0.110 0.001 0.856 0.904 0.892 -0.178 0.018 0.930 0.948 0.939 -0.091 0.007 
UFM1 0.732 0.755 0.742 -0.429 0.001 0.439 0.412 0.358 -1.317 0.004 0.507 0.494 0.484 -1.015 0.000 
DDX6 2.711 2.453 2.608 1.372 0.001 2.394 2.398 2.642 1.308 0.001 0.913 0.917 0.990 -0.090 0.139 
RPS23 0.901 0.910 0.908 -0.141 0.001 0.883 0.894 0.903 -0.162 0.003 0.999 0.976 0.917 -0.054 0.282 
HDLBP 0.746 0.758 0.734 -0.423 0.001 0.753 0.712 0.678 -0.487 0.008 0.917 0.970 0.953 -0.080 0.079 
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HSPA5 0.942 0.943 0.948 -0.083 0.001 0.706 0.712 0.663 -0.529 0.004 0.701 0.792 0.717 -0.442 0.015 
WARS 1.491 1.560 1.493 0.599 0.001 1.264 1.173 1.290 0.312 0.017 0.852 0.763 0.869 -0.275 0.043 
RPL6 0.841 0.852 0.834 -0.247 0.001 1.280 1.089 1.220 0.255 0.066 1.638 1.239 1.429 0.512 0.048 
YTHDF1 0.842 0.859 0.847 -0.236 0.001 0.822 0.899 0.879 -0.208 0.033 1.015 0.991 0.958 -0.018 0.536 
MYO1E 1.269 1.306 1.274 0.359 0.001 1.532 1.439 1.707 0.637 0.013 1.427 1.695 1.387 0.582 0.023 
RPS4X 0.877 0.875 0.862 -0.199 0.001 1.157 1.132 1.069 0.162 0.041 1.332 1.221 1.180 0.313 0.026 
HNRPDL 1.568 1.564 1.491 0.624 0.001 1.363 1.582 1.600 0.596 0.015 0.961 1.034 1.043 0.017 0.691 
RPL18 0.861 0.870 0.877 -0.202 0.001 1.177 1.086 1.045 0.139 0.111 1.395 1.214 1.159 0.324 0.056 
SNRPA 1.147 1.166 1.168 0.214 0.002 1.620 1.982 1.966 0.886 0.011 1.333 1.446 1.594 0.540 0.019 
DNM2 1.141 1.122 1.127 0.176 0.002 0.615 0.523 0.520 -0.860 0.008 0.508 0.508 0.540 -0.948 0.001 
RBX1 1.436 1.390 1.459 0.514 0.002 0.803 0.838 0.851 -0.268 0.009 0.582 0.608 0.560 -0.778 0.002 
HNRNPU 1.234 1.200 1.222 0.285 0.002 1.002 1.146 1.196 0.153 0.186 0.890 0.920 0.849 -0.175 0.035 
S100P 1.489 1.529 1.445 0.573 0.002 0.804 1.011 0.979 -0.110 0.399 0.510 0.631 0.532 -0.848 0.012 
178 
 
IST1 1.127 1.132 1.147 0.183 0.002 1.103 0.962 0.830 -0.062 0.655 1.053 0.943 0.862 -0.075 0.462 
HMGB1 1.251 1.294 1.284 0.352 0.002 1.897 1.618 1.759 0.811 0.007 1.382 1.360 1.217 0.398 0.020 
SSBP1 1.701 1.628 1.586 0.712 0.002 0.819 0.930 0.961 -0.151 0.165 0.463 0.545 0.532 -0.966 0.006 
ADRBK1 0.815 0.812 0.792 -0.310 0.002 0.944 0.893 0.914 -0.125 0.032 1.121 1.030 1.105 0.117 0.089 
SND1 0.777 0.770 0.747 -0.387 0.002 1.030 0.965 0.982 -0.012 0.712 1.258 1.252 1.270 0.333 0.000 
VASP 0.512 0.520 0.561 -0.914 0.002 0.166 0.272 0.174 -2.332 0.009 0.236 0.329 0.276 -1.849 0.006 
NUDT21 0.731 0.742 0.764 -0.424 0.002 1.289 1.209 1.206 0.303 0.010 1.610 1.580 1.412 0.615 0.009 
ARSB 1.338 1.400 1.351 0.446 0.002 1.033 1.011 1.008 0.025 0.166 0.732 0.742 0.704 -0.462 0.003 
LRRC47 0.813 0.830 0.803 -0.295 0.002 0.517 0.458 0.504 -1.023 0.003 0.617 0.609 0.652 -0.677 0.002 
PTMS 0.789 0.766 0.794 -0.353 0.002 0.139 0.236 0.189 -2.444 0.008 0.184 0.273 0.194 -2.228 0.006 
GSDMD 1.496 1.530 1.602 0.625 0.002 1.993 2.207 2.218 1.095 0.002 1.270 1.329 1.304 0.379 0.002 
MAGEB1 0.810 0.806 0.831 -0.294 0.002 0.950 0.961 0.774 -0.167 0.242 1.241 1.445 1.066 0.312 0.133 
DNAJB1 0.818 0.836 0.842 -0.265 0.002 0.972 1.039 1.045 0.026 0.514 1.166 1.149 1.155 0.210 0.001 
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UBL5 0.928 0.938 0.929 -0.103 0.002 0.899 0.869 0.903 -0.168 0.011 0.883 0.937 0.921 -0.131 0.036 
SRSF3 0.777 0.781 0.750 -0.379 0.002 0.715 0.728 0.732 -0.464 0.000 0.840 0.895 0.876 -0.201 0.018 
KARS 1.229 1.277 1.251 0.324 0.002 1.368 1.314 1.421 0.451 0.005 1.026 1.093 1.059 0.083 0.089 
SERPINH
1 1.382 1.316 1.334 0.426 0.002 1.512 1.555 1.325 0.547 0.017 0.996 1.006 0.964 -0.017 0.466 
MAP1A 0.825 0.819 0.797 -0.298 0.002 0.507 0.527 0.441 -1.029 0.006 0.634 0.681 0.706 -0.571 0.006 
YTHDF3 0.869 0.867 0.886 -0.194 0.002 0.861 0.937 0.724 -0.258 0.142 0.932 1.087 0.792 -0.106 0.506 
PRMT3 1.442 1.512 1.543 0.583 0.002 1.016 1.421 0.971 0.163 0.447 0.980 0.912 0.895 -0.108 0.113 
FARSA 1.150 1.126 1.130 0.183 0.002 1.240 1.151 1.219 0.266 0.015 1.116 0.981 1.029 0.058 0.400 
SPTBN2 1.358 1.298 1.357 0.419 0.003 1.626 1.467 1.494 0.611 0.006 1.428 1.233 1.144 0.337 0.070 
GSTK1 1.171 1.160 1.193 0.232 0.003 0.947 0.920 0.966 -0.083 0.056 0.739 0.786 0.773 -0.385 0.005 
RBMS2 3.069 3.282 2.701 1.589 0.003 1.085 1.142 1.147 0.169 0.022 0.251 0.336 0.358 -1.684 0.009 
EIF3K 0.945 0.954 0.947 -0.076 0.003 0.760 0.875 0.847 -0.276 0.046 0.731 0.867 0.833 -0.308 0.054 
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CCT6A 1.067 1.073 1.081 0.102 0.003 1.293 1.367 1.344 0.416 0.003 1.211 1.218 1.185 0.269 0.002 
TPT1 0.677 0.625 0.647 -0.622 0.003 0.576 0.587 0.576 -0.787 0.000 0.810 1.000 0.844 -0.183 0.188 
HNRNPR;
HNRPR 0.874 0.883 0.895 -0.178 0.003 0.883 0.804 1.007 -0.161 0.229 0.909 0.952 1.251 0.038 0.814 
HSD17B4 0.650 0.672 0.701 -0.570 0.003 0.772 0.528 0.787 -0.547 0.101 0.931 0.781 0.752 -0.290 0.093 
YTHDF2 0.841 0.830 0.858 -0.246 0.003 0.786 0.968 0.775 -0.254 0.134 0.960 1.138 0.981 0.033 0.710 
EEF1A1;E
EF1A1P5 0.896 0.910 0.912 -0.142 0.003 0.880 0.877 0.998 -0.126 0.176 1.011 0.988 1.123 0.055 0.433 
A1CF 0.806 0.810 0.836 -0.291 0.003 0.931 0.996 1.032 -0.021 0.673 1.151 1.155 1.158 0.207 0.000 
SNX5 1.485 1.578 1.620 0.641 0.003 1.809 1.943 1.992 0.936 0.002 1.085 1.111 1.180 0.169 0.042 
GLT25D1 1.254 1.297 1.318 0.367 0.003 2.020 1.810 1.731 0.887 0.006 1.523 1.398 1.318 0.496 0.015 
EPB41L2 1.232 1.189 1.228 0.282 0.003 1.337 1.386 1.346 0.439 0.001 1.009 1.019 0.942 -0.016 0.699 
NHP2L1 0.699 0.746 0.730 -0.465 0.003 1.196 1.021 1.270 0.211 0.154 1.441 1.236 1.550 0.488 0.037 
181 
 
LDHA 1.155 1.165 1.191 0.226 0.003 0.925 1.003 1.011 -0.031 0.533 0.802 0.829 0.799 -0.305 0.003 
RPL21 0.875 0.894 0.894 -0.172 0.004 1.044 0.961 1.000 0.002 0.964 1.195 1.083 1.015 0.131 0.195 
IGF2BP2 0.913 0.924 0.929 -0.117 0.004 0.821 0.831 0.771 -0.309 0.012 0.794 0.837 0.800 -0.304 0.006 
SYNCRIP 0.799 0.830 0.827 -0.289 0.004 0.856 0.831 0.959 -0.184 0.100 1.102 1.041 1.101 0.112 0.054 
LMO7 1.458 1.520 1.404 0.546 0.004 1.787 1.701 1.915 0.847 0.003 1.143 1.282 1.252 0.292 0.029 
AP2S1 1.163 1.203 1.175 0.239 0.004 1.388 1.303 1.811 0.570 0.059 1.134 0.977 1.246 0.155 0.270 
MCM3 1.121 1.096 1.108 0.148 0.004 1.422 1.465 0.662 0.155 0.720 1.071 1.237 0.570 -0.135 0.732 
EEF1G 1.223 1.229 1.276 0.313 0.004 1.065 1.344 0.977 0.161 0.362 0.791 0.948 0.772 -0.263 0.106 
EEF1E1 1.145 1.166 1.183 0.220 0.004 1.168 1.250 1.308 0.311 0.023 0.934 0.984 1.078 -0.005 0.946 
RPL32 0.888 0.862 0.873 -0.194 0.004 1.220 1.185 1.245 0.283 0.005 1.303 1.277 1.202 0.333 0.011 
BRK1 1.162 1.201 1.167 0.234 0.004 0.984 0.981 1.047 0.005 0.884 0.893 0.882 0.810 -0.216 0.040 
AP3D1 0.757 0.790 0.797 -0.356 0.004 0.878 0.785 1.122 -0.124 0.501 1.055 0.974 1.234 0.114 0.372 
STAT2 0.773 0.815 0.793 -0.334 0.004 0.898 0.994 0.855 -0.130 0.180 1.133 1.205 1.065 0.180 0.073 
182 
 
ARPC1A 1.425 1.557 1.534 0.589 0.004 1.383 1.608 1.326 0.520 0.025 0.939 0.944 0.933 -0.091 0.003 
PPP1R14
A 0.567 0.583 0.512 -0.854 0.004 0.179 0.168 0.184 -2.496 0.000 0.229 0.266 0.343 -1.861 0.008 
HDAC6 0.748 0.784 0.736 -0.404 0.005 0.415 0.504 0.349 -1.259 0.014 0.670 0.743 0.400 -0.776 0.106 
BCCIP 1.272 1.257 1.210 0.318 0.005 1.249 1.091 1.186 0.231 0.056 0.781 1.061 0.929 -0.126 0.429 
RPL19 0.876 0.900 0.894 -0.168 0.005 1.453 0.894 1.145 0.191 0.444 1.627 1.113 1.279 0.404 0.128 
HIST1H3A 0.662 0.593 0.610 -0.687 0.005 0.897 0.815 1.144 -0.086 0.614 1.178 1.284 1.850 0.495 0.132 
PSMA3 1.161 1.192 1.150 0.223 0.005 0.924 1.019 1.059 -0.001 0.983 0.735 0.811 0.821 -0.344 0.021 
GLUL 0.729 0.740 0.687 -0.477 0.005 0.905 0.901 0.841 -0.182 0.034 1.271 1.206 1.169 0.280 0.015 
RPL18A 0.873 0.854 0.883 -0.201 0.005 1.172 1.090 1.039 0.136 0.114 1.241 1.185 1.167 0.260 0.010 
DHX9 0.890 0.871 0.896 -0.175 0.005 0.999 1.012 0.993 0.002 0.842 1.065 1.158 1.118 0.154 0.048 
EIF5 0.989 0.986 0.986 -0.019 0.005 0.660 0.705 0.809 -0.470 0.032 0.707 0.755 0.891 -0.358 0.069 
HNRNPM 1.283 1.216 1.270 0.329 0.005 1.803 1.941 2.221 0.986 0.008 1.264 1.398 1.547 0.483 0.029 
183 
 
EIF4B 0.624 0.560 0.625 -0.732 0.005 0.156 0.063 0.125 -3.226 0.015 0.152 0.077 0.125 -3.135 0.008 
MCM6 1.601 1.710 1.830 0.775 0.005 1.115 1.229 1.838 0.444 0.182 0.709 0.632 0.640 -0.601 0.008 
EPB41L5 1.642 1.652 1.489 0.672 0.005 1.399 1.617 1.523 0.595 0.010 0.844 1.154 1.080 0.025 0.874 
TMEM189
;UBE2V2;
UBE2V1 1.141 1.156 1.119 0.187 0.005 0.897 1.074 0.986 -0.025 0.773 0.884 1.209 1.071 0.065 0.672 
LSM12 1.722 2.005 1.947 0.916 0.005 0.621 0.760 0.757 -0.495 0.036 0.350 0.455 0.342 -1.400 0.009 
SWAP70 0.882 0.864 0.850 -0.209 0.005 0.957 0.972 1.131 0.024 0.780 1.069 1.031 1.621 0.279 0.314 
TUFM 0.699 0.740 0.678 -0.503 0.005 0.507 0.526 0.518 -0.952 0.000 0.718 0.761 0.735 -0.439 0.003 
PSMB1 1.126 1.165 1.154 0.199 0.005 0.881 1.166 1.021 0.023 0.863 0.776 0.996 0.755 -0.259 0.179 
TUBB4B 1.089 1.079 1.103 0.125 0.005 1.140 1.136 1.054 0.150 0.055 0.935 0.989 0.933 -0.071 0.122 
RNASET2 1.312 1.422 1.385 0.456 0.006 1.159 1.117 1.200 0.212 0.019 0.771 0.771 0.749 -0.389 0.001 




KR1C2 1.417 1.416 1.317 0.467 0.006 1.388 1.515 1.239 0.461 0.032 0.994 0.987 0.911 -0.054 0.310 
AHNAK 0.545 0.515 0.458 -0.986 0.006 0.143 0.088 0.193 -2.897 0.013 0.224 0.167 0.350 -2.085 0.022 
POLR1C 1.336 1.426 1.453 0.490 0.006 1.508 1.708 1.927 0.771 0.017 1.180 1.392 1.200 0.326 0.050 
MSN 1.215 1.208 1.269 0.299 0.006 0.843 0.840 0.877 -0.229 0.008 0.636 0.660 0.690 -0.596 0.003 
NUMB;NU
MBL 1.177 1.204 1.153 0.236 0.006 1.119 1.066 1.295 0.209 0.131 1.012 1.145 0.965 0.054 0.540 
EFTUD2 0.887 0.910 0.888 -0.160 0.006 1.488 1.607 1.487 0.610 0.004 1.608 1.755 1.632 0.735 0.003 
SPTAN1 1.326 1.362 1.440 0.460 0.006 1.699 1.773 1.494 0.723 0.010 1.219 1.375 1.073 0.282 0.112 
KIAA1033 0.745 0.777 0.719 -0.422 0.006 0.904 0.957 0.895 -0.123 0.056 1.236 1.326 1.182 0.318 0.022 
PFKM 1.376 1.439 1.321 0.462 0.006 2.147 1.957 2.201 1.070 0.002 1.504 1.385 1.566 0.569 0.008 
ADAT3 1.573 1.439 1.605 0.620 0.006 1.297 1.709 2.257 0.774 0.079 0.815 1.287 1.256 0.132 0.600 
PROSC 0.789 0.756 0.732 -0.398 0.006 0.712 0.767 0.733 -0.440 0.005 0.914 0.956 1.007 -0.062 0.264 
185 
 
EIF2AK2 0.728 0.749 0.786 -0.407 0.006 0.682 0.741 0.830 -0.418 0.037 0.906 0.928 1.059 -0.056 0.510 
EHHADH 0.812 0.761 0.775 -0.354 0.006 1.004 0.896 0.918 -0.092 0.204 1.171 1.241 1.107 0.229 0.041 
CORO1C 1.400 1.534 1.550 0.578 0.006 1.168 1.333 1.282 0.333 0.028 0.889 0.800 0.852 -0.241 0.032 
SUPT4H1 1.394 1.345 1.284 0.423 0.007 1.095 1.325 1.257 0.289 0.072 0.781 0.912 0.824 -0.256 0.060 
TUBB4A 1.156 1.190 1.142 0.217 0.007 1.235 0.929 1.139 0.129 0.402 0.951 0.722 1.023 -0.170 0.382 
CLIC1 0.894 0.894 0.917 -0.149 0.007 2.177 2.553 3.084 1.366 0.011 2.615 2.844 2.829 1.465 0.001 
ASCC3 0.568 0.530 0.471 -0.939 0.007 0.509 0.299 0.311 -1.468 0.027 1.022 0.598 0.671 -0.429 0.210 
NCL 1.148 1.145 1.110 0.181 0.007 1.040 1.168 1.038 0.112 0.187 0.824 0.905 0.851 -0.219 0.031 
NARS 0.889 0.881 0.856 -0.193 0.007 0.856 0.830 0.864 -0.234 0.005 0.960 0.937 1.003 -0.049 0.227 
RPS15A 0.925 0.901 0.905 -0.135 0.007 0.959 1.017 1.008 -0.008 0.780 1.028 1.078 1.036 0.066 0.090 
TRA2B 0.804 0.745 0.778 -0.367 0.007 1.788 1.676 1.887 0.833 0.003 1.977 2.136 2.032 1.034 0.001 
SRGAP1;
SRGAP2 1.528 1.366 1.464 0.537 0.008 1.832 1.477 1.798 0.761 0.017 0.715 1.052 0.973 -0.150 0.471 
186 
 
ACACA 1.688 1.534 1.479 0.646 0.008 1.408 1.139 1.187 0.310 0.080 0.929 0.748 0.851 -0.252 0.108 
FOCAD 0.836 0.793 0.835 -0.284 0.008 0.695 0.605 0.826 -0.508 0.059 0.914 0.844 1.067 -0.094 0.445 
RPS27 0.879 0.872 0.843 -0.210 0.008 1.028 0.973 0.868 -0.068 0.444 1.132 0.996 0.981 0.049 0.535 
IGF2R 1.162 1.128 1.119 0.184 0.008 0.926 0.823 0.759 -0.263 0.087 0.816 0.826 0.688 -0.369 0.049 
TARS 1.260 1.184 1.227 0.291 0.008 1.187 1.208 1.297 0.298 0.017 0.904 1.028 1.036 -0.019 0.798 
TPRKB 1.126 1.164 1.175 0.208 0.008 0.949 1.038 1.123 0.048 0.562 0.812 0.773 0.879 -0.286 0.034 
FERMT2 1.134 1.157 1.188 0.213 0.008 1.233 1.331 1.472 0.424 0.029 1.169 1.225 1.285 0.294 0.018 
RPS6 0.884 0.883 0.851 -0.197 0.008 0.999 1.018 1.046 0.030 0.255 1.121 1.127 1.169 0.188 0.010 
EIF1 0.861 0.814 0.830 -0.261 0.008 0.813 0.803 0.774 -0.328 0.004 0.830 0.917 0.912 -0.176 0.063 
RPS27A;U
BC;UBB;U
BA52 0.872 0.851 0.828 -0.234 0.008 0.937 0.865 0.645 -0.312 0.197 0.974 1.010 0.903 -0.057 0.354 
RPL15 0.869 0.880 0.841 -0.212 0.008 1.235 1.123 1.093 0.200 0.065 1.412 1.190 1.188 0.332 0.057 
187 
 
MAPK1 1.203 1.278 1.283 0.327 0.008 1.630 1.733 1.810 0.785 0.003 1.348 1.274 1.367 0.410 0.006 
ACOX3 1.427 1.447 1.604 0.575 0.008 1.946 1.662 1.596 0.789 0.012 1.274 1.166 1.091 0.233 0.070 
MCM4 1.576 1.727 1.488 0.673 0.009 1.263 1.270 1.281 0.346 0.000 0.755 0.757 0.796 -0.379 0.004 
RPL31 0.913 0.882 0.901 -0.154 0.009 1.094 1.097 1.000 0.087 0.184 1.136 1.149 1.125 0.185 0.002 
STRAP 0.723 0.685 0.761 -0.469 0.009 0.331 0.372 0.417 -1.428 0.004 0.486 0.528 0.511 -0.978 0.001 
NXT2;NXT
1 1.133 1.108 1.153 0.178 0.009 1.197 0.987 1.179 0.159 0.217 0.941 0.905 0.954 -0.100 0.049 
DARS;DK
FZp781B1
1202 1.093 1.119 1.087 0.137 0.009 1.188 1.234 1.330 0.321 0.021 1.108 1.086 1.195 0.175 0.053 
MOV10 0.913 0.907 0.884 -0.149 0.009 1.009 1.016 1.031 0.027 0.107 1.040 1.113 1.131 0.130 0.073 
COMMD3 1.286 1.257 1.198 0.318 0.009 1.076 1.053 1.072 0.093 0.010 0.715 0.771 0.765 -0.415 0.007 
DYNC1LI1 1.282 1.385 1.411 0.442 0.009 2.741 2.705 4.207 1.654 0.016 1.971 2.077 2.823 1.177 0.018 
PPA2 1.294 1.397 1.283 0.404 0.009 0.849 1.805 1.250 0.313 0.425 0.637 1.205 0.866 -0.196 0.536 
188 
 
SNX2 1.412 1.573 1.615 0.614 0.009 1.706 1.534 1.538 0.669 0.006 1.168 1.031 0.949 0.064 0.539 
EIF3I 0.940 0.930 0.917 -0.106 0.009 0.816 0.867 0.812 -0.267 0.012 0.879 0.876 0.868 -0.194 0.001 
RPL9 0.920 0.918 0.894 -0.135 0.009 1.138 1.095 1.121 0.160 0.010 1.189 1.103 1.141 0.194 0.026 




1C 0.831 0.877 0.855 -0.228 0.010 1.457 1.348 1.358 0.472 0.006 1.512 1.435 1.334 0.511 0.010 
RPS7 0.890 0.921 0.897 -0.148 0.010 0.912 0.914 0.906 -0.135 0.001 0.994 0.926 0.936 -0.072 0.151 
PRDX3 1.659 1.575 1.879 0.765 0.010 2.174 2.083 2.310 1.129 0.001 1.249 1.284 1.132 0.287 0.035 
S100A11 1.876 1.731 1.559 0.780 0.010 2.753 3.119 3.143 1.585 0.002 1.623 1.680 1.942 0.802 0.010 
HIST1H4A 0.535 0.433 0.416 -1.125 0.010 0.882 0.907 0.919 -0.148 0.013 1.664 1.883 2.597 1.008 0.034 
RPL8 0.908 0.888 0.871 -0.170 0.010 1.293 1.346 1.248 0.373 0.007 1.361 1.406 1.373 0.464 0.001 
TARDBP 0.653 0.739 0.705 -0.518 0.010 0.961 0.868 2.831 0.413 0.528 1.278 1.251 3.617 0.844 0.237 
189 
 
HNRNPA3 1.138 1.189 1.199 0.233 0.010 1.904 2.150 1.978 1.006 0.003 1.467 1.568 1.361 0.549 0.011 
CLINT1 1.343 1.455 1.309 0.451 0.010 1.191 1.111 1.095 0.178 0.041 0.819 0.775 0.729 -0.371 0.017 
CORO1B 1.186 1.160 1.126 0.210 0.010 0.758 0.700 0.684 -0.487 0.008 0.689 0.524 0.465 -0.858 0.036 
PCBD1 1.504 1.733 1.507 0.658 0.010 1.019 1.219 1.199 0.192 0.146 0.668 0.698 0.747 -0.507 0.008 
PDCD4 0.779 0.830 0.766 -0.338 0.011 0.792 0.679 0.769 -0.425 0.025 1.045 0.828 0.900 -0.120 0.346 
GRWD1 0.809 0.757 0.818 -0.332 0.011 0.581 0.538 0.621 -0.789 0.006 0.708 0.702 0.784 -0.454 0.012 
HSPB1 0.669 0.753 0.677 -0.518 0.011 0.396 0.432 0.292 -1.440 0.014 0.528 0.627 0.494 -0.871 0.014 
TRMT1 0.907 0.871 0.875 -0.178 0.011 0.832 0.719 0.958 -0.268 0.155 0.865 0.869 0.968 -0.153 0.102 
TMA16 1.276 1.240 1.357 0.367 0.011 1.212 1.065 0.947 0.096 0.447 0.849 0.784 0.642 -0.409 0.077 
AP3B1 0.797 0.785 0.845 -0.307 0.011 0.940 0.875 1.005 -0.091 0.253 1.182 1.125 1.217 0.231 0.020 
WASF2 1.164 1.209 1.142 0.228 0.011 1.577 1.709 1.308 0.606 0.034 1.258 1.274 1.024 0.238 0.145 
UBE2O 0.587 0.532 0.464 -0.928 0.011 0.149 0.227 0.230 -2.336 0.008 0.273 0.462 0.496 -1.332 0.039 
CALR 1.140 1.146 1.100 0.174 0.011 0.355 0.579 0.564 -1.037 0.046 0.324 0.603 0.514 -1.104 0.054 
190 
 
FN1 0.829 0.767 0.770 -0.344 0.011 0.655 0.601 0.572 -0.717 0.006 0.801 0.808 0.766 -0.337 0.005 
KPNA2 0.901 0.877 0.859 -0.186 0.011 0.532 0.545 0.564 -0.870 0.001 0.599 0.621 0.641 -0.689 0.002 
TFAM 2.132 2.947 2.352 1.295 0.011 1.325 1.587 1.168 0.432 0.078 0.553 0.471 0.484 -0.995 0.005 
RPS5 0.884 0.915 0.880 -0.164 0.011 1.043 1.016 1.031 0.043 0.058 1.159 1.060 1.084 0.138 0.072 
HNRNPK 0.857 0.861 0.814 -0.245 0.011 0.657 0.871 0.421 -0.685 0.154 0.738 0.961 0.585 -0.424 0.177 
DYNLL1 1.166 1.232 1.250 0.282 0.011 0.966 1.086 1.044 0.044 0.471 0.761 0.873 0.792 -0.309 0.034 
DRG1 1.240 1.161 1.188 0.258 0.012 1.088 1.069 1.088 0.113 0.005 0.929 0.878 0.908 -0.145 0.026 
CSDE1 0.828 0.828 0.772 -0.306 0.012 1.098 1.080 0.692 -0.095 0.706 1.226 1.279 0.939 0.186 0.313 
SORD 0.867 0.905 0.896 -0.169 0.012 0.863 0.923 0.826 -0.202 0.050 1.024 0.972 0.888 -0.059 0.429 
RPL13 0.911 0.885 0.917 -0.145 0.012 1.017 1.008 0.918 -0.030 0.597 1.095 1.104 0.937 0.060 0.516 
CDC37 1.186 1.145 1.222 0.243 0.012 0.865 1.018 0.929 -0.096 0.291 0.729 0.817 0.659 -0.450 0.038 
ERI3;PRN




1 0.822 0.805 0.864 -0.269 0.013 0.548 0.611 0.500 -0.860 0.009 0.690 0.721 0.582 -0.596 0.024 
RPL36AL 0.936 0.938 0.914 -0.106 0.013 0.829 0.815 0.700 -0.360 0.043 0.826 0.825 0.818 -0.281 0.000 
EIF4E 0.873 0.816 0.836 -0.249 0.013 0.804 0.816 0.998 -0.204 0.181 0.963 1.034 1.043 0.018 0.677 
SF3B1 0.854 0.862 0.898 -0.199 0.013 1.823 1.988 1.863 0.918 0.002 2.086 2.182 2.027 1.068 0.001 
RRBP1 1.140 1.195 1.134 0.209 0.013 1.108 1.108 1.080 0.136 0.008 0.917 0.941 0.853 -0.148 0.075 
EIF3A 0.840 0.890 0.863 -0.211 0.013 0.917 0.954 0.893 -0.119 0.051 0.978 1.035 1.027 0.019 0.545 
PABPC1 0.380 0.399 0.520 -1.221 0.013 0.296 0.356 0.413 -1.507 0.008 0.739 0.831 0.879 -0.297 0.056 
PAPOLA;
PAPOLB 0.857 0.869 0.815 -0.240 0.013 0.882 1.030 1.230 0.053 0.738 0.849 0.799 1.157 -0.116 0.555 
MCM7 1.821 2.428 2.002 1.049 0.013 1.110 1.343 1.098 0.237 0.129 0.686 0.586 0.544 -0.731 0.018 
RPS28 0.941 0.946 0.923 -0.095 0.014 0.995 0.921 0.887 -0.099 0.180 0.965 0.982 0.984 -0.034 0.063 
CNOT1 1.982 1.714 1.580 0.808 0.014 1.701 1.601 2.392 0.901 0.038 0.883 0.983 1.208 0.023 0.880 
192 
 
AP3M1 0.808 0.829 0.757 -0.326 0.014 0.870 0.827 0.706 -0.326 0.070 1.222 1.114 0.981 0.139 0.269 
PFKL 1.149 1.234 1.188 0.251 0.014 1.628 1.474 1.536 0.627 0.004 1.231 1.244 1.242 0.309 0.000 
PABPC4 0.457 0.488 0.596 -0.971 0.014 0.402 0.420 0.482 -1.207 0.004 0.789 0.853 0.841 -0.273 0.016 
XRCC6 1.186 1.177 1.264 0.273 0.014 0.793 0.832 0.927 -0.236 0.071 0.681 0.717 0.736 -0.492 0.004 
ATIC 0.823 0.806 0.868 -0.266 0.014 0.857 0.841 0.744 -0.299 0.043 0.966 1.145 0.894 -0.005 0.965 
DHX30 0.880 0.910 0.866 -0.176 0.014 1.284 1.148 1.096 0.231 0.077 1.349 1.234 1.257 0.355 0.012 
COMMD7 1.791 1.604 1.469 0.693 0.014 1.576 1.091 1.210 0.352 0.156 0.752 0.702 0.799 -0.415 0.016 
RPS29 0.928 0.953 0.936 -0.091 0.014 0.997 0.946 1.092 0.014 0.835 1.049 1.011 1.043 0.048 0.103 
DDX1 1.051 1.079 1.072 0.094 0.014 1.210 1.162 1.155 0.233 0.008 1.059 1.047 1.051 0.074 0.005 
SNX1 1.266 1.337 1.433 0.426 0.014 1.685 1.567 1.784 0.745 0.005 1.231 1.027 1.219 0.208 0.134 
MAVS 1.245 1.301 1.395 0.392 0.015 1.907 2.051 2.439 1.085 0.009 1.419 1.746 1.662 0.681 0.017 
FAU 0.826 0.884 0.842 -0.234 0.015 0.787 0.816 0.875 -0.277 0.026 0.847 0.890 1.052 -0.112 0.359 
ITIH2 0.702 0.773 0.671 -0.486 0.015 0.605 0.667 0.647 -0.646 0.004 0.842 0.952 0.922 -0.145 0.110 
193 
 
SERF2 0.838 0.882 0.823 -0.239 0.015 0.134 0.182 0.158 -2.673 0.002 0.165 0.229 0.210 -2.329 0.004 
HMGB3 1.140 1.215 1.219 0.252 0.015 1.478 1.262 1.214 0.393 0.045 1.201 1.041 0.861 0.036 0.821 
PSMB5 1.212 1.246 1.151 0.266 0.015 0.944 1.118 1.081 0.063 0.488 0.734 0.913 0.846 -0.273 0.098 
MAP4 0.784 0.696 0.692 -0.468 0.015 0.230 0.261 0.240 -2.037 0.001 0.289 0.293 0.259 -1.837 0.001 
EEF1D 1.323 1.416 1.252 0.410 0.015 1.095 1.135 1.145 0.170 0.013 0.770 0.896 0.830 -0.268 0.051 
NAP1L1 1.290 1.178 1.252 0.309 0.015 1.021 1.100 1.118 0.109 0.114 0.736 0.862 0.809 -0.321 0.040 
LARS2 1.755 1.595 1.435 0.669 0.015 1.810 1.583 1.450 0.685 0.018 1.025 1.193 1.001 0.097 0.345 




F3C 0.584 0.458 0.435 -1.034 0.016 0.810 0.821 0.844 -0.278 0.004 1.421 1.786 1.229 0.547 0.073 
MSI2 1.221 1.138 1.170 0.234 0.016 1.235 1.329 1.321 0.372 0.008 0.939 1.338 0.911 0.065 0.751 
RPS3A 0.904 0.916 0.875 -0.155 0.016 1.196 1.107 1.099 0.180 0.044 1.340 1.261 1.247 0.358 0.008 
194 
 
EIF4G1 0.752 0.810 0.828 -0.330 0.016 0.257 0.201 0.186 -2.234 0.004 0.337 0.253 0.223 -1.907 0.008 
EPS8L3 0.895 0.840 0.854 -0.213 0.016 0.869 0.832 0.899 -0.208 0.024 0.927 0.876 0.892 -0.155 0.023 
MYH10 0.478 0.514 0.624 -0.902 0.016 0.515 0.478 0.368 -1.155 0.016 0.924 0.918 0.567 -0.352 0.270 
YBX1 0.904 0.869 0.910 -0.161 0.016 0.884 0.876 0.944 -0.151 0.047 0.980 1.073 1.033 0.039 0.408 
FKBP2 1.047 1.075 1.065 0.087 0.016 0.918 0.994 0.971 -0.058 0.232 0.851 0.822 0.853 -0.249 0.005 
CTPS2 1.137 1.207 1.221 0.248 0.016 1.311 1.241 1.317 0.366 0.006 1.003 1.003 1.132 0.062 0.397 
PARG 0.655 0.761 0.725 -0.489 0.016 0.681 0.839 1.040 -0.250 0.292 0.919 1.210 1.368 0.202 0.356 
RPL24 0.922 0.885 0.916 -0.140 0.016 0.900 0.856 0.855 -0.200 0.015 0.926 0.914 0.976 -0.092 0.085 
ECH1 1.118 1.185 1.132 0.195 0.017 1.151 1.221 1.051 0.188 0.096 1.025 1.107 1.027 0.074 0.181 
NCAPD2 0.680 0.781 0.693 -0.481 0.017 0.272 0.407 0.566 -1.332 0.049 0.452 0.582 0.607 -0.882 0.022 
DR1 0.835 0.849 0.892 -0.221 0.017 0.447 0.483 0.420 -1.153 0.003 0.494 0.559 0.404 -1.055 0.016 
TUBB 1.077 1.104 1.125 0.140 0.017 0.959 1.113 1.084 0.070 0.401 0.869 0.885 0.820 -0.221 0.022 
TPP2 1.100 1.119 1.159 0.171 0.017 1.455 1.266 1.378 0.448 0.017 1.185 1.181 1.150 0.229 0.004 
195 
 
FTL 1.400 1.460 1.268 0.458 0.017 0.882 0.949 1.183 -0.005 0.973 0.537 0.649 0.947 -0.533 0.157 
RPS9 0.875 0.878 0.918 -0.169 0.017 1.065 1.035 1.009 0.051 0.152 1.198 1.083 1.067 0.156 0.097 
FGG 0.832 0.886 0.829 -0.237 0.017 0.937 1.278 1.057 0.113 0.478 0.997 1.253 1.125 0.164 0.228 
TCP1 1.018 1.022 1.028 0.033 0.017 1.277 1.302 1.277 0.362 0.001 1.200 1.235 1.227 0.288 0.002 
EEF1B2 1.229 1.382 1.283 0.375 0.017 1.017 1.407 1.218 0.267 0.187 0.856 0.999 0.855 -0.151 0.181 
C20orf27 0.862 0.793 0.841 -0.266 0.017 0.558 0.517 0.686 -0.779 0.024 0.643 0.660 0.837 -0.498 0.055 
RPL23A 1.180 1.192 1.117 0.217 0.018 1.197 1.203 1.131 0.235 0.015 0.904 0.990 1.009 -0.049 0.420 
COMMD1 1.415 1.498 1.283 0.481 0.018 1.170 1.080 1.953 0.434 0.246 0.740 0.636 0.910 -0.408 0.113 
XRCC5 1.127 1.171 1.213 0.226 0.018 0.769 0.867 0.557 -0.477 0.129 0.598 0.714 0.483 -0.759 0.043 
HNRNPH3 1.337 1.582 1.566 0.576 0.018 1.201 1.374 1.578 0.460 0.056 0.812 0.972 0.898 -0.165 0.159 
GOLGA3 0.836 0.849 0.895 -0.218 0.018 1.793 1.838 1.547 0.783 0.010 1.880 2.236 1.515 0.890 0.032 
MTHFD1 0.823 0.879 0.815 -0.254 0.018 0.891 0.834 0.608 -0.382 0.154 0.968 0.905 0.741 -0.207 0.216 
AIMP1 1.162 1.240 1.153 0.244 0.018 1.127 1.153 1.103 0.173 0.011 0.971 0.999 0.985 -0.022 0.196 
196 
 
RPS3 0.868 0.896 0.837 -0.207 0.018 1.201 1.119 1.110 0.192 0.033 1.390 1.273 1.284 0.395 0.010 
COMMD9 1.547 1.322 1.374 0.497 0.018 1.148 1.149 1.330 0.270 0.062 0.723 0.793 0.863 -0.338 0.045 
UPF1 1.075 1.125 1.098 0.136 0.018 1.210 1.210 1.204 0.273 0.000 1.038 1.081 1.069 0.087 0.037 
ABHD10 1.434 1.432 1.257 0.456 0.019 1.554 1.402 1.573 0.592 0.008 1.051 1.067 0.929 0.019 0.790 
NAP1L4b;
NAP1L4 1.317 1.196 1.213 0.311 0.019 0.862 1.087 0.883 -0.091 0.483 0.725 0.869 0.808 -0.324 0.050 
EZR 1.022 1.035 1.036 0.044 0.019 0.832 0.772 0.843 -0.295 0.018 0.790 0.767 0.824 -0.334 0.008 
GNB2L1 0.875 0.889 0.831 -0.210 0.019 1.118 1.091 1.071 0.129 0.019 1.279 1.186 1.308 0.330 0.016 
LAGE3 1.376 1.236 1.243 0.360 0.019 1.151 1.293 1.533 0.396 0.081 0.777 1.161 1.177 0.029 0.898 
ARHGAP1
8 1.279 1.498 1.441 0.489 0.019 1.647 1.916 1.727 0.816 0.006 1.286 1.150 1.157 0.258 0.039 
DDB1 0.901 0.899 0.936 -0.133 0.019 0.907 0.972 1.015 -0.053 0.375 0.963 1.209 1.083 0.112 0.360 
PKM2 0.841 0.852 0.900 -0.211 0.019 0.785 0.980 0.812 -0.226 0.152 0.945 1.171 0.916 0.006 0.961 
197 
 
SPTBN1 1.285 1.235 1.404 0.385 0.020 1.651 1.575 1.631 0.695 0.001 1.403 1.259 1.176 0.351 0.042 
PPHLN1 1.471 1.324 1.595 0.545 0.020 0.935 0.683 1.260 -0.105 0.722 0.609 0.511 0.822 -0.655 0.082 
STXBP1 1.382 1.218 1.358 0.397 0.020 1.144 1.059 1.131 0.151 0.049 0.732 0.864 0.817 -0.317 0.046 
DHX36 0.863 0.899 0.837 -0.208 0.020 0.936 0.850 0.875 -0.174 0.051 1.024 0.997 1.029 0.023 0.241 
RPP25L 1.077 1.051 1.087 0.100 0.020 0.794 0.959 0.968 -0.146 0.257 0.717 0.848 0.855 -0.315 0.063 
COMMD4 1.397 1.285 1.226 0.379 0.020 1.125 1.386 1.080 0.251 0.153 0.819 0.956 0.850 -0.196 0.100 
EEA1 1.173 1.180 1.278 0.274 0.020 1.153 1.144 0.870 0.066 0.668 1.040 0.994 0.910 -0.030 0.651 
RPL5 0.895 0.924 0.876 -0.155 0.020 1.395 1.390 1.722 0.580 0.030 1.571 1.481 1.658 0.649 0.005 
PAIP1 0.338 0.394 0.525 -1.280 0.021 0.163 0.169 0.355 -2.225 0.026 0.485 0.477 0.578 -0.968 0.008 
PDAP1 0.796 0.721 0.680 -0.453 0.021 0.341 0.318 0.485 -1.416 0.017 0.756 0.521 0.688 -0.627 0.060 
ABI1 1.139 1.231 1.157 0.232 0.021 1.295 1.385 1.232 0.381 0.016 0.969 1.027 0.935 -0.035 0.476 
MAPRE1 1.181 1.304 1.204 0.297 0.021 1.423 1.408 1.561 0.548 0.007 0.921 1.132 1.067 0.051 0.622 
STXBP3 1.460 1.880 1.614 0.716 0.021 2.092 2.364 2.621 1.232 0.006 1.351 1.453 1.665 0.570 0.023 
198 
 
RPS25 0.857 0.911 0.863 -0.190 0.021 1.086 1.039 1.388 0.216 0.239 1.335 1.124 1.170 0.271 0.069 
METAP2 0.748 0.834 0.739 -0.373 0.021 1.155 0.895 0.751 -0.122 0.569 1.500 1.007 0.978 0.188 0.444 
FKBP3 0.760 0.821 0.846 -0.307 0.021 0.717 0.826 1.034 -0.236 0.265 1.101 0.981 1.235 0.138 0.285 
PSMB3 1.142 1.141 1.224 0.225 0.022 0.852 1.052 0.975 -0.065 0.541 0.840 0.895 0.773 -0.261 0.051 
ADSL 0.909 0.877 0.923 -0.148 0.022 0.964 0.912 0.853 -0.139 0.114 1.004 1.138 0.894 0.010 0.927 
S100A6 2.183 2.346 1.653 1.027 0.022 2.173 2.904 2.236 1.273 0.011 1.014 1.184 1.132 0.147 0.157 
LRRC40 0.876 0.924 0.907 -0.148 0.022 0.865 0.740 0.822 -0.309 0.043 0.911 0.860 0.850 -0.195 0.024 
RPL13A 0.872 0.910 0.917 -0.153 0.022 1.154 1.055 1.156 0.164 0.064 1.346 1.155 1.268 0.326 0.037 
VARS 1.371 1.212 1.371 0.396 0.022 1.565 1.863 2.029 0.855 0.016 1.049 1.480 1.438 0.386 0.136 
DIP2B 0.804 0.798 0.712 -0.377 0.022 1.088 1.063 1.052 0.094 0.022 1.291 1.325 1.301 0.385 0.001 
HNRNPL 1.282 1.156 1.237 0.291 0.022 1.698 1.769 1.526 0.732 0.007 1.259 1.382 1.085 0.306 0.095 
CSNK2A2 1.092 1.072 1.124 0.132 0.022 0.804 0.983 0.942 -0.142 0.250 0.758 0.918 0.846 -0.255 0.086 
SMG1 0.871 0.831 0.790 -0.269 0.022 0.919 0.857 0.706 -0.282 0.132 1.020 1.159 0.956 0.059 0.548 
199 
 
TJP1 1.196 1.355 1.258 0.343 0.022 1.339 1.402 1.217 0.397 0.022 1.162 1.008 0.980 0.066 0.475 
SET 1.347 1.194 1.335 0.368 0.022 0.724 0.934 1.044 -0.168 0.395 0.517 0.759 0.697 -0.624 0.065 
CUL4A 1.118 1.141 1.079 0.154 0.023 1.063 1.029 0.921 0.003 0.962 0.939 1.015 1.011 -0.018 0.671 
ARRB1 0.820 0.748 0.836 -0.321 0.023 0.970 1.039 0.994 0.001 0.976 1.207 1.286 0.992 0.208 0.207 
MRPS25 0.758 0.620 0.647 -0.573 0.023 0.989 0.926 0.846 -0.123 0.202 1.208 1.259 1.170 0.277 0.012 
VPS35 1.095 1.150 1.171 0.186 0.023 1.225 1.312 1.236 0.330 0.009 1.075 1.119 1.064 0.119 0.033 
ACTN4;A
CTN1;AC
TN2 1.787 1.749 1.407 0.712 0.023 0.845 1.154 0.921 -0.052 0.736 0.469 0.727 0.732 -0.668 0.088 
EIF3B 0.918 0.926 0.882 -0.138 0.024 0.920 0.958 0.901 -0.111 0.050 0.939 1.048 0.964 -0.025 0.651 
AHSA1 1.164 1.124 1.224 0.226 0.024 2.471 2.545 3.027 1.417 0.004 2.094 2.422 2.239 1.168 0.003 
LIN7C;LIN
7A 1.253 1.201 1.137 0.258 0.024 0.834 0.870 0.846 -0.235 0.006 0.574 0.683 0.499 -0.784 0.027 
RPS18 0.932 0.923 0.889 -0.129 0.024 1.086 1.043 1.083 0.098 0.035 1.115 1.103 1.102 0.146 0.001 
200 
 
PLD3 1.353 1.246 1.192 0.335 0.024 1.043 1.245 1.180 0.205 0.113 0.917 0.963 0.866 -0.129 0.100 
TIMM13 1.099 1.060 1.109 0.123 0.025 1.043 1.014 0.937 -0.004 0.933 0.842 0.907 0.798 -0.238 0.047 
DDX3X;D
DX3Y 0.921 0.945 0.904 -0.115 0.025 0.642 0.649 0.661 -0.620 0.000 0.679 0.659 0.666 -0.583 0.000 
CNOT10 1.468 1.511 1.872 0.685 0.025 2.017 1.790 1.690 0.870 0.007 0.989 0.991 0.758 -0.142 0.382 
RPL4 0.802 0.871 0.870 -0.240 0.026 1.238 1.028 1.135 0.176 0.150 1.454 1.231 1.228 0.378 0.043 
CAPN1 0.725 0.820 0.814 -0.350 0.026 0.587 0.590 0.629 -0.734 0.002 0.714 0.720 0.752 -0.457 0.003 
CBS 1.161 1.244 1.311 0.307 0.026 0.922 1.350 1.361 0.253 0.305 0.808 0.916 0.875 -0.209 0.058 
APOB 0.764 0.861 0.784 -0.318 0.026 0.644 0.876 0.766 -0.404 0.088 0.888 0.990 0.941 -0.091 0.183 
SPR 0.614 0.740 0.581 -0.641 0.026 0.732 0.722 0.647 -0.516 0.012 1.031 0.972 1.128 0.059 0.446 
KPNA3 0.888 0.805 0.827 -0.253 0.026 0.490 0.571 0.534 -0.915 0.005 0.579 0.640 0.599 -0.724 0.003 
RPS15 0.893 0.892 0.834 -0.197 0.026 1.065 1.060 1.048 0.081 0.007 1.115 1.106 1.154 0.170 0.012 
EDF1 0.773 0.865 0.781 -0.312 0.026 1.086 0.902 1.030 0.005 0.959 1.325 0.949 1.088 0.150 0.394 
201 
 
MATR3 0.826 0.877 0.788 -0.269 0.026 1.907 1.802 1.829 0.884 0.001 2.200 2.073 2.119 1.091 0.001 
AP2B1 1.140 1.267 1.202 0.265 0.026 1.662 1.641 1.415 0.649 0.013 1.439 1.467 1.231 0.459 0.029 
POP7 1.296 1.197 1.162 0.283 0.026 1.016 1.022 1.122 0.073 0.255 0.709 0.807 0.799 -0.377 0.024 
CCDC53 0.751 0.854 0.782 -0.332 0.026 0.637 0.742 0.475 -0.718 0.062 0.879 0.939 0.770 -0.218 0.123 
RPS10 0.943 0.899 0.922 -0.118 0.027 0.998 0.994 1.045 0.017 0.533 1.042 1.060 1.067 0.079 0.016 
PCNA 1.319 1.167 1.297 0.332 0.027 0.686 0.711 0.784 -0.462 0.015 0.494 0.616 0.594 -0.823 0.014 
ABCF1 0.746 0.727 0.614 -0.529 0.027 0.209 0.195 0.133 -2.511 0.007 0.284 0.267 0.271 -1.866 0.000 
FAM129B 1.121 1.211 1.228 0.246 0.027 1.108 1.050 1.413 0.239 0.211 0.829 0.852 0.931 -0.201 0.057 
HDGF 1.404 1.407 1.726 0.590 0.027 2.659 2.838 3.358 1.554 0.004 1.501 1.565 1.576 0.629 0.001 
HNRNPA0 0.921 0.865 0.903 -0.158 0.027 0.829 0.906 0.794 -0.248 0.047 0.816 1.030 0.727 -0.237 0.250 
NMT1 0.861 0.897 0.821 -0.219 0.027 0.808 0.708 0.613 -0.504 0.049 0.960 0.716 0.778 -0.301 0.139 
PRDX2 1.057 1.101 1.105 0.121 0.027 0.813 0.964 0.916 -0.159 0.161 0.742 0.831 0.720 -0.390 0.025 
HSD17B1




DHX15 1.270 1.160 1.315 0.318 0.028 1.248 1.281 1.323 0.360 0.005 0.952 1.066 1.010 0.011 0.831 
KIAA0196 0.764 0.799 0.676 -0.425 0.028 0.946 0.983 0.837 -0.120 0.227 1.162 1.209 1.124 0.220 0.018 
RPL7A 0.897 0.900 0.841 -0.186 0.028 1.210 1.606 1.710 0.577 0.064 1.114 1.320 1.431 0.358 0.079 
BIN1 1.366 1.698 1.414 0.571 0.028 0.945 1.015 1.462 0.163 0.492 0.694 0.784 0.944 -0.320 0.131 
GCLM 1.246 1.311 1.476 0.423 0.028 2.272 2.312 1.660 1.041 0.022 1.644 1.153 1.142 0.372 0.165 
PSMA2 1.098 1.155 1.191 0.198 0.028 0.908 1.110 1.009 0.008 0.932 0.824 0.895 0.773 -0.270 0.048 
CTSL1 0.873 0.928 0.879 -0.163 0.029 0.615 0.689 0.587 -0.668 0.010 0.642 0.661 0.730 -0.564 0.010 
DNAJA1 0.842 0.883 0.910 -0.189 0.029 1.392 1.191 1.178 0.322 0.054 1.284 1.234 1.368 0.372 0.013 
ARPC5L 1.078 1.132 1.151 0.164 0.029 0.929 1.033 1.023 -0.009 0.872 0.888 0.935 0.928 -0.126 0.032 
SEC23B 1.105 1.150 1.080 0.152 0.029 1.083 1.126 1.100 0.141 0.013 1.071 0.936 0.959 -0.019 0.779 
ANP32E 1.229 1.124 1.238 0.258 0.029 0.646 0.745 0.898 -0.404 0.099 0.505 0.656 0.720 -0.689 0.046 
UGGT1 1.348 1.592 1.314 0.499 0.029 0.844 0.927 1.145 -0.053 0.725 0.693 0.684 0.905 -0.407 0.090 
203 
 
PTGR1 0.883 0.853 0.798 -0.245 0.029 1.042 1.188 0.988 0.097 0.347 1.271 1.334 1.283 0.374 0.003 
CHMP4B 1.249 1.157 1.315 0.308 0.029 1.829 1.604 1.753 0.787 0.005 1.295 1.371 1.310 0.406 0.004 
SEPSECS 0.632 0.688 0.513 -0.722 0.029 0.564 0.601 0.589 -0.775 0.001 0.906 0.938 1.045 -0.057 0.454 
UTRN 1.299 1.183 1.373 0.359 0.029 0.277 3.329 0.340 -0.557 0.676 0.224 2.895 0.366 -0.691 0.603 
RBM14 1.275 1.230 1.439 0.392 0.029 1.483 1.616 1.648 0.661 0.005 0.992 1.187 1.049 0.102 0.314 
KHDRBS1 0.733 0.813 0.677 -0.437 0.030 0.447 0.575 0.519 -0.969 0.012 0.631 0.768 0.681 -0.532 0.023 
LRRC59 1.170 1.342 1.318 0.350 0.030 1.305 1.451 1.859 0.605 0.057 0.967 1.052 1.241 0.112 0.401 
CS 1.140 1.284 1.251 0.291 0.030 1.037 1.209 1.164 0.182 0.112 1.140 0.952 1.048 0.062 0.496 
NPM1 1.204 1.126 1.255 0.255 0.030 0.720 0.931 0.961 -0.212 0.250 0.483 0.802 0.688 -0.636 0.099 
RPS13 0.897 0.935 0.878 -0.147 0.031 1.036 1.041 1.037 0.054 0.001 1.084 1.059 1.067 0.097 0.011 
SRP72 0.801 0.873 0.876 -0.236 0.031 0.543 0.550 0.638 -0.797 0.009 0.655 0.600 0.667 -0.644 0.005 
XPOT 1.165 1.096 1.193 0.202 0.031 0.723 0.855 1.103 -0.185 0.407 0.831 0.804 1.031 -0.179 0.251 
KTN1 1.422 1.238 1.515 0.471 0.032 2.079 2.262 1.949 1.066 0.003 1.588 1.884 1.346 0.670 0.041 
204 
 
PSMD13 1.083 1.091 1.149 0.147 0.032 1.179 1.351 1.217 0.319 0.033 1.145 1.182 1.083 0.184 0.038 
HNRPLL 1.193 1.408 1.302 0.377 0.032 1.414 1.872 1.382 0.624 0.047 0.947 1.328 1.212 0.202 0.299 
PELO 0.786 0.884 0.827 -0.267 0.032 0.792 0.822 0.832 -0.295 0.005 0.924 1.088 0.963 -0.016 0.844 
DNAJB4 1.222 1.122 1.132 0.212 0.032 1.846 1.691 1.916 0.860 0.004 1.402 1.481 1.497 0.546 0.003 
SNTB1 1.287 1.634 1.567 0.573 0.032 0.999 1.106 1.111 0.098 0.188 0.699 0.640 0.678 -0.574 0.004 
GMPS 1.166 1.188 1.092 0.199 0.033 1.013 1.087 1.078 0.082 0.124 0.857 0.966 0.989 -0.096 0.273 
EIF5B 0.784 0.882 0.837 -0.263 0.033 0.792 0.807 0.837 -0.301 0.006 0.821 0.890 0.965 -0.168 0.130 
HSDL2 1.054 1.100 1.108 0.121 0.034 1.497 1.171 1.151 0.337 0.110 1.378 1.074 0.902 0.139 0.517 
TIMM8B 1.073 1.104 1.147 0.147 0.034 0.894 0.875 0.913 -0.162 0.012 0.765 0.784 0.711 -0.410 0.010 
OLA1 1.076 1.054 1.038 0.078 0.034 0.863 0.911 0.996 -0.118 0.191 0.787 0.850 0.891 -0.249 0.042 
DYNLRB1
;DYNLRB
2 0.899 0.939 0.940 -0.112 0.034 0.928 0.929 0.802 -0.178 0.127 0.919 0.975 0.844 -0.134 0.156 
205 
 
HNRNPC 1.195 1.119 1.252 0.248 0.034 1.474 1.498 1.801 0.664 0.019 1.200 1.168 1.720 0.423 0.143 
PLOD2 1.019 1.038 1.026 0.039 0.034 0.866 0.736 0.705 -0.384 0.051 0.793 0.722 0.708 -0.435 0.013 
MDK 0.848 0.771 0.718 -0.363 0.035 0.662 0.559 0.596 -0.727 0.009 0.765 0.796 0.752 -0.375 0.004 
DDX19B 0.616 0.651 0.786 -0.555 0.035 0.719 0.824 0.905 -0.300 0.090 1.166 1.203 1.129 0.221 0.014 
EIF4G1 0.800 0.890 0.799 -0.271 0.035 0.637 0.720 0.675 -0.564 0.008 0.741 0.761 0.789 -0.390 0.004 
COPG1 1.067 1.131 1.086 0.130 0.035 0.753 0.800 0.723 -0.400 0.011 0.681 0.712 0.661 -0.547 0.003 
TRMT5 1.545 1.240 1.466 0.497 0.035 0.689 0.923 0.993 -0.221 0.304 0.498 0.779 0.649 -0.663 0.071 
RPL17 0.875 0.935 0.883 -0.156 0.035 1.021 0.907 0.991 -0.041 0.508 1.010 0.956 1.172 0.060 0.568 
RPLP0;RP
LP0P6 0.893 0.932 0.866 -0.158 0.036 1.130 1.145 1.087 0.164 0.018 1.207 1.231 1.222 0.287 0.001 
XPO1 1.080 1.064 1.039 0.085 0.036 1.963 0.916 0.717 0.122 0.806 1.508 0.849 0.746 -0.022 0.951 
NT5C2 1.388 1.770 1.392 0.591 0.037 1.391 1.566 1.270 0.489 0.031 0.998 0.949 0.898 -0.078 0.217 
FIG4 1.372 1.672 1.922 0.713 0.037 1.745 1.798 1.773 0.825 0.000 1.124 1.231 0.949 0.131 0.355 
206 
 
HSPG2 0.812 0.719 0.652 -0.465 0.037 1.216 0.916 0.801 -0.055 0.786 1.582 1.062 1.465 0.433 0.133 
RPS8 0.906 0.911 0.846 -0.172 0.037 1.094 1.016 0.987 0.044 0.423 1.207 1.089 1.056 0.157 0.114 
EWSR1 1.222 1.508 1.472 0.480 0.038 0.935 1.100 1.028 0.026 0.735 0.720 0.769 0.632 -0.504 0.026 
EIF4A2 0.831 0.874 0.914 -0.197 0.038 0.637 0.687 0.716 -0.558 0.008 0.891 0.831 0.853 -0.221 0.017 
PLOD1 1.065 1.034 1.039 0.065 0.038 1.494 1.330 1.472 0.516 0.010 1.301 1.320 1.179 0.339 0.022 
ETF1 1.079 1.168 1.162 0.184 0.038 1.290 1.340 1.349 0.407 0.003 1.169 1.087 1.107 0.164 0.035 
OAS3 0.566 0.761 0.589 -0.659 0.039 0.707 0.840 0.690 -0.429 0.041 1.428 1.398 1.290 0.455 0.009 
DFNA5 0.731 0.736 0.579 -0.561 0.039 2.596 2.104 2.831 1.317 0.009 2.733 2.898 5.326 1.799 0.028 
MACF1 1.230 1.523 1.335 0.441 0.039 1.002 0.902 0.827 -0.140 0.223 0.819 0.650 0.643 -0.516 0.046 
ILF3 0.912 0.958 0.924 -0.103 0.039 0.761 0.752 0.806 -0.372 0.007 0.832 0.822 0.890 -0.239 0.021 
TARBP2 0.765 0.693 0.839 -0.389 0.040 0.630 0.900 0.737 -0.420 0.106 0.625 1.340 0.894 -0.139 0.704 
MRTO4 1.156 1.190 1.084 0.192 0.040 1.113 1.134 1.090 0.153 0.011 0.973 0.988 0.912 -0.063 0.213 
RPL12 0.904 0.903 0.952 -0.121 0.040 1.126 1.166 1.226 0.229 0.023 1.181 1.204 1.225 0.267 0.003 
207 
 
KPNB1 1.357 1.429 1.181 0.398 0.040 1.070 1.275 1.057 0.176 0.180 0.804 0.856 1.085 -0.141 0.397 
ANP32B 1.190 1.085 1.164 0.195 0.040 0.807 0.971 1.043 -0.098 0.470 0.679 0.914 0.836 -0.316 0.131 
PACS1 1.120 1.115 1.056 0.133 0.040 0.674 0.769 0.645 -0.527 0.020 0.505 0.548 0.556 -0.900 0.002 
METTL16 1.176 1.098 1.093 0.165 0.040 1.917 1.974 1.848 0.935 0.001 1.608 1.816 1.548 0.725 0.009 
RPS24 0.875 0.906 0.818 -0.209 0.041 0.941 0.940 0.938 -0.090 0.000 1.034 0.982 0.996 0.005 0.844 
ATPIF1 1.080 1.062 1.036 0.083 0.041 1.197 1.231 1.215 0.280 0.002 1.187 1.099 1.152 0.196 0.026 
RPS19 0.930 0.908 0.864 -0.152 0.041 1.053 1.038 1.005 0.045 0.150 1.079 1.052 1.130 0.120 0.059 
PDE12 0.886 0.859 0.932 -0.165 0.041 0.321 0.362 0.445 -1.425 0.009 0.377 0.420 0.458 -1.262 0.004 
EIF4A1 0.983 0.976 0.989 -0.026 0.041 0.998 0.989 0.963 -0.024 0.264 0.984 0.949 0.981 -0.042 0.132 
G3BP2 1.398 1.173 1.396 0.399 0.042 0.746 0.766 0.931 -0.304 0.095 0.535 0.588 0.637 -0.773 0.009 
TATDN1 1.029 1.040 1.018 0.041 0.042 0.838 0.912 0.880 -0.191 0.033 0.792 0.784 0.886 -0.287 0.037 
SMC4 0.980 0.956 0.967 -0.047 0.042 0.994 1.155 1.120 0.121 0.208 1.097 1.107 1.140 0.156 0.012 
CKAP5 0.612 0.800 0.646 -0.554 0.042 0.273 0.414 0.315 -1.605 0.012 0.521 0.504 0.517 -0.961 0.000 
208 
 
SRP14 0.919 0.958 0.910 -0.106 0.042 1.089 0.907 0.905 -0.053 0.608 1.467 0.880 1.020 0.133 0.606 
MITD1 0.717 0.861 0.756 -0.367 0.043 0.750 0.836 0.862 -0.296 0.040 0.972 0.973 0.925 -0.064 0.118 
ACAD11 0.663 0.597 0.792 -0.558 0.043 0.473 0.438 0.620 -0.987 0.023 0.749 0.739 0.752 -0.421 0.000 
NHP2 0.835 0.796 0.695 -0.371 0.043 1.171 1.186 1.281 0.277 0.021 1.359 1.390 1.522 0.508 0.010 
DDX19A 0.791 0.614 0.725 -0.502 0.043 0.937 0.835 0.992 -0.122 0.235 1.092 1.470 1.277 0.345 0.109 
SLIRP 1.365 1.159 1.374 0.374 0.043 1.339 1.595 1.751 0.634 0.031 1.125 1.372 1.149 0.275 0.093 
FLNB 1.244 1.209 1.103 0.243 0.043 1.125 1.053 1.126 0.138 0.050 0.961 0.866 1.034 -0.072 0.433 
RPL26 0.840 0.837 0.921 -0.210 0.043 1.042 1.033 0.990 0.030 0.315 1.228 1.100 1.049 0.167 0.130 
PPP1CA;
PPP1CC 1.088 1.051 1.044 0.085 0.043 0.817 0.971 0.905 -0.159 0.157 0.763 0.707 0.853 -0.373 0.042 
MAP2 0.699 0.753 0.562 -0.585 0.044 0.173 0.151 0.220 -2.479 0.004 0.259 0.180 0.400 -1.915 0.029 
EIF3EIP;E
IF3L 0.932 0.922 0.871 -0.140 0.044 0.893 0.911 0.901 -0.150 0.003 0.975 0.965 1.008 -0.026 0.312 
209 
 
AP2A1 1.085 1.196 1.136 0.187 0.044 1.730 1.545 1.021 0.482 0.172 1.481 1.216 0.792 0.171 0.587 
RPL38 0.941 0.945 0.897 -0.109 0.045 0.788 0.732 0.609 -0.503 0.045 0.838 0.793 0.632 -0.418 0.079 
AARS 1.476 1.197 1.474 0.460 0.045 0.678 0.781 0.903 -0.355 0.097 0.437 0.657 0.605 -0.842 0.043 
MVD 0.609 0.784 0.739 -0.501 0.045 0.693 1.116 0.967 -0.140 0.563 1.213 1.323 1.431 0.400 0.028 
TLN2 0.763 0.879 0.749 -0.331 0.045 0.368 0.320 0.307 -1.596 0.002 0.785 0.555 0.439 -0.796 0.082 
TSR1 0.801 0.861 0.723 -0.335 0.045 0.705 0.661 0.588 -0.622 0.015 0.796 0.953 0.809 -0.235 0.105 
OSBP 1.063 1.091 1.140 0.134 0.045 1.398 1.395 1.513 0.520 0.005 1.128 1.085 1.138 0.159 0.018 
RPS12 0.921 0.958 0.906 -0.108 0.045 1.064 1.047 1.031 0.067 0.037 1.061 1.043 1.102 0.095 0.055 
PUS1 1.154 1.066 1.145 0.165 0.045 0.965 1.139 0.981 0.036 0.685 0.848 1.045 0.895 -0.112 0.342 
CNOT7 1.607 1.877 1.322 0.665 0.045 1.629 2.019 1.400 0.734 0.041 1.032 1.085 1.167 0.128 0.130 
AP1M1 1.166 1.421 1.325 0.378 0.046 1.395 1.551 1.361 0.520 0.012 1.176 1.122 0.998 0.132 0.202 
PSMB4 1.081 1.183 1.188 0.201 0.046 0.841 1.184 0.958 -0.023 0.889 0.765 0.971 0.709 -0.308 0.152 
CDV3 0.575 0.776 0.567 -0.661 0.046 0.176 0.391 0.284 -1.893 0.030 0.325 0.467 0.473 -1.266 0.019 
210 
 
SARS 1.316 1.139 1.346 0.337 0.047 0.746 0.899 1.020 -0.182 0.299 0.574 0.807 0.741 -0.514 0.074 
RPL22 1.060 1.094 1.043 0.091 0.047 1.087 1.174 1.175 0.195 0.035 1.096 1.070 1.129 0.135 0.026 
NSUN2 1.132 1.077 1.062 0.124 0.047 0.584 0.579 0.608 -0.761 0.001 0.512 0.617 0.546 -0.846 0.009 
RBM47 0.686 0.814 0.823 -0.374 0.047 0.853 0.911 0.984 -0.129 0.163 1.328 1.066 1.174 0.245 0.117 
HUWE1 0.863 0.792 0.717 -0.343 0.047 0.348 0.332 0.232 -1.740 0.011 0.366 0.427 0.325 -1.434 0.006 
TUBB2A 1.184 1.091 1.228 0.222 0.048 1.108 0.922 1.065 0.040 0.666 0.754 0.786 0.823 -0.346 0.011 
ECI2 1.226 1.592 1.566 0.537 0.048 0.999 1.336 1.191 0.223 0.210 0.760 0.850 1.000 -0.210 0.208 
MAP1S 0.894 0.857 0.935 -0.161 0.048 0.573 0.532 0.571 -0.841 0.002 0.462 0.540 0.668 -0.861 0.031 
GAR1 0.793 0.903 0.852 -0.237 0.048 1.220 1.336 1.176 0.313 0.029 1.420 1.446 1.386 0.503 0.001 
TTC37 0.775 0.878 0.736 -0.332 0.048 0.635 0.946 0.849 -0.323 0.200 0.876 1.060 1.226 0.062 0.700 
CSDA 0.692 0.591 0.795 -0.540 0.048 0.444 0.541 0.675 -0.874 0.037 0.618 0.826 0.916 -0.366 0.165 
SEC24C 1.059 1.059 1.026 0.067 0.049 1.080 1.216 1.084 0.170 0.094 1.010 1.074 1.054 0.064 0.134 
SERBP1 0.715 0.865 0.724 -0.387 0.049 0.411 0.436 0.595 -1.076 0.023 0.443 0.539 0.655 -0.893 0.032 
211 
 
RPL36 0.841 0.920 0.904 -0.172 0.049 1.146 1.031 1.034 0.096 0.196 1.252 1.167 1.087 0.222 0.064 
SRSF7 0.837 0.904 0.789 -0.248 0.049 1.086 1.069 0.910 0.026 0.776 1.288 1.234 1.052 0.247 0.109 
ENAH 1.069 1.171 1.133 0.168 0.049 1.055 1.050 0.793 -0.062 0.692 0.968 0.901 0.934 -0.099 0.080 
GRB10 0.931 0.847 0.852 -0.191 0.049 0.839 0.762 0.835 -0.302 0.022 0.892 0.946 0.972 -0.096 0.119 
NOB1 0.809 0.821 0.679 -0.383 0.050 0.589 0.572 0.604 -0.765 0.001 0.654 0.705 0.721 -0.529 0.006 
SNRPD3 0.968 0.926 0.930 -0.088 0.050 1.377 1.355 1.628 0.534 0.024 1.295 1.416 1.550 0.502 0.022 
EIF2A 0.876 0.746 0.830 -0.294 0.050 0.778 0.655 0.877 -0.387 0.086 0.918 0.782 1.025 -0.148 0.322 
ANP32A 1.233 1.125 1.323 0.292 0.050 0.661 0.826 0.915 -0.333 0.137 0.521 0.737 0.670 -0.653 0.048 
S100A13 0.903 0.883 0.950 -0.133 0.050 0.759 0.868 0.782 -0.319 0.033 0.769 0.967 0.824 -0.236 0.137 
SRPK1 0.537 0.729 0.465 -0.820 0.051 1.050 1.376 0.849 0.098 0.674 1.279 1.691 1.919 0.684 0.058 
SRC;YES
1;FYN 1.420 1.509 1.185 0.448 0.051 1.582 1.869 1.727 0.784 0.008 1.257 1.274 1.256 0.336 0.000 
PPP1R12




TRIM4 0.802 0.907 0.795 -0.263 0.051 0.827 0.872 0.876 -0.221 0.014 1.102 1.052 1.010 0.076 0.171 
TRA2A 0.749 0.874 0.722 -0.360 0.051 1.773 1.959 1.909 0.910 0.002 2.370 2.204 2.297 1.195 0.001 
DLD 1.096 1.239 1.237 0.250 0.051 1.332 1.404 1.278 0.419 0.009 1.325 1.164 1.035 0.225 0.161 
SUPT5H 1.119 1.141 1.264 0.230 0.051 1.152 1.050 1.386 0.248 0.170 0.980 0.951 1.078 0.002 0.976 
FLNA 1.055 1.022 1.049 0.060 0.052 1.253 1.188 1.198 0.278 0.007 1.285 1.104 1.191 0.252 0.058 
PDIA6 1.066 1.156 1.169 0.176 0.052 0.654 0.810 0.657 -0.508 0.038 0.616 0.648 0.585 -0.700 0.004 
RTCD1 0.878 0.862 0.942 -0.163 0.052 0.901 0.909 1.022 -0.085 0.283 1.055 0.991 1.115 0.074 0.272 
DDX39B;B
AT1 1.107 1.140 1.054 0.137 0.053 1.558 1.604 1.476 0.628 0.003 1.339 1.365 1.398 0.451 0.002 
PRKCI 1.115 1.049 1.070 0.108 0.053 0.730 0.645 0.868 -0.430 0.075 0.670 0.602 0.642 -0.650 0.005 
ATP6V1E
1 1.685 1.328 1.287 0.509 0.053 1.002 1.116 1.084 0.093 0.184 0.630 0.879 0.767 -0.412 0.098 
213 
 
GAS2 0.687 0.648 0.841 -0.473 0.054 1.839 1.742 1.723 0.821 0.001 2.368 2.611 1.991 1.207 0.009 
PCBP2 0.934 0.865 0.923 -0.142 0.054 0.973 0.912 0.924 -0.095 0.079 0.936 0.950 0.855 -0.132 0.109 
DNM1L 1.152 1.177 1.066 0.177 0.054 1.601 1.604 1.420 0.622 0.009 1.191 1.202 1.114 0.224 0.023 
PFDN2 1.084 1.187 1.099 0.166 0.055 0.967 1.075 1.162 0.091 0.358 0.972 0.988 0.929 -0.055 0.174 
CCDC58 1.284 1.162 1.117 0.245 0.055 1.011 1.020 0.972 0.001 0.957 0.771 0.896 0.948 -0.203 0.149 
ESYT2 1.611 1.207 1.523 0.522 0.055 1.636 1.488 1.935 0.745 0.021 0.950 0.994 0.939 -0.058 0.146 
PSME4 0.925 0.835 0.896 -0.177 0.056 0.875 0.860 0.968 -0.152 0.103 1.048 1.042 1.111 0.093 0.086 
MAGOH 0.945 0.978 0.948 -0.063 0.056 1.037 1.142 0.944 0.053 0.570 1.039 1.091 0.937 0.029 0.701 
HNRNPH1 1.131 1.054 1.080 0.121 0.056 1.377 1.482 1.579 0.563 0.010 1.124 1.349 1.305 0.328 0.056 
AP1S1 1.120 1.226 1.329 0.289 0.056 1.178 1.440 1.491 0.446 0.052 1.016 1.141 1.014 0.077 0.302 
EIF3D 0.973 0.931 0.944 -0.076 0.056 0.909 0.909 0.930 -0.126 0.007 0.916 0.994 0.967 -0.062 0.217 
IFIT5 0.625 0.781 0.798 -0.454 0.057 0.794 0.816 0.796 -0.318 0.002 1.236 1.251 0.996 0.208 0.191 
LARP1 0.912 0.862 0.798 -0.225 0.057 0.632 0.781 0.606 -0.580 0.036 0.721 0.882 0.711 -0.381 0.063 
214 
 
FARSB 1.088 1.083 1.179 0.158 0.058 1.303 1.194 1.289 0.335 0.014 1.121 1.059 1.088 0.123 0.036 
CBR1 0.849 0.916 0.797 -0.230 0.058 0.961 0.900 0.995 -0.072 0.229 1.047 0.965 1.193 0.090 0.419 
UFD1L 1.117 1.251 1.118 0.215 0.058 1.592 1.554 1.004 0.437 0.180 1.589 1.420 0.915 0.349 0.287 
TRIO 0.813 0.671 0.581 -0.553 0.059 0.567 0.282 0.218 -1.614 0.059 0.838 0.428 0.451 -0.876 0.107 
POLR2L 1.167 1.073 1.207 0.199 0.060 1.197 1.235 1.361 0.336 0.027 0.904 1.057 1.176 0.056 0.662 
GRSF1 2.135 1.331 1.753 0.772 0.060 1.396 1.148 0.900 0.176 0.437 0.669 0.840 0.526 -0.586 0.095 
TIMM9 1.242 1.767 1.497 0.572 0.060 1.106 1.181 1.030 0.143 0.129 0.922 0.599 0.727 -0.439 0.135 
ACLY 1.331 1.295 1.112 0.313 0.061 1.068 0.791 0.514 -0.401 0.320 0.679 0.688 0.423 -0.780 0.077 
EMG1 0.919 0.931 0.969 -0.090 0.061 1.388 1.388 1.284 0.436 0.007 1.445 1.666 1.285 0.543 0.037 
ARHGEF1
0L 0.771 0.691 0.869 -0.370 0.061 0.725 0.660 0.710 -0.519 0.006 0.845 0.798 0.791 -0.302 0.010 
RPL11 0.823 0.913 0.905 -0.186 0.061 0.983 0.961 0.943 -0.056 0.082 0.998 1.006 1.004 0.004 0.338 
ACOX1 0.959 0.973 0.934 -0.067 0.062 1.018 1.061 0.975 0.025 0.555 1.085 1.051 0.946 0.037 0.604 
215 
 
GARS 1.249 1.088 1.248 0.254 0.062 0.790 0.870 1.053 -0.156 0.330 0.634 0.830 0.840 -0.393 0.098 
HMGB2 1.078 1.139 1.216 0.193 0.062 0.951 0.937 1.141 0.008 0.939 0.832 0.836 0.860 -0.247 0.004 
RPL7 0.849 0.922 0.926 -0.155 0.063 1.357 1.159 1.242 0.322 0.039 1.551 1.330 1.364 0.497 0.018 
RPL10A 0.837 0.932 0.895 -0.172 0.063 1.302 1.262 1.200 0.326 0.011 1.542 1.257 1.256 0.428 0.049 
RPL35A 0.927 0.973 0.930 -0.084 0.064 1.170 1.091 1.088 0.158 0.044 1.203 1.116 1.075 0.177 0.066 
CSTB 1.115 1.043 1.069 0.105 0.065 0.799 0.817 0.812 -0.305 0.001 0.645 0.721 0.712 -0.532 0.009 
RBMX;RB
MXL2;RB
MXL1 1.232 1.077 1.172 0.213 0.065 0.601 0.640 0.694 -0.635 0.009 0.480 0.509 0.559 -0.958 0.004 
HNRNPA2
B1 1.104 1.038 1.066 0.096 0.065 1.315 1.407 1.491 0.488 0.011 1.082 1.332 1.277 0.293 0.085 
PSMB6 1.127 1.189 1.065 0.171 0.065 0.930 1.093 1.012 0.014 0.857 0.821 0.927 0.922 -0.170 0.096 
TRMT6 1.131 1.044 1.117 0.133 0.065 1.211 1.359 1.171 0.316 0.040 0.987 0.990 0.939 -0.042 0.236 
RPL27A 0.899 0.881 0.957 -0.133 0.065 1.038 1.022 1.023 0.039 0.033 1.204 1.117 1.022 0.153 0.154 
216 
 
ALYREF 0.913 0.912 0.824 -0.181 0.066 0.444 0.254 0.472 -1.409 0.038 0.432 0.276 0.532 -1.326 0.042 
WDR11 0.857 0.885 0.748 -0.273 0.067 0.963 0.590 0.457 -0.648 0.177 1.163 0.753 0.609 -0.302 0.386 
NIPSNAP
3A;NIPSN
AP3B 1.212 1.755 1.582 0.583 0.067 1.560 1.231 1.957 0.637 0.081 1.264 0.668 1.159 -0.010 0.975 
ORF1 0.915 0.860 0.787 -0.231 0.068 0.836 0.855 0.815 -0.260 0.006 0.974 0.961 0.988 -0.038 0.083 
PHGDH 1.087 1.035 1.106 0.105 0.068 0.952 1.205 1.021 0.076 0.529 0.940 0.988 0.924 -0.074 0.125 
SKA2 1.390 1.124 1.250 0.322 0.068 1.000 1.166 0.863 0.003 0.984 0.727 0.875 0.618 -0.449 0.090 
PAPSS2 1.207 1.686 1.407 0.506 0.068 1.156 0.854 1.349 0.137 0.552 0.934 0.668 0.919 -0.268 0.232 
SURF2 0.750 0.650 0.858 -0.419 0.069 0.812 0.834 0.805 -0.292 0.003 1.014 1.212 1.104 0.147 0.188 
RPSA;RP
SAP58 0.943 0.930 0.870 -0.130 0.069 1.220 1.101 1.195 0.227 0.038 1.290 1.243 1.332 0.365 0.006 
SKIV2L 0.901 0.821 0.744 -0.287 0.070 1.290 1.195 1.397 0.369 0.030 1.396 1.491 1.646 0.592 0.013 
GDI2;GDI




TJP2 1.462 1.142 1.289 0.369 0.070 0.875 0.762 0.847 -0.275 0.045 0.511 0.750 0.606 -0.702 0.048 
PET112 1.362 1.107 1.285 0.318 0.070 0.820 0.874 1.041 -0.141 0.305 0.691 0.767 0.775 -0.428 0.015 
PRPF8 0.942 0.864 0.833 -0.187 0.071 0.804 0.782 0.676 -0.412 0.034 0.912 0.920 0.828 -0.176 0.069 
C11orf48 0.816 0.921 0.778 -0.258 0.071 0.902 0.939 0.875 -0.144 0.039 1.076 1.042 1.021 0.065 0.100 
OSBPL2 1.234 1.653 1.901 0.652 0.071 1.604 1.778 1.672 0.751 0.003 1.068 1.272 1.014 0.154 0.261 
PDIA5 0.840 0.944 0.880 -0.173 0.072 1.123 1.012 1.101 0.108 0.143 1.291 1.148 1.147 0.255 0.046 
EIF4G2 1.145 1.142 1.046 0.151 0.072 1.031 1.063 1.061 0.073 0.036 0.931 1.013 1.003 -0.026 0.565 
RBM8A 0.732 0.891 0.833 -0.294 0.072 0.370 0.777 0.974 -0.613 0.283 0.478 0.769 0.668 -0.675 0.080 
ZC3H15 1.483 1.218 1.179 0.363 0.072 0.798 0.668 0.737 -0.449 0.026 0.506 0.564 0.565 -0.878 0.004 
FUS 1.062 1.163 1.207 0.192 0.073 1.588 1.749 1.822 0.780 0.006 1.494 1.395 1.252 0.461 0.025 
RRM1 0.902 0.941 0.963 -0.097 0.073 1.055 1.057 1.008 0.056 0.130 1.059 1.131 1.129 0.145 0.043 
RPS26;RP




ACADVL 1.193 1.172 1.445 0.338 0.073 2.274 2.298 2.562 1.247 0.002 1.833 2.014 1.599 0.854 0.013 
SNAPIN 1.128 1.220 1.074 0.188 0.073 0.875 1.112 1.050 0.010 0.931 0.752 0.904 0.831 -0.275 0.070 
PRDX1 1.025 1.082 1.075 0.085 0.074 0.897 0.989 0.953 -0.081 0.188 0.853 0.875 0.794 -0.251 0.027 
TKT 0.875 0.958 0.902 -0.134 0.074 1.080 1.064 0.962 0.048 0.453 1.185 1.147 1.061 0.176 0.065 
EIF2D 0.867 0.690 0.635 -0.466 0.074 0.435 0.392 0.592 -1.102 0.025 0.579 0.559 0.874 -0.608 0.099 
UBR4 0.929 0.921 0.841 -0.159 0.074 0.707 0.799 0.604 -0.517 0.048 0.771 0.813 0.658 -0.426 0.043 
TP53RK 1.223 1.066 1.169 0.203 0.074 1.191 1.153 1.363 0.301 0.055 0.973 1.006 1.099 0.035 0.571 
PDIA4 1.102 1.031 1.094 0.105 0.075 0.954 0.976 1.088 0.006 0.927 0.809 0.970 0.984 -0.124 0.306 
S100A16 1.139 1.091 1.044 0.125 0.075 0.939 1.091 0.953 -0.011 0.884 0.893 0.884 0.789 -0.228 0.058 
CASK 1.157 1.076 1.060 0.133 0.076 0.873 0.767 0.767 -0.320 0.035 0.674 0.813 0.680 -0.475 0.032 
EIF3C;EIF
3CL 0.915 0.905 0.810 -0.192 0.076 0.873 0.871 0.694 -0.308 0.107 0.906 0.960 0.772 -0.192 0.178 
219 
 
APEX1 0.904 0.968 0.934 -0.097 0.076 0.862 0.831 0.840 -0.244 0.004 0.831 0.930 0.905 -0.172 0.073 
EIF4H 0.881 0.693 0.807 -0.340 0.078 0.327 0.312 0.457 -1.473 0.014 0.293 0.349 0.450 -1.479 0.014 
RPS2 0.949 0.907 0.856 -0.147 0.078 1.205 1.093 1.092 0.175 0.066 1.328 1.234 1.279 0.356 0.007 
PPIF 1.106 1.341 1.398 0.351 0.078 1.448 1.197 1.238 0.367 0.049 1.012 1.030 0.718 -0.139 0.498 
SCYL1 1.081 1.295 1.245 0.267 0.078 1.412 1.590 1.463 0.572 0.008 1.331 1.045 1.249 0.265 0.126 
PUS10 1.175 1.653 1.690 0.571 0.078 1.882 1.805 2.008 0.923 0.002 1.176 1.174 1.379 0.310 0.057 
ACOT13 1.128 1.222 1.070 0.187 0.078 0.935 1.117 0.964 0.003 0.971 0.792 0.840 0.836 -0.283 0.009 
SNRNP20
0 0.948 0.873 0.837 -0.177 0.079 1.304 1.121 1.108 0.232 0.092 1.501 1.281 1.340 0.455 0.022 
CUL1 0.901 0.912 0.799 -0.202 0.080 1.079 0.905 0.952 -0.035 0.687 0.985 1.125 1.001 0.050 0.498 
PSMA5 1.093 1.160 1.051 0.137 0.080 0.971 1.193 1.002 0.071 0.521 0.783 0.998 0.838 -0.203 0.191 
FASN 1.247 1.067 1.202 0.226 0.080 0.796 0.764 0.854 -0.315 0.022 0.675 0.643 0.744 -0.543 0.013 
GTF2I 1.193 1.055 1.133 0.170 0.080 1.361 1.205 1.764 0.511 0.088 1.232 1.158 1.207 0.261 0.010 
220 
 
NUDT16 1.119 1.045 1.161 0.147 0.081 0.837 0.878 1.047 -0.126 0.328 0.724 0.777 0.606 -0.518 0.040 
TSEN34 1.349 1.486 1.123 0.390 0.081 1.368 1.777 0.988 0.422 0.227 0.899 1.213 0.952 0.018 0.902 
TXNRD1 0.919 0.909 0.813 -0.186 0.081 0.694 0.697 0.680 -0.535 0.000 0.663 0.759 0.839 -0.414 0.052 
 
1.224 1.349 1.095 0.285 0.082 1.497 1.357 1.466 0.525 0.007 1.194 1.078 1.237 0.224 0.064 
H6PD 1.350 1.185 1.107 0.275 0.082 1.377 1.057 1.601 0.407 0.146 1.119 0.903 1.415 0.172 0.455 
RPS14 0.928 0.955 0.875 -0.122 0.083 1.025 1.030 1.017 0.034 0.025 1.048 1.048 1.026 0.057 0.029 
PSMG1 1.812 1.195 1.481 0.560 0.084 0.986 1.172 3.488 0.670 0.361 0.679 1.239 1.261 0.029 0.931 
PHAX 1.112 1.200 1.379 0.293 0.084 1.512 1.868 2.027 0.839 0.022 1.368 1.443 1.351 0.472 0.004 
DTYMK 1.274 1.083 1.335 0.294 0.084 0.919 1.010 0.870 -0.103 0.243 0.797 0.844 0.640 -0.405 0.079 
EIF3S3;EI
F3H 0.960 0.937 0.887 -0.108 0.085 0.846 0.904 0.889 -0.186 0.023 0.949 0.960 0.938 -0.075 0.015 
FAM120A 0.914 0.789 0.893 -0.212 0.085 1.015 0.856 0.878 -0.131 0.230 1.000 0.742 0.889 -0.201 0.251 
RBM3 1.072 1.031 1.029 0.062 0.086 0.857 0.829 0.948 -0.190 0.082 0.738 0.798 0.788 -0.369 0.009 
221 
 
BLVRB 1.009 1.032 1.029 0.033 0.086 0.945 0.907 1.009 -0.070 0.256 0.884 0.908 0.958 -0.127 0.066 
RPS17;RP
S17L 0.885 0.953 0.842 -0.165 0.086 1.021 1.014 0.979 0.006 0.773 1.070 1.051 1.110 0.107 0.045 
DECR2 0.761 0.894 0.890 -0.241 0.087 0.816 0.910 0.897 -0.195 0.058 0.878 0.996 0.706 -0.232 0.251 
P4HB 1.221 1.131 1.062 0.184 0.087 0.940 1.022 0.900 -0.070 0.324 0.777 0.911 0.830 -0.256 0.062 
RPL27 0.885 0.965 0.925 -0.113 0.087 1.228 1.095 1.168 0.217 0.045 1.230 1.175 1.181 0.257 0.007 
PGK1 0.710 0.781 0.910 -0.329 0.087 0.760 0.941 0.824 -0.255 0.105 0.975 1.115 0.896 -0.012 0.906 
GCN1L1 0.905 0.910 0.792 -0.206 0.087 0.433 0.466 0.341 -1.286 0.011 0.526 0.520 0.473 -0.984 0.002 
URGCP 1.112 1.454 1.485 0.421 0.088 2.108 2.376 2.428 1.202 0.003 1.718 1.456 1.544 0.650 0.011 
PPIH 1.279 1.133 1.089 0.219 0.088 0.982 0.764 0.641 -0.352 0.187 0.570 0.681 0.570 -0.725 0.014 
PC 1.183 1.223 1.055 0.203 0.088 1.335 1.356 1.465 0.469 0.008 1.055 1.008 0.996 0.027 0.394 
AP1G1 1.093 1.142 1.300 0.233 0.090 1.516 1.380 1.706 0.612 0.020 1.305 1.237 1.114 0.282 0.052 
CMC1 0.882 0.842 0.955 -0.165 0.090 0.674 0.647 0.763 -0.529 0.018 0.741 0.816 0.805 -0.346 0.015 
222 
 
WIBG 0.638 0.803 0.473 -0.681 0.091 0.397 0.446 0.180 -1.656 0.056 0.500 0.591 0.496 -0.924 0.008 
TSN 1.216 1.197 1.051 0.204 0.092 0.480 0.391 0.443 -1.196 0.005 0.343 0.318 0.364 -1.551 0.001 
DYNLT1 1.047 1.016 1.063 0.059 0.093 0.980 0.953 1.045 -0.012 0.792 0.897 0.968 0.945 -0.095 0.099 
EIF3F 0.950 0.965 0.901 -0.092 0.093 0.915 0.935 0.888 -0.132 0.026 0.953 0.954 0.985 -0.053 0.076 
RPS27L 0.905 0.848 0.731 -0.278 0.093 0.946 1.085 0.832 -0.075 0.565 0.875 1.013 1.205 0.031 0.835 
METTL1 1.380 1.731 1.173 0.496 0.093 2.108 2.229 1.604 0.971 0.022 1.317 1.312 1.288 0.384 0.001 
TUBG1;T
UBG2 0.978 0.961 0.929 -0.065 0.093 0.945 1.009 0.916 -0.065 0.254 1.012 0.937 0.884 -0.085 0.273 
CDK1 1.270 1.184 1.064 0.226 0.093 1.060 0.964 0.914 -0.033 0.654 0.883 0.972 0.908 -0.120 0.101 
H2AFZ;H2
AFV 1.229 1.092 1.382 0.297 0.094 0.961 0.897 1.317 0.061 0.754 0.653 0.782 0.689 -0.502 0.023 
RPL30 0.848 0.951 0.914 -0.147 0.094 1.131 1.110 1.124 0.166 0.002 1.136 1.079 1.094 0.141 0.024 
PATL1 0.967 0.874 0.906 -0.128 0.094 0.657 0.620 0.681 -0.617 0.004 0.659 0.646 0.707 -0.577 0.005 
223 
 
RPS20 0.940 0.958 0.880 -0.112 0.094 1.059 1.063 1.008 0.061 0.132 1.095 1.097 1.077 0.124 0.005 
LAP3 1.320 1.071 1.287 0.288 0.094 2.122 2.209 1.710 1.001 0.013 2.133 2.076 1.264 0.828 0.078 
RFC2 1.351 1.122 1.562 0.415 0.096 1.279 1.155 1.351 0.332 0.038 1.065 0.885 0.929 -0.064 0.508 
DUS2L 1.189 1.057 1.090 0.152 0.096 0.782 0.841 0.730 -0.353 0.027 0.615 0.857 0.686 -0.489 0.073 
PDCD5 0.719 0.915 0.687 -0.383 0.097 0.647 0.792 0.702 -0.492 0.028 0.903 0.902 0.876 -0.162 0.008 
EIF1AX;EI
F1AY 0.948 0.930 0.855 -0.136 0.097 0.723 0.782 0.793 -0.387 0.011 0.751 0.800 0.820 -0.341 0.012 
UBE2I 1.088 1.020 1.066 0.081 0.097 1.001 1.040 0.981 0.010 0.726 0.912 0.975 0.843 -0.138 0.150 
STAT1 0.952 0.984 0.937 -0.063 0.098 1.204 1.203 1.062 0.207 0.075 1.186 1.268 1.096 0.241 0.058 
FEN1 0.886 0.966 0.934 -0.107 0.098 0.721 0.828 0.763 -0.378 0.023 0.778 0.852 0.802 -0.304 0.016 
CSNK2B 1.177 1.040 1.125 0.153 0.099 0.663 0.825 0.892 -0.345 0.115 0.560 0.784 0.753 -0.532 0.074 
RPL37A 0.937 0.869 0.955 -0.121 0.099 1.058 1.124 1.393 0.242 0.182 1.128 1.176 1.783 0.414 0.189 
TACO1 1.093 1.468 1.447 0.405 0.100 1.185 1.450 1.439 0.435 0.045 0.999 0.988 0.951 -0.031 0.291 
224 
 
MARS 0.969 0.940 0.895 -0.098 0.100 0.775 0.758 0.928 -0.292 0.087 0.977 0.927 0.937 -0.079 0.078 
NARS2 0.949 0.801 0.793 -0.243 0.101 1.178 1.158 1.063 0.179 0.059 1.129 1.323 1.506 0.389 0.083 
TYW3 1.041 1.065 1.138 0.112 0.101 1.199 1.161 1.090 0.201 0.038 1.052 0.910 0.786 -0.137 0.377 
DUSP9 1.133 1.087 1.030 0.115 0.103 0.950 1.727 2.195 0.616 0.229 0.756 1.431 1.946 0.358 0.467 
ETFB 1.060 1.064 1.169 0.132 0.104 0.723 0.673 0.710 -0.511 0.004 0.570 0.650 0.547 -0.768 0.009 
GYG1 0.911 0.661 0.745 -0.385 0.104 0.626 0.485 0.551 -0.860 0.015 0.766 0.746 0.800 -0.376 0.006 
TBC1D23 0.774 0.905 0.910 -0.217 0.105 0.832 0.915 0.931 -0.165 0.083 0.949 1.009 0.965 -0.037 0.291 
SF3B5 1.021 1.107 1.096 0.103 0.107 1.347 1.470 1.310 0.458 0.012 1.204 1.197 1.204 0.265 0.000 
STX5 1.140 1.028 1.134 0.137 0.107 1.500 1.532 1.059 0.427 0.132 1.348 1.656 0.726 0.232 0.583 
HMMR 0.625 0.907 0.637 -0.490 0.107 0.372 0.268 0.272 -1.736 0.008 0.767 0.288 0.522 -1.039 0.127 
SRSF10;F
USIP1 0.775 0.511 0.780 -0.565 0.107 1.244 0.931 1.303 0.198 0.323 1.571 1.843 1.512 0.710 0.015 
YWHAZ 1.471 1.107 1.232 0.335 0.108 0.619 0.816 0.692 -0.506 0.049 0.461 0.640 0.471 -0.950 0.025 
225 
 
FAM115A 1.107 1.115 1.022 0.112 0.109 0.937 1.090 1.169 0.085 0.462 0.875 0.988 1.037 -0.052 0.548 
CTSC 1.268 1.223 1.049 0.234 0.109 0.872 1.050 0.845 -0.123 0.333 0.669 0.846 0.710 -0.439 0.050 
PAICS 0.854 0.964 0.908 -0.140 0.110 0.943 0.902 0.890 -0.134 0.033 1.097 0.987 0.949 0.013 0.852 
ALDOC 0.898 0.979 0.922 -0.101 0.110 0.689 0.710 0.678 -0.531 0.001 0.769 0.762 0.771 -0.383 0.000 
QARS 1.060 1.033 1.015 0.051 0.110 1.254 1.184 0.892 0.134 0.469 1.175 1.162 0.954 0.127 0.323 
VPS29 1.039 1.218 1.200 0.201 0.110 1.062 1.189 1.080 0.149 0.100 0.903 0.968 0.832 -0.153 0.135 
CTSB 0.959 0.938 0.869 -0.118 0.111 0.848 0.881 0.901 -0.191 0.017 0.848 0.820 1.052 -0.150 0.314 
ILK 1.109 1.119 1.022 0.114 0.111 0.880 0.846 0.765 -0.271 0.047 0.764 0.742 0.763 -0.403 0.001 
41889 1.319 1.062 1.192 0.246 0.112 1.392 1.340 1.308 0.429 0.004 1.039 1.195 1.123 0.159 0.112 
BLOC1S1 1.094 1.365 1.155 0.262 0.112 1.015 1.320 1.133 0.201 0.209 0.837 0.896 0.944 -0.166 0.081 
MAP1B 0.883 0.655 0.541 -0.559 0.113 0.327 0.334 0.204 -1.828 0.016 0.476 0.498 0.809 -0.794 0.083 
RPS21 0.930 0.963 0.867 -0.122 0.113 0.999 0.978 0.872 -0.077 0.333 1.000 0.989 0.989 -0.010 0.184 
RPLP1 0.819 0.817 0.962 -0.212 0.113 0.924 0.983 0.981 -0.056 0.196 1.029 1.094 0.912 0.012 0.887 
226 
 
PWP1 1.239 1.992 1.339 0.575 0.113 1.757 2.192 2.244 1.037 0.012 1.137 1.159 1.470 0.318 0.116 
HSPA9 1.379 1.162 1.094 0.270 0.114 1.155 0.986 1.040 0.081 0.351 0.914 0.959 0.893 -0.118 0.061 
ERP29 1.008 1.040 1.026 0.035 0.115 1.108 1.080 0.997 0.085 0.206 1.080 0.980 0.897 -0.025 0.778 
ZC3HAV1 0.856 0.919 0.963 -0.133 0.115 0.770 0.958 0.963 -0.164 0.264 0.961 1.110 0.853 -0.046 0.718 
EIF2S2 0.957 0.970 0.902 -0.086 0.115 0.847 0.702 0.717 -0.410 0.041 0.947 0.729 0.778 -0.299 0.119 
FUBP3 1.607 1.527 1.089 0.472 0.116 0.801 0.900 0.640 -0.372 0.124 0.479 0.624 0.540 -0.877 0.015 
CYFIP1 1.019 1.082 1.044 0.067 0.116 1.220 1.154 1.208 0.255 0.009 1.177 1.093 1.144 0.186 0.027 
MAP2K1 1.371 1.281 1.059 0.298 0.116 1.441 1.220 1.301 0.398 0.030 0.861 0.975 1.256 0.025 0.888 
DDX39A;
DDX39 1.340 1.125 1.097 0.242 0.116 1.511 1.455 1.278 0.497 0.021 1.237 1.186 0.961 0.165 0.279 
HSPA8 0.971 0.925 0.974 -0.064 0.117 0.884 0.839 0.831 -0.233 0.014 0.832 0.907 0.807 -0.238 0.042 
C14orf166 1.017 1.077 1.044 0.064 0.117 0.977 0.945 1.000 -0.038 0.249 0.999 0.901 0.904 -0.099 0.179 
CCT8 1.008 1.032 1.045 0.040 0.118 1.231 1.250 1.265 0.320 0.001 1.162 1.223 1.181 0.249 0.007 
227 
 
HSPE1 0.921 0.764 0.895 -0.222 0.118 0.930 1.079 1.168 0.076 0.514 1.054 1.322 1.288 0.281 0.112 
KIAA0664 1.035 1.190 1.118 0.154 0.118 0.482 0.938 0.993 -0.385 0.369 0.493 0.806 0.864 -0.514 0.181 
NMD3 0.717 0.636 0.922 -0.416 0.119 1.157 1.097 1.398 0.275 0.122 1.516 1.806 1.463 0.667 0.019 
CDC42BP
B 0.666 0.566 0.902 -0.519 0.119 0.821 0.334 0.715 -0.784 0.192 0.779 0.672 0.706 -0.479 0.017 
IDH2 1.166 1.244 1.683 0.429 0.119 1.248 1.135 1.258 0.278 0.028 1.059 1.061 0.740 -0.089 0.660 
MRPL11 1.043 1.050 1.137 0.105 0.120 0.752 0.865 0.870 -0.274 0.058 0.730 0.804 0.780 -0.376 0.012 
PPM1G 1.168 1.032 1.207 0.181 0.120 0.541 0.648 0.644 -0.716 0.014 0.440 0.678 0.535 -0.883 0.039 
MTTP 1.090 1.142 1.026 0.118 0.121 1.218 1.156 1.260 0.276 0.017 0.999 1.106 1.188 0.131 0.213 
CTU2 1.039 1.049 1.131 0.101 0.121 0.644 0.695 0.747 -0.527 0.013 0.547 0.616 0.614 -0.758 0.005 
IGF2BP1 1.137 1.170 1.026 0.150 0.121 1.035 1.031 1.106 0.079 0.136 0.811 0.861 0.930 -0.208 0.069 
SPATS2L 1.039 1.021 1.009 0.032 0.121 1.062 1.109 1.038 0.097 0.075 0.858 0.955 0.942 -0.125 0.125 
CSNK2A1;
hCG_2198




CCT2 1.019 1.086 1.118 0.102 0.124 1.191 1.251 1.313 0.323 0.015 1.177 1.208 1.242 0.273 0.007 
PLEC 1.356 1.078 1.153 0.251 0.125 1.776 1.330 1.001 0.414 0.225 1.256 1.126 0.925 0.129 0.423 
PIN4 0.905 0.859 0.697 -0.294 0.125 0.626 0.638 0.620 -0.671 0.000 0.750 0.853 0.920 -0.255 0.097 
NQO1 1.027 1.067 1.132 0.104 0.126 1.011 1.123 1.018 0.070 0.288 0.908 1.070 0.957 -0.036 0.661 
QKI 1.102 1.638 1.889 0.590 0.127 2.532 3.620 3.854 1.714 0.012 1.565 1.602 1.699 0.697 0.003 
BTF3 0.980 0.985 0.949 -0.042 0.128 0.956 1.038 1.032 0.011 0.796 0.981 0.962 0.943 -0.056 0.076 
COPB2 1.030 1.061 1.014 0.049 0.128 1.359 1.416 1.372 0.467 0.001 1.234 1.322 1.268 0.350 0.007 
CUL2 1.032 1.177 1.234 0.195 0.128 1.121 1.377 1.285 0.330 0.063 0.994 1.063 1.120 0.081 0.247 
SKIV2L2 0.913 0.985 0.939 -0.081 0.128 2.033 1.513 1.361 0.688 0.058 1.898 1.814 1.470 0.780 0.021 
NCAPG 0.811 0.971 0.835 -0.202 0.129 0.862 0.864 0.914 -0.185 0.021 1.006 0.729 0.969 -0.164 0.380 
SKP1 0.969 0.821 0.797 -0.219 0.129 0.579 0.624 0.678 -0.677 0.009 0.600 0.727 0.747 -0.540 0.032 
DHX29 0.972 0.877 0.830 -0.167 0.129 0.797 0.694 0.560 -0.564 0.062 0.828 0.825 0.654 -0.388 0.075 
229 
 
TRMT61A 1.181 1.080 1.407 0.281 0.129 1.028 1.261 1.516 0.325 0.182 0.808 1.258 1.032 0.023 0.914 
WDR1 1.013 1.035 1.067 0.054 0.130 1.265 1.266 1.230 0.326 0.002 1.170 1.233 1.063 0.206 0.081 
IGF2BP3 0.966 0.898 0.828 -0.159 0.131 1.043 0.839 0.825 -0.157 0.288 0.859 0.880 0.925 -0.172 0.032 
ELAC2 1.113 1.114 1.014 0.110 0.133 1.022 1.083 0.923 0.010 0.894 0.865 0.956 0.849 -0.170 0.086 
SFPQ 1.006 1.038 1.048 0.043 0.133 2.102 2.000 2.086 1.044 0.000 2.188 1.876 1.889 0.985 0.005 
SAR1A;S
AR1B 1.080 1.097 1.298 0.207 0.135 1.869 1.704 2.766 1.046 0.039 1.601 1.393 2.181 0.761 0.058 
SRSF6 1.295 1.109 1.069 0.206 0.135 2.340 2.122 2.275 1.166 0.001 1.805 2.242 1.929 0.988 0.009 
MARK3 0.954 0.824 0.923 -0.154 0.136 0.614 0.501 0.743 -0.710 0.050 0.632 0.676 0.838 -0.494 0.056 
EIF1B 0.846 0.973 0.808 -0.196 0.136 0.794 0.846 0.838 -0.277 0.010 0.775 0.773 0.901 -0.296 0.056 
RPF2;BX
DC1 0.846 0.868 0.620 -0.379 0.136 1.470 1.593 1.499 0.604 0.003 1.599 1.738 2.135 0.856 0.020 
GRN 1.031 1.211 1.272 0.222 0.137 0.699 0.853 0.794 -0.360 0.050 0.637 0.904 0.621 -0.495 0.105 
230 
 
TDRD7 0.603 0.633 0.941 -0.492 0.137 0.412 0.348 0.478 -1.289 0.010 0.582 0.561 0.562 -0.815 0.000 
CPOX 1.100 1.242 1.051 0.174 0.137 0.629 0.598 0.936 -0.503 0.133 0.626 0.452 0.967 -0.623 0.189 
PPID 0.761 0.952 0.864 -0.225 0.137 0.914 1.041 0.772 -0.148 0.357 1.151 1.260 0.858 0.105 0.595 
EDC3 0.989 0.913 0.920 -0.089 0.137 0.738 0.785 0.702 -0.433 0.011 0.693 0.837 0.699 -0.434 0.040 
CTPS 1.052 1.289 1.133 0.207 0.137 1.059 1.237 1.098 0.175 0.124 0.954 0.911 1.031 -0.053 0.416 
ARPC4;A
RPC4-
TTLL3 1.017 1.144 1.114 0.124 0.137 1.005 1.102 1.068 0.081 0.176 0.949 0.951 0.853 -0.126 0.138 
KDELC1 1.285 1.802 1.147 0.469 0.139 1.262 1.438 1.219 0.381 0.034 1.033 0.958 1.042 0.015 0.743 
DNAJC21 0.904 0.875 0.984 -0.121 0.139 1.114 0.833 1.084 0.003 0.983 1.147 0.831 1.112 0.028 0.868 
DHX57 0.668 0.945 0.615 -0.455 0.139 0.695 0.739 0.841 -0.403 0.038 0.991 0.833 1.518 0.108 0.715 
TUBB6 1.053 1.367 1.194 0.260 0.139 0.912 1.442 1.218 0.226 0.362 0.826 1.064 0.846 -0.143 0.346 
ACAA1 0.962 0.986 0.927 -0.062 0.140 0.775 0.749 0.675 -0.450 0.018 0.825 0.728 0.739 -0.391 0.021 
231 
 
SRPK2 0.963 0.766 0.720 -0.304 0.140 1.513 0.777 0.734 -0.071 0.852 1.631 0.966 0.923 0.180 0.564 
EIF3M 0.934 0.971 0.865 -0.116 0.141 0.884 0.986 0.902 -0.116 0.138 1.003 0.917 1.033 -0.025 0.677 
ZCCHC6 0.959 0.952 0.864 -0.114 0.141 0.714 1.310 0.880 -0.094 0.750 0.767 1.069 1.121 -0.040 0.837 
EIF2S3;EI
F2S3L 1.018 1.038 1.008 0.030 0.141 1.038 1.010 1.008 0.026 0.199 1.019 0.930 1.001 -0.025 0.594 
SEC24A 1.095 1.172 1.025 0.132 0.142 0.987 0.957 0.871 -0.094 0.225 1.015 0.845 0.828 -0.165 0.221 
PIN1 1.383 1.519 1.047 0.379 0.143 1.247 1.241 0.924 0.172 0.353 0.752 0.678 0.838 -0.409 0.044 
YWHAQ 1.722 1.080 1.391 0.457 0.143 0.820 0.874 0.587 -0.417 0.144 0.477 0.740 0.375 -0.973 0.077 
CCDC72 0.938 0.727 0.867 -0.252 0.146 0.439 0.355 0.437 -1.292 0.006 0.450 0.480 0.487 -1.083 0.001 
POLR2H 1.194 1.123 1.600 0.367 0.146 1.462 1.618 1.788 0.693 0.014 1.138 1.331 1.040 0.219 0.170 
HSP90B1 1.142 1.017 1.087 0.112 0.146 0.791 0.874 0.853 -0.254 0.028 0.661 0.857 0.752 -0.410 0.063 
SPATA5L
1 0.632 0.951 0.577 -0.509 0.148 1.090 0.968 0.925 -0.011 0.888 1.561 1.054 1.289 0.361 0.158 
232 
 
UPF2 0.730 0.872 0.939 -0.247 0.148 0.343 0.665 0.551 -0.998 0.072 0.498 0.755 0.534 -0.772 0.053 
RPL36A 1.084 1.079 1.295 0.199 0.148 1.641 1.547 1.396 0.608 0.012 1.450 1.462 1.150 0.429 0.063 
STXBP2 1.030 1.098 1.203 0.148 0.150 0.750 0.965 0.950 -0.180 0.266 0.625 0.727 0.818 -0.476 0.051 
TIAL1 0.977 0.827 0.891 -0.159 0.151 0.952 1.076 0.865 -0.058 0.588 0.937 1.167 0.987 0.036 0.739 
DEK 0.915 0.766 0.932 -0.204 0.152 1.691 1.993 1.769 0.859 0.007 2.002 2.347 1.827 1.034 0.010 
CKS1B 1.201 1.323 1.031 0.237 0.152 0.853 0.839 0.723 -0.317 0.053 0.709 0.601 0.665 -0.606 0.013 
SAMD4B 1.460 1.189 1.069 0.297 0.153 0.832 0.939 0.765 -0.248 0.101 0.562 0.823 0.774 -0.494 0.102 
PSMA4 1.014 1.203 1.168 0.170 0.155 0.894 1.165 1.177 0.098 0.529 0.888 0.866 1.097 -0.082 0.530 
ACSL4 0.956 0.960 0.997 -0.043 0.156 1.122 1.055 1.061 0.109 0.062 1.136 1.006 0.906 0.017 0.876 
PPIC 0.959 0.934 0.993 -0.057 0.156 0.942 0.990 1.097 0.011 0.881 0.858 1.183 0.967 -0.009 0.953 
QTRTD1 1.025 1.034 1.104 0.076 0.156 0.688 0.854 0.872 -0.321 0.099 0.622 0.761 0.810 -0.461 0.057 
NCBP2 0.976 0.936 0.865 -0.114 0.157 0.929 0.932 0.905 -0.117 0.012 0.986 0.938 0.861 -0.109 0.195 





B3P 1.108 1.015 1.053 0.081 0.157 0.730 0.951 0.760 -0.308 0.122 0.626 0.942 0.718 -0.413 0.140 
THUMPD3 1.070 1.008 1.099 0.081 0.157 0.718 1.042 1.115 -0.087 0.703 0.733 1.079 0.747 -0.253 0.299 
VCP 1.177 1.019 1.097 0.132 0.158 0.500 0.644 0.654 -0.749 0.027 0.406 0.652 0.570 -0.910 0.046 
COMMD6 1.178 1.754 1.167 0.423 0.161 1.002 0.792 1.126 -0.055 0.749 0.820 0.642 0.993 -0.312 0.228 
C22orf28 1.091 1.103 1.006 0.092 0.161 1.060 1.049 1.135 0.112 0.088 1.007 0.945 1.107 0.025 0.743 
NCBP1 0.949 0.902 0.766 -0.203 0.161 1.143 1.194 0.598 -0.097 0.791 1.177 1.330 0.699 0.044 0.892 
TPP1 0.974 0.986 0.933 -0.053 0.161 1.027 1.069 1.126 0.102 0.119 1.093 1.139 1.129 0.164 0.012 
STIP1 0.991 0.852 0.844 -0.163 0.162 0.586 0.766 0.589 -0.640 0.038 0.593 0.802 0.679 -0.544 0.049 
YWHAE 1.377 1.290 1.019 0.285 0.163 0.778 0.810 0.616 -0.456 0.066 0.529 0.568 0.590 -0.831 0.003 
QTRT1 1.038 1.030 1.125 0.088 0.163 0.702 0.900 0.961 -0.240 0.223 0.664 0.740 0.850 -0.420 0.055 
ENO1 1.618 1.573 1.025 0.461 0.163 1.152 1.515 0.990 0.263 0.281 0.868 0.875 0.859 -0.205 0.001 
234 
 
LYAR 1.045 1.152 1.355 0.236 0.164 2.011 2.098 1.990 1.023 0.001 2.090 1.569 1.527 0.775 0.033 
NDUFAB1 1.552 1.557 1.022 0.435 0.164 0.901 1.272 0.396 -0.379 0.527 0.571 0.684 0.538 -0.750 0.019 
IMPDH2 1.044 1.037 1.002 0.039 0.164 1.177 1.240 1.633 0.418 0.104 1.140 1.499 1.640 0.495 0.088 
PARVA 0.966 0.763 0.872 -0.213 0.165 0.742 0.685 0.764 -0.455 0.011 0.797 0.967 0.767 -0.253 0.134 
VAV2 0.816 0.987 0.870 -0.171 0.168 0.720 0.696 0.835 -0.419 0.035 0.876 0.815 0.898 -0.214 0.036 
ALDOA 0.997 0.947 0.958 -0.048 0.168 0.827 0.822 0.840 -0.270 0.001 0.842 0.866 0.837 -0.237 0.004 
SNRNP70 0.833 0.980 0.909 -0.143 0.169 1.702 1.845 1.991 0.881 0.005 1.897 1.927 2.106 0.982 0.002 
MANF 1.025 1.006 1.051 0.039 0.170 0.961 0.972 1.008 -0.029 0.298 0.851 0.936 0.885 -0.168 0.052 
KIAA1967 1.029 1.142 1.044 0.099 0.172 1.898 1.955 1.749 0.899 0.003 1.673 1.568 1.575 0.682 0.002 
PACSIN2 1.084 1.318 1.069 0.204 0.172 1.266 1.309 1.259 0.354 0.002 1.063 0.954 1.213 0.099 0.426 
SF3B14 0.912 0.942 0.754 -0.209 0.172 0.889 0.914 1.149 -0.033 0.804 0.921 1.004 1.768 0.237 0.506 
LARS 0.998 0.947 0.947 -0.053 0.172 1.150 1.077 1.172 0.179 0.040 1.111 1.159 1.216 0.215 0.029 
C12orf29 1.107 1.009 1.162 0.125 0.172 0.719 0.769 0.896 -0.337 0.070 0.717 0.842 0.709 -0.408 0.036 
235 
 
TSPAN10 0.942 0.879 0.984 -0.098 0.173 1.008 1.110 1.209 0.145 0.195 1.071 1.046 1.261 0.166 0.189 
NAA20 1.118 1.003 1.129 0.113 0.173 1.063 0.943 1.145 0.066 0.504 0.884 0.947 0.899 -0.137 0.045 
CPSF7 0.987 0.640 0.685 -0.403 0.174 0.772 0.972 1.042 -0.118 0.460 0.753 1.550 1.390 0.233 0.547 
TLN1 0.963 0.934 0.821 -0.146 0.174 0.378 0.351 0.323 -1.515 0.002 0.424 0.366 0.409 -1.326 0.002 
GPD1L 0.878 0.881 0.613 -0.359 0.175 1.224 1.001 0.903 0.048 0.743 1.239 1.115 1.466 0.339 0.099 
USP16 0.706 0.949 0.867 -0.261 0.175 0.821 0.799 0.947 -0.229 0.095 1.156 0.982 1.092 0.103 0.274 
RPLP2 0.868 0.951 0.974 -0.105 0.175 0.905 0.984 0.989 -0.061 0.281 0.911 0.954 0.934 -0.101 0.034 
CHMP2B 1.249 1.232 1.004 0.209 0.176 1.058 1.124 0.759 -0.050 0.804 0.949 0.935 0.714 -0.219 0.242 
DOCK7 1.035 1.446 1.211 0.286 0.176 1.235 1.390 1.426 0.431 0.021 1.131 0.999 1.056 0.085 0.241 
SNRPE 0.890 0.930 0.993 -0.094 0.177 1.996 1.966 1.813 0.943 0.002 1.916 1.957 1.657 0.878 0.007 
VPS13C 1.047 1.170 1.036 0.115 0.178 0.509 0.545 0.362 -1.106 0.026 0.536 0.509 0.380 -1.090 0.019 
DIS3L2 0.978 0.799 0.895 -0.172 0.178 0.998 1.101 0.991 0.041 0.495 1.018 1.317 1.105 0.189 0.227 
AMBP 0.690 0.705 0.998 -0.347 0.181 0.948 0.775 5.645 0.684 0.531 1.132 1.192 5.536 0.967 0.327 
236 
 
PLS1 1.025 1.157 1.053 0.107 0.182 1.082 0.897 0.963 -0.033 0.718 1.227 0.869 0.809 -0.071 0.740 
CNPY2 1.000 0.877 0.867 -0.132 0.184 0.532 0.646 0.508 -0.839 0.016 0.543 0.788 0.579 -0.671 0.056 
CEP78 0.916 0.722 0.929 -0.235 0.184 1.408 1.272 1.287 0.402 0.013 1.386 1.573 1.556 0.587 0.010 
GRIPAP1 0.877 0.932 0.991 -0.101 0.185 1.355 1.402 1.318 0.441 0.003 1.312 1.334 1.193 0.354 0.020 
KRT18 0.768 0.663 0.987 -0.330 0.187 0.578 0.810 0.358 -0.858 0.128 0.661 1.204 0.324 -0.651 0.356 
GTF2B 1.030 1.118 1.026 0.080 0.187 1.062 1.306 1.075 0.192 0.186 1.115 1.259 0.982 0.154 0.275 
PSMA7;P
SMA8 1.000 1.119 1.145 0.119 0.188 1.015 1.127 1.033 0.080 0.230 1.006 1.046 0.846 -0.056 0.614 
EIF6 0.985 0.873 0.943 -0.101 0.188 0.687 0.744 0.708 -0.489 0.005 0.742 0.815 0.683 -0.426 0.029 
PDLIM5 0.932 0.987 0.863 -0.111 0.188 0.971 0.867 0.900 -0.133 0.108 0.989 0.917 0.874 -0.112 0.163 
ANXA1 1.107 1.033 1.294 0.188 0.189 2.927 2.955 4.033 1.708 0.008 2.737 3.007 3.135 1.563 0.001 
RPL10 1.001 0.955 0.954 -0.044 0.190 0.960 0.937 0.935 -0.083 0.021 0.963 0.944 0.903 -0.095 0.074 




XO17 1.096 1.019 1.026 0.065 0.191 0.960 1.010 1.000 -0.015 0.576 0.861 0.931 0.989 -0.111 0.195 
ARHGEF2 1.320 1.242 0.999 0.237 0.191 2.458 1.426 1.053 0.628 0.221 1.479 1.251 0.973 0.282 0.249 
AK3 0.731 0.939 0.916 -0.223 0.192 1.131 1.566 1.113 0.326 0.179 1.378 1.385 1.366 0.461 0.000 
HADHA 1.260 1.054 1.707 0.393 0.192 1.393 1.456 1.308 0.469 0.009 1.135 1.189 0.859 0.071 0.676 
USP39 0.913 0.995 0.953 -0.070 0.193 1.345 1.295 1.468 0.451 0.014 1.690 1.317 1.448 0.563 0.033 
METAP1 1.112 1.042 1.013 0.077 0.194 1.173 1.020 0.911 0.042 0.731 0.972 0.811 1.049 -0.091 0.494 
YARS 0.978 0.991 0.938 -0.046 0.195 0.860 0.830 0.878 -0.225 0.011 0.858 0.860 0.921 -0.186 0.031 
PLOD3 1.006 1.102 1.050 0.073 0.195 1.268 1.296 1.028 0.252 0.142 1.151 1.117 0.983 0.112 0.248 
CUL3 1.147 1.009 1.070 0.103 0.195 0.846 0.658 0.818 -0.378 0.080 0.684 0.624 0.822 -0.503 0.050 
XPO5 1.251 1.043 1.065 0.158 0.196 0.756 0.612 0.446 -0.759 0.075 0.650 0.614 0.309 -1.006 0.100 
PYGL 0.996 1.143 1.154 0.131 0.196 0.885 0.971 0.961 -0.092 0.162 1.039 0.890 0.866 -0.107 0.322 
PSMB2 1.125 1.232 1.007 0.161 0.197 0.970 1.112 0.920 -0.004 0.965 0.821 0.917 0.749 -0.275 0.082 
238 
 
PSMD9 1.454 1.037 2.063 0.546 0.197 1.252 2.840 3.963 1.272 0.124 0.834 2.393 1.621 0.564 0.332 
CFL1;CFL
2 1.158 1.125 1.770 0.402 0.198 1.241 2.201 1.715 0.743 0.090 1.153 1.728 0.927 0.295 0.379 
EIF3G 0.934 0.961 0.795 -0.162 0.198 0.674 0.713 0.752 -0.490 0.009 0.792 0.689 0.800 -0.399 0.029 
NACA 1.058 1.011 1.138 0.094 0.198 1.275 1.216 1.198 0.298 0.008 1.266 1.157 1.192 0.268 0.020 
HIST1H1B 0.972 0.750 0.891 -0.208 0.199 1.363 1.467 1.527 0.537 0.008 1.434 1.825 1.801 0.745 0.022 
KPNA6;K
PNA5 1.106 0.998 1.149 0.114 0.200 0.538 0.617 0.560 -0.809 0.005 0.370 0.684 0.531 -0.966 0.064 
C6orf130 1.000 0.926 0.891 -0.092 0.200 1.085 0.914 0.939 -0.034 0.702 1.038 1.045 1.070 0.072 0.032 
CASP7 1.359 1.125 1.033 0.220 0.201 1.714 1.714 1.399 0.680 0.020 1.460 1.306 1.269 0.425 0.021 
FLII 1.199 1.191 0.992 0.168 0.202 2.210 0.774 0.953 0.235 0.663 1.661 0.685 1.234 0.163 0.707 
GOT2 1.080 1.320 1.050 0.194 0.203 1.168 1.496 1.150 0.335 0.112 0.904 1.059 0.961 -0.040 0.607 
SNRPC 0.935 0.936 1.003 -0.063 0.204 1.615 1.627 1.754 0.735 0.003 1.541 1.662 1.786 0.731 0.007 
239 
 
PPIA 1.124 1.046 1.011 0.083 0.205 0.973 1.048 0.948 -0.016 0.749 0.834 0.922 0.861 -0.198 0.044 
COPS2 1.047 1.002 1.024 0.034 0.205 0.451 1.133 1.021 -0.313 0.534 0.391 0.982 0.956 -0.482 0.385 
PTGES3 1.173 0.992 1.172 0.149 0.205 0.654 0.792 0.759 -0.449 0.033 0.553 0.762 0.620 -0.646 0.041 
RAB3IL1 0.776 0.736 1.013 -0.263 0.205 1.502 1.242 1.248 0.406 0.046 1.598 1.719 1.190 0.569 0.073 
CALM2;C
ALM1 1.180 1.000 1.105 0.127 0.207 0.850 0.872 0.872 -0.210 0.003 0.696 0.816 0.730 -0.423 0.025 
GSTCD 0.816 0.802 1.011 -0.198 0.207 0.255 0.320 0.628 -1.429 0.067 0.320 0.410 0.710 -1.141 0.078 
EPB41 0.943 0.982 0.846 -0.118 0.208 1.166 1.221 1.151 0.237 0.012 1.222 1.386 1.354 0.399 0.019 
NLE1 1.123 1.291 1.014 0.185 0.209 1.167 1.009 1.033 0.094 0.284 1.052 0.863 1.046 -0.025 0.818 
TRIM25 0.979 1.409 1.393 0.314 0.210 2.080 2.436 2.497 1.220 0.005 2.057 1.950 1.709 0.926 0.007 
ILF2 1.004 1.005 1.020 0.013 0.210 0.858 0.867 0.938 -0.173 0.051 0.843 0.871 0.889 -0.205 0.012 
UBE2N;U
BE2NL 0.917 0.982 0.798 -0.159 0.212 0.912 0.918 1.022 -0.075 0.292 0.929 0.906 1.100 -0.037 0.714 
240 
 
CTTN 0.972 0.921 0.780 -0.172 0.213 0.434 0.432 0.490 -1.148 0.003 0.448 0.512 0.559 -0.988 0.009 
SCYL2 0.766 0.878 0.992 -0.194 0.213 1.060 1.237 0.794 0.019 0.928 1.324 1.294 0.724 0.103 0.751 
ISG20 0.685 1.026 0.697 -0.343 0.213 0.778 1.017 0.645 -0.324 0.232 1.114 0.935 0.765 -0.109 0.558 
SHC1 1.020 1.083 1.249 0.155 0.215 2.349 1.937 2.431 1.156 0.008 1.962 1.691 1.838 0.869 0.005 
PURA 0.986 0.927 0.821 -0.139 0.215 1.012 0.983 0.947 -0.029 0.401 1.043 1.069 0.989 0.047 0.287 
DDX5 0.933 1.003 0.897 -0.084 0.217 1.144 1.168 1.132 0.199 0.004 1.288 1.259 1.388 0.390 0.012 
COASY 1.012 0.829 0.857 -0.158 0.217 0.736 1.001 0.904 -0.196 0.273 0.712 1.230 0.997 -0.065 0.804 
GTF3C5 1.258 0.995 1.149 0.175 0.218 1.348 1.143 1.468 0.392 0.066 1.076 1.096 1.342 0.221 0.163 
CTNNBL1 1.342 0.978 1.486 0.321 0.219 1.507 1.415 1.195 0.450 0.046 1.123 1.246 0.848 0.082 0.668 
OSBPL8 1.266 1.151 0.995 0.179 0.219 1.264 1.401 1.066 0.306 0.117 0.945 1.011 1.186 0.060 0.599 
AP2M1 1.054 1.016 1.174 0.110 0.221 1.537 1.375 1.419 0.528 0.008 1.378 1.281 1.163 0.346 0.040 
AK2 0.730 0.888 0.979 -0.219 0.221 0.919 1.147 1.081 0.063 0.577 1.138 1.366 1.111 0.263 0.108 
ATE1 1.303 0.999 1.651 0.368 0.221 0.582 0.595 0.854 -0.586 0.082 0.399 0.649 0.494 -0.988 0.040 
241 
 
KHSRP 0.948 0.978 0.997 -0.037 0.222 1.132 0.921 1.389 0.178 0.407 1.154 0.997 1.406 0.231 0.249 
G6PD 0.996 1.306 1.162 0.198 0.222 1.085 1.167 1.139 0.176 0.029 1.025 0.956 0.861 -0.082 0.380 
ANXA6 1.166 1.071 1.004 0.108 0.225 0.519 0.561 0.511 -0.917 0.002 0.394 0.496 0.509 -1.110 0.011 
ARF6 1.125 1.023 1.023 0.079 0.228 1.028 1.060 1.079 0.078 0.063 0.800 0.793 0.993 -0.223 0.171 
ARPC1B 0.988 1.116 1.150 0.114 0.229 1.362 1.211 1.141 0.304 0.056 1.281 1.223 1.182 0.296 0.013 
LUC7L2 1.031 0.756 0.749 -0.259 0.229 0.591 0.198 0.428 -1.438 0.091 0.545 0.251 0.668 -1.152 0.116 
HECTD1 0.742 1.001 0.865 -0.213 0.230 0.440 0.315 1.338 -0.810 0.328 0.597 0.321 1.136 -0.733 0.298 
ARPC5 1.013 1.264 1.090 0.160 0.230 1.051 1.144 1.067 0.120 0.087 0.915 0.907 0.862 -0.161 0.026 
WDR6 1.153 1.003 1.064 0.100 0.230 0.901 1.067 1.243 0.085 0.590 0.767 0.967 0.851 -0.221 0.149 
TDP2 1.021 1.358 1.110 0.207 0.232 0.929 1.065 1.016 0.003 0.966 0.877 0.852 0.888 -0.198 0.008 
CDC123 1.008 0.788 0.878 -0.173 0.233 1.099 0.879 0.801 -0.123 0.459 1.091 1.075 1.081 0.114 0.003 
ARHGAP5 0.885 0.965 0.988 -0.082 0.234 0.426 0.340 0.582 -1.190 0.034 0.478 0.453 0.550 -1.023 0.007 
HEXB 0.850 0.844 1.020 -0.150 0.235 0.717 0.997 0.794 -0.272 0.193 0.828 1.029 0.817 -0.174 0.248 
242 
 
C19orf66 0.586 0.733 1.025 -0.395 0.235 0.712 0.704 0.709 -0.497 0.000 1.239 0.989 0.800 -0.009 0.963 
SART3 1.107 1.083 0.990 0.083 0.236 1.058 0.977 0.391 -0.436 0.444 0.834 0.897 0.574 -0.407 0.179 
IPO7 0.931 0.907 1.009 -0.077 0.237 0.709 0.912 0.767 -0.337 0.088 0.730 1.053 0.720 -0.284 0.254 
ACO1;IRP
1 0.897 0.952 1.000 -0.076 0.238 1.222 1.214 1.310 0.320 0.012 1.208 1.363 1.177 0.318 0.039 
CCT3 1.019 1.013 1.091 0.057 0.238 1.261 1.310 1.314 0.373 0.003 1.191 1.280 1.178 0.282 0.017 
PRDX4 0.796 0.877 1.012 -0.167 0.239 1.675 2.646 2.068 1.065 0.031 2.150 2.956 1.973 1.216 0.021 
UBE2H 1.022 0.835 0.849 -0.155 0.240 0.494 0.642 0.428 -0.961 0.030 0.472 0.610 0.497 -0.934 0.014 
NUP205 1.052 1.013 1.181 0.110 0.241 1.064 1.130 1.032 0.104 0.113 0.949 0.978 0.851 -0.113 0.204 
TANC1 1.214 1.025 1.047 0.127 0.241 1.568 1.320 1.395 0.510 0.020 1.163 1.221 1.245 0.274 0.011 
RPL39;RP
L39P5 1.004 0.950 0.905 -0.071 0.243 1.020 0.945 0.845 -0.099 0.339 1.007 1.065 0.916 -0.009 0.904 
SNX4 1.138 1.341 0.998 0.202 0.243 1.063 0.978 0.834 -0.069 0.571 1.000 0.877 0.790 -0.177 0.214 
243 
 
COPA 0.938 0.963 1.004 -0.047 0.244 1.346 1.302 1.214 0.363 0.014 1.295 1.311 1.225 0.352 0.007 
CNN2 1.044 0.697 0.746 -0.293 0.245 0.674 0.535 0.380 -0.955 0.058 0.628 0.706 0.419 -0.810 0.071 
DENND4A 1.207 1.010 1.062 0.124 0.246 1.274 1.208 1.383 0.363 0.024 1.087 1.185 1.362 0.270 0.104 
LASP1 1.150 1.264 0.983 0.172 0.246 0.775 0.918 0.637 -0.381 0.130 0.645 0.668 0.641 -0.619 0.001 
CTNNB1 0.619 0.962 0.876 -0.313 0.247 0.299 0.249 0.733 -1.400 0.101 0.452 0.265 0.927 -1.058 0.181 
MIF 1.117 1.054 0.997 0.077 0.247 0.883 0.977 1.013 -0.065 0.388 0.731 0.924 0.882 -0.249 0.137 
TUBB3 0.907 0.896 1.015 -0.093 0.247 1.055 1.062 1.095 0.099 0.027 1.018 0.888 1.146 0.017 0.886 
DDX17 1.002 0.985 0.977 -0.017 0.248 1.444 1.382 1.314 0.463 0.007 1.402 1.326 1.279 0.416 0.008 
SRP68 0.974 0.820 0.960 -0.128 0.249 0.965 0.384 0.676 -0.666 0.228 0.864 0.472 0.744 -0.574 0.160 
RPL23 1.055 0.992 1.082 0.060 0.250 1.111 0.969 1.060 0.064 0.387 1.017 0.889 0.996 -0.051 0.488 
FN3KRP 2.445 1.310 1.048 0.582 0.252 2.786 1.238 0.855 0.521 0.410 1.153 0.925 0.852 -0.046 0.755 
TBCB;CK
AP1 1.020 1.000 1.008 0.013 0.255 0.798 0.884 0.904 -0.217 0.060 0.768 0.830 0.897 -0.269 0.053 
244 
 
COPZ1 1.093 0.986 1.151 0.104 0.256 0.830 1.009 0.849 -0.164 0.207 0.736 0.920 0.750 -0.326 0.087 
MYO6 0.930 0.971 1.001 -0.048 0.256 1.283 1.459 1.169 0.377 0.055 1.295 1.474 1.138 0.373 0.074 
REEP6 1.009 0.904 0.806 -0.147 0.256 0.822 0.785 0.708 -0.377 0.027 0.869 0.893 0.746 -0.263 0.083 
SH3GL1 0.945 1.501 1.376 0.322 0.256 0.829 1.021 1.237 0.022 0.909 0.881 0.678 0.660 -0.447 0.078 
YWHAG 0.984 1.189 1.457 0.257 0.257 0.818 0.955 0.765 -0.248 0.120 0.655 0.708 0.459 -0.744 0.061 
CAPNS1 0.917 1.001 0.793 -0.153 0.258 0.846 0.501 0.352 -0.915 0.130 1.063 0.539 0.374 -0.741 0.235 
CAB39 0.768 0.857 1.025 -0.189 0.259 1.068 0.953 1.001 0.009 0.870 1.391 1.076 0.942 0.165 0.422 
LGMN 1.238 1.210 3.609 0.811 0.259 0.915 0.881 4.481 0.618 0.508 0.787 0.794 1.153 -0.157 0.477 
LIN28B 0.975 0.872 0.982 -0.087 0.260 0.772 0.776 0.786 -0.362 0.000 0.719 0.783 0.751 -0.414 0.007 
DENR 0.874 0.933 1.010 -0.094 0.260 0.486 0.525 1.093 -0.614 0.241 0.553 0.621 0.870 -0.581 0.097 
BYSL 0.819 0.884 1.021 -0.145 0.260 0.775 0.757 1.225 -0.159 0.556 0.951 0.956 0.986 -0.053 0.083 
RPL34 0.914 1.016 0.910 -0.081 0.260 1.103 1.171 1.089 0.164 0.037 0.955 0.876 1.141 -0.022 0.863 
41891 0.985 1.083 1.112 0.082 0.261 0.932 1.432 1.262 0.251 0.305 0.898 1.198 1.199 0.122 0.470 
245 
 
LHPP 0.761 1.049 0.767 -0.236 0.262 0.940 0.873 1.004 -0.093 0.250 1.240 0.832 1.290 0.137 0.567 
LACTB 0.340 0.877 0.818 -0.679 0.263 1.420 1.138 0.856 0.156 0.539 4.299 1.343 0.882 0.782 0.371 
ELP4 0.676 0.958 0.926 -0.246 0.264 0.702 0.731 0.800 -0.428 0.016 0.911 0.853 0.761 -0.253 0.080 
MDH2 0.994 1.051 1.033 0.036 0.265 1.072 1.157 1.046 0.125 0.103 1.077 1.053 1.008 0.064 0.148 
PSMC3 0.770 1.027 0.861 -0.185 0.265 0.797 0.881 0.673 -0.361 0.087 0.934 0.859 0.679 -0.292 0.167 
HIBCH 0.975 1.161 1.329 0.197 0.268 1.281 1.042 1.040 0.158 0.254 1.294 1.135 0.783 0.067 0.786 
MRPL34 1.106 0.991 1.055 0.069 0.268 1.066 0.949 0.874 -0.059 0.549 0.867 1.033 0.849 -0.132 0.279 
MYH14 0.909 0.906 0.513 -0.414 0.270 0.834 0.942 0.887 -0.174 0.075 0.968 1.048 1.633 0.242 0.410 
GSR 1.084 1.161 0.986 0.103 0.270 0.941 1.280 0.894 0.035 0.847 0.875 1.081 0.944 -0.054 0.604 
PSMD2 1.025 1.019 1.165 0.095 0.271 1.290 1.248 1.114 0.281 0.048 1.216 1.368 0.958 0.224 0.277 
KPNA4 0.998 0.934 0.982 -0.043 0.272 0.553 0.693 0.740 -0.607 0.041 0.553 0.707 0.747 -0.592 0.048 
NOP10 0.693 0.903 0.989 -0.231 0.273 0.926 1.019 1.170 0.047 0.677 1.339 1.178 1.167 0.293 0.045 
RBM12 1.178 0.968 1.340 0.204 0.274 1.525 0.752 0.870 -0.001 0.997 1.505 0.806 0.619 -0.138 0.752 
246 
 
STAU2 0.959 0.872 0.540 -0.382 0.275 1.324 0.920 0.606 -0.146 0.698 1.203 0.903 1.134 0.100 0.509 
HSP90AA
1 1.104 0.988 1.061 0.070 0.275 0.704 0.849 0.857 -0.322 0.073 0.613 0.871 0.785 -0.418 0.109 
AIMP2 1.101 1.099 0.981 0.082 0.275 1.224 1.268 1.320 0.345 0.008 1.080 1.121 1.261 0.203 0.095 
PIP4K2A 1.072 1.316 1.012 0.171 0.276 0.938 0.790 0.759 -0.277 0.098 0.844 0.545 0.687 -0.554 0.093 
GOLGA4 0.993 1.033 1.056 0.038 0.276 1.069 1.124 0.859 0.015 0.911 1.140 1.115 0.907 0.069 0.579 
DRAP1 1.116 1.047 0.994 0.072 0.276 0.930 1.249 0.929 0.036 0.823 0.742 1.225 0.793 -0.158 0.559 
PEG10 1.068 0.730 0.743 -0.262 0.279 0.650 0.567 1.131 -0.420 0.301 0.828 0.870 1.346 -0.015 0.953 
FH 0.906 0.750 1.007 -0.182 0.281 0.810 1.084 0.880 -0.124 0.425 1.108 1.308 0.937 0.147 0.401 
LDHB 0.989 0.995 0.938 -0.039 0.285 0.909 1.043 0.949 -0.051 0.477 0.940 1.076 1.130 0.065 0.500 
GLUD1;G
LUD2 1.031 1.223 1.021 0.122 0.286 1.237 1.235 1.284 0.324 0.003 1.276 1.069 1.139 0.212 0.106 
PSMD7 0.977 1.150 1.096 0.100 0.287 1.087 1.041 1.212 0.152 0.145 1.105 1.034 0.842 -0.019 0.889 
247 
 
DNAJC2 0.786 0.853 1.041 -0.173 0.288 0.616 0.519 0.894 -0.602 0.121 0.742 0.633 0.601 -0.608 0.022 
CAP1 1.045 1.176 1.001 0.100 0.288 0.995 1.110 0.970 0.033 0.632 0.939 0.903 0.993 -0.083 0.173 
HNRNPA1
;HNRNPA
1L2 0.994 0.895 0.978 -0.067 0.288 1.474 1.708 1.637 0.681 0.008 1.348 1.898 1.497 0.646 0.047 
CTNND1 1.065 1.175 0.989 0.103 0.289 1.143 1.268 1.877 0.481 0.158 1.110 0.941 1.322 0.155 0.387 
ACTR1A;
ACTR1B 1.064 1.002 1.262 0.143 0.289 1.161 1.644 1.657 0.554 0.082 1.209 1.543 1.244 0.405 0.068 
DDX46 1.115 1.166 0.971 0.112 0.292 1.864 1.339 1.479 0.628 0.047 1.440 1.169 1.543 0.459 0.062 
MYL12B;
MYL12A;
MYL9 0.959 1.170 1.284 0.175 0.294 1.004 1.529 0.988 0.200 0.434 0.983 1.156 0.724 -0.094 0.681 
CCT4 1.006 1.019 1.103 0.059 0.294 1.243 1.245 1.268 0.324 0.001 1.238 1.235 1.165 0.278 0.011 
ASPH 0.990 1.057 1.037 0.039 0.294 1.197 1.178 1.284 0.285 0.017 1.276 1.100 1.169 0.238 0.061 
248 
 
PTBP3 0.982 1.118 1.070 0.077 0.295 1.256 1.313 1.528 0.445 0.035 1.366 1.182 1.353 0.376 0.031 
BTF3L4 0.892 0.751 1.024 -0.182 0.296 0.931 0.846 0.848 -0.194 0.050 0.945 0.890 0.820 -0.178 0.095 
NPLOC4 1.183 1.149 0.963 0.130 0.298 1.159 0.955 0.982 0.040 0.691 0.878 0.891 1.010 -0.113 0.220 
LSM3 1.175 1.023 1.015 0.096 0.299 0.604 0.631 0.719 -0.622 0.014 0.503 0.636 0.598 -0.795 0.016 
RPL29 1.021 0.829 0.920 -0.121 0.300 1.099 0.612 0.712 -0.354 0.296 0.951 0.838 0.776 -0.231 0.114 
ALDH18A
1 0.900 1.444 1.660 0.370 0.301 2.225 1.950 2.293 1.105 0.004 2.715 1.392 1.353 0.785 0.139 
DNAJC10 0.884 1.032 0.894 -0.098 0.305 1.317 1.188 1.223 0.312 0.020 1.315 1.270 1.169 0.322 0.023 
ATP6V1G
1 1.044 1.222 1.003 0.119 0.305 0.931 0.916 0.827 -0.168 0.088 0.792 0.765 0.743 -0.384 0.005 
PIR 1.006 1.350 1.065 0.177 0.306 1.067 1.179 1.093 0.153 0.072 1.040 0.875 0.976 -0.057 0.518 
EIF4A3 1.011 0.956 0.888 -0.073 0.307 1.237 1.163 1.021 0.185 0.152 1.129 1.225 1.193 0.241 0.020 
EIF2S1 1.047 1.055 0.986 0.041 0.310 1.013 0.974 0.968 -0.022 0.396 1.009 0.929 0.954 -0.054 0.266 
249 
 
TBC1D15 1.020 1.013 1.171 0.091 0.313 0.892 0.998 0.986 -0.062 0.348 0.829 0.930 0.867 -0.194 0.056 
CKB 0.958 1.234 1.141 0.144 0.313 0.697 0.866 0.746 -0.384 0.053 0.844 0.693 0.713 -0.421 0.042 
PRPF19 0.965 1.011 0.927 -0.048 0.315 1.175 1.151 1.192 0.230 0.004 1.223 1.048 1.208 0.210 0.099 
PRKAG1 1.019 0.886 0.943 -0.078 0.316 1.149 1.378 1.038 0.239 0.184 1.185 1.512 1.048 0.303 0.191 
PURB 0.931 0.984 0.646 -0.252 0.316 1.023 1.097 0.830 -0.034 0.804 1.124 1.058 1.282 0.203 0.132 
TRIP10 0.946 1.328 1.181 0.190 0.317 1.215 1.231 1.054 0.219 0.092 1.102 0.952 0.812 -0.077 0.605 
PITRM1 0.982 1.076 1.248 0.133 0.318 1.622 1.485 1.323 0.557 0.023 1.512 1.261 0.955 0.288 0.274 
ERI1 1.039 0.790 0.894 -0.149 0.321 0.788 0.831 0.896 -0.256 0.042 0.898 0.899 0.947 -0.129 0.036 
NAA25 0.985 0.917 0.999 -0.049 0.322 1.260 1.097 1.035 0.172 0.176 1.201 1.187 1.079 0.207 0.051 
KPNA1 1.111 0.964 1.177 0.111 0.323 0.475 0.539 0.631 -0.876 0.018 0.441 0.562 0.581 -0.932 0.018 
NAA50 0.986 0.958 1.004 -0.025 0.325 0.970 1.005 0.969 -0.027 0.259 0.955 0.971 0.859 -0.109 0.187 
GART 0.598 1.078 0.807 -0.314 0.329 0.731 0.729 0.601 -0.548 0.028 1.000 0.763 0.766 -0.259 0.183 
CTNNA1 1.036 1.033 0.989 0.027 0.331 0.925 0.918 0.654 -0.282 0.228 0.820 0.803 0.654 -0.405 0.060 
250 
 
PSMD12 1.038 1.005 1.279 0.139 0.332 1.110 1.224 1.408 0.312 0.089 1.143 1.214 1.089 0.198 0.049 
G3BP1 0.994 1.039 1.191 0.100 0.332 0.992 1.150 0.893 0.009 0.939 0.670 0.801 0.650 -0.507 0.033 
HNRNPA
B 0.969 0.852 1.003 -0.091 0.334 0.817 0.871 0.865 -0.234 0.015 0.887 1.038 0.962 -0.059 0.466 
HYPK 0.726 0.955 0.993 -0.179 0.334 0.878 1.032 1.094 -0.004 0.970 1.111 0.941 0.725 -0.133 0.534 
UBA6 0.766 0.778 1.088 -0.209 0.334 1.008 1.136 1.566 0.281 0.277 1.276 1.425 1.448 0.466 0.015 
PYGB 0.981 1.104 1.051 0.062 0.337 1.095 1.389 1.415 0.368 0.091 1.150 1.178 1.179 0.225 0.003 
SAMHD1 1.009 1.136 1.011 0.071 0.337 1.229 0.961 1.039 0.098 0.445 1.146 0.982 0.814 -0.042 0.796 
KIF2A 0.953 0.860 1.016 -0.088 0.337 0.811 0.547 0.954 -0.414 0.225 0.860 0.616 0.956 -0.327 0.229 
SNRPG 0.992 1.021 1.036 0.023 0.340 1.353 1.374 1.730 0.562 0.039 1.268 1.360 1.490 0.454 0.021 
TUBA1C 1.029 0.991 1.117 0.063 0.342 1.185 2.148 2.012 0.786 0.102 1.041 1.976 1.668 0.593 0.166 
HNRNPD 0.918 0.936 1.026 -0.061 0.346 0.963 1.031 0.948 -0.029 0.514 1.071 1.141 1.021 0.107 0.148 
FAM21A;F
AM21C;F




EHD1 0.978 1.320 1.069 0.155 0.349 1.086 1.164 1.119 0.167 0.029 0.918 0.939 1.040 -0.052 0.444 
LSM5 1.027 1.039 0.989 0.026 0.351 0.535 0.611 0.573 -0.805 0.005 0.457 0.562 0.566 -0.928 0.012 
CARS 1.072 0.978 1.059 0.050 0.352 1.021 0.953 1.030 0.001 0.983 0.925 0.982 0.938 -0.077 0.098 
PSMA6 0.984 1.051 1.040 0.035 0.352 0.934 1.129 0.924 -0.013 0.904 1.095 0.949 0.872 -0.048 0.669 
UBE2E2;U
BE2E3 1.012 1.276 1.020 0.132 0.352 1.251 1.265 1.238 0.324 0.001 1.291 0.907 1.122 0.131 0.470 
IQGAP1 1.051 1.017 0.993 0.028 0.353 0.495 0.215 0.440 -1.471 0.059 0.422 0.212 0.449 -1.546 0.047 
RAN 1.171 1.327 0.933 0.179 0.353 0.970 1.157 0.987 0.049 0.605 0.858 0.835 1.073 -0.127 0.384 
RPP14 1.040 0.917 0.804 -0.128 0.354 1.070 1.064 1.087 0.103 0.008 0.974 1.120 1.104 0.090 0.296 
API5 1.106 1.090 0.967 0.074 0.355 1.042 0.947 0.872 -0.072 0.434 0.924 0.935 0.949 -0.096 0.012 
DARS2 1.024 1.254 1.004 0.122 0.357 1.266 1.480 1.142 0.366 0.078 1.305 1.133 1.176 0.266 0.049 
DICER1 0.677 1.034 0.914 -0.215 0.358 0.471 0.872 0.814 -0.526 0.202 0.726 0.864 0.836 -0.310 0.057 
252 
 
DPP9 0.928 0.972 1.013 -0.043 0.361 0.743 1.091 0.832 -0.190 0.368 0.810 0.978 0.922 -0.151 0.202 
RPP40 0.778 0.703 1.117 -0.237 0.364 0.983 0.835 1.543 0.114 0.710 1.331 1.215 1.314 0.362 0.013 
RAB10 0.922 1.294 1.202 0.173 0.364 0.778 0.888 0.964 -0.195 0.162 0.873 0.726 0.709 -0.385 0.056 
IARS 1.010 0.979 0.955 -0.027 0.366 1.196 1.155 1.285 0.276 0.026 1.189 1.200 1.338 0.311 0.030 
MCM5 1.040 1.126 0.981 0.066 0.369 0.828 0.638 0.551 -0.594 0.074 0.742 0.597 0.546 -0.683 0.035 
POLR3A 1.064 1.131 0.970 0.074 0.369 0.877 1.497 1.076 0.166 0.537 0.816 1.290 1.158 0.095 0.682 
POP1 1.032 0.937 0.901 -0.066 0.372 0.802 0.858 0.672 -0.371 0.072 0.794 0.896 0.687 -0.345 0.090 
TMEM167
A 0.930 0.907 1.034 -0.066 0.372 0.702 0.754 0.604 -0.548 0.029 0.762 0.857 0.636 -0.423 0.078 
PRKDC 1.017 1.171 0.997 0.083 0.375 0.717 0.859 0.708 -0.399 0.047 0.817 0.734 0.761 -0.378 0.014 
MRPL33 0.766 0.911 1.051 -0.149 0.375 0.847 1.126 1.294 0.101 0.631 0.956 1.134 0.891 -0.016 0.888 
HSP90AB
2P 1.056 0.980 1.048 0.039 0.375 0.687 0.884 0.733 -0.389 0.070 0.606 0.937 0.687 -0.453 0.136 
253 
 
RBM28 0.973 0.505 0.974 -0.354 0.378 3.003 1.654 1.659 1.014 0.071 3.200 2.978 1.912 1.396 0.027 
NME1 0.903 1.055 0.823 -0.117 0.380 0.893 1.075 1.069 0.012 0.902 0.949 1.056 1.179 0.080 0.467 
SNRPA1 0.984 1.009 0.950 -0.028 0.382 1.650 1.714 1.484 0.690 0.008 1.668 1.715 1.394 0.665 0.019 
HADH 1.023 0.988 1.091 0.047 0.382 1.150 1.080 1.254 0.213 0.076 1.084 1.093 0.958 0.061 0.425 
SRP19 1.077 1.008 0.996 0.038 0.391 0.958 0.941 1.075 -0.015 0.823 0.860 0.887 0.966 -0.147 0.099 
PSMA1 1.039 1.234 0.978 0.109 0.392 0.880 0.853 1.368 0.013 0.959 1.006 0.799 1.296 0.020 0.931 
DKC1 0.863 1.088 0.745 -0.172 0.392 1.603 1.783 1.528 0.709 0.009 1.808 1.634 1.576 0.740 0.006 
RANGAP1 1.229 0.914 1.218 0.151 0.395 0.582 0.527 0.658 -0.770 0.014 0.387 0.584 0.506 -1.043 0.027 
C1QBP 0.771 1.961 1.672 0.446 0.396 1.550 1.796 1.630 0.727 0.007 1.667 0.999 0.816 0.147 0.679 
PNPT1 0.903 0.762 1.065 -0.150 0.396 1.180 1.323 1.234 0.315 0.022 1.253 2.039 1.134 0.512 0.189 
SNRPB2 0.962 0.970 1.016 -0.026 0.401 1.349 1.438 1.552 0.530 0.012 1.319 1.368 1.502 0.479 0.013 
SSB 0.991 0.903 1.005 -0.051 0.401 0.698 0.762 0.834 -0.391 0.034 0.736 0.881 0.826 -0.301 0.058 
PALLD 1.170 0.992 1.013 0.078 0.407 0.614 0.526 0.395 -0.989 0.034 0.645 0.523 0.385 -0.982 0.045 
254 
 
PTRHD1 0.978 1.016 0.838 -0.088 0.409 0.628 0.494 0.491 -0.904 0.016 0.456 0.420 0.517 -1.112 0.006 
RANBP2 0.788 1.059 0.919 -0.127 0.410 1.139 0.876 0.982 -0.010 0.936 1.894 0.983 0.948 0.273 0.488 
MCTS1 1.011 0.985 0.947 -0.028 0.412 0.755 0.749 0.859 -0.347 0.032 0.716 0.735 0.827 -0.400 0.025 
PUS7L 1.008 0.936 0.990 -0.033 0.415 0.858 0.988 0.818 -0.176 0.164 0.823 1.060 0.847 -0.145 0.334 
C14orf126 0.791 1.078 0.890 -0.133 0.415 0.782 0.821 0.801 -0.320 0.004 0.882 0.797 0.801 -0.276 0.029 
ARPC3 0.971 1.052 1.077 0.046 0.415 0.956 1.028 0.986 -0.015 0.677 0.867 0.982 0.819 -0.174 0.155 
GUSB 0.940 1.410 1.083 0.174 0.417 1.340 1.259 1.130 0.310 0.050 1.483 0.963 1.062 0.200 0.400 
DYNC1I2 0.989 1.008 0.763 -0.131 0.418 1.003 1.149 0.630 -0.154 0.617 0.911 1.095 0.791 -0.114 0.491 
LARP7 1.169 1.479 0.896 0.211 0.419 1.464 2.357 1.902 0.905 0.045 1.359 1.485 2.599 0.797 0.112 
CCNL1 1.116 0.933 1.215 0.113 0.420 1.317 1.329 1.188 0.352 0.021 1.088 1.632 0.984 0.268 0.352 
SNRPF 0.990 1.059 1.012 0.028 0.423 1.311 1.366 1.532 0.485 0.019 1.253 1.327 1.412 0.410 0.014 
DYNC1H1 1.085 1.024 0.981 0.041 0.427 1.095 1.023 0.976 0.043 0.470 1.089 1.000 1.018 0.050 0.317 
A2M 0.918 1.055 0.875 -0.079 0.429 0.494 0.622 0.898 -0.619 0.133 0.538 1.051 1.090 -0.233 0.555 
255 
 
TEX2 0.761 0.806 1.133 -0.175 0.431 1.584 1.522 2.324 0.829 0.051 2.162 1.914 1.734 0.948 0.009 
NAA10 0.930 1.061 0.802 -0.113 0.434 0.692 0.641 0.565 -0.665 0.016 0.733 0.623 0.622 -0.606 0.016 
ACTR2 0.984 1.135 1.014 0.060 0.437 1.111 1.227 1.113 0.200 0.051 1.119 1.037 1.033 0.087 0.147 
EIF2C2 1.010 0.913 0.991 -0.043 0.438 1.101 1.091 1.172 0.165 0.037 1.047 1.140 1.126 0.142 0.066 
ZCCHC3 1.085 0.987 1.013 0.039 0.441 1.341 1.376 2.106 0.653 0.090 1.328 1.319 1.835 0.561 0.070 
KIF11 1.053 0.961 1.124 0.062 0.443 0.623 0.491 0.447 -0.957 0.021 0.589 0.503 0.362 -1.074 0.035 
PTRH2 0.770 1.154 0.768 -0.184 0.446 0.464 0.491 0.583 -0.971 0.010 0.616 0.489 0.673 -0.767 0.030 
POP5 1.012 0.995 0.859 -0.070 0.447 1.093 0.990 1.149 0.105 0.238 1.066 1.003 1.174 0.109 0.240 
RSU1 0.893 1.099 0.739 -0.155 0.449 0.730 0.888 0.857 -0.282 0.083 0.893 0.819 0.923 -0.189 0.067 
ATP6V1A 1.000 1.216 0.991 0.090 0.449 1.170 1.030 0.850 0.012 0.937 1.040 0.857 1.046 -0.034 0.756 
SNRPN;S
NRPB 0.985 1.021 1.043 0.023 0.449 1.586 1.591 1.742 0.712 0.004 1.606 1.620 1.539 0.667 0.001 
TXLNG 0.958 1.133 1.055 0.065 0.449 1.004 1.346 1.180 0.225 0.207 1.078 1.342 1.206 0.268 0.099 
256 
 
LAMA5 0.979 1.036 0.710 -0.158 0.450 0.754 0.783 0.464 -0.623 0.125 0.783 0.883 0.619 -0.408 0.113 
FAM98A 0.997 1.163 0.995 0.069 0.453 1.063 1.036 0.941 0.017 0.779 1.159 0.903 0.957 0.001 0.991 
NME1-
NME2;NM
E2;NME1 1.011 0.981 0.982 -0.013 0.455 0.978 1.096 1.017 0.041 0.483 0.918 1.021 0.954 -0.054 0.354 
NCKAP1 0.965 1.031 0.907 -0.049 0.455 1.175 1.084 0.897 0.064 0.634 1.150 1.072 0.968 0.085 0.359 
SMARCA1 1.101 0.929 0.549 -0.278 0.455 1.087 0.932 0.531 -0.298 0.443 0.974 0.982 0.921 -0.061 0.170 
PCBP1 1.035 0.951 0.930 -0.043 0.457 1.008 1.017 1.067 0.043 0.234 0.950 1.030 0.975 -0.023 0.576 
KIF5B 0.964 1.081 1.057 0.046 0.457 1.197 1.188 1.108 0.219 0.025 1.159 1.128 1.061 0.157 0.053 
GTF2E1 1.130 1.092 0.942 0.072 0.465 1.162 1.039 0.939 0.060 0.569 0.904 0.891 0.945 -0.131 0.036 
OSBPL3 1.091 0.813 0.894 -0.112 0.466 1.065 0.905 1.158 0.053 0.661 1.014 1.166 1.080 0.117 0.182 
GNPNAT1 1.045 1.059 0.971 0.035 0.467 0.786 0.922 0.784 -0.271 0.073 0.904 0.861 0.844 -0.202 0.021 
LIMS1;LIM





H2AC 1.048 0.966 1.077 0.042 0.469 1.372 1.431 1.494 0.518 0.005 1.346 1.459 1.341 0.466 0.007 
SNRPD1 0.886 1.062 0.919 -0.070 0.471 1.406 1.551 2.512 0.818 0.087 1.468 1.356 3.025 0.863 0.144 
USP10 0.971 1.183 1.018 0.075 0.473 1.744 1.515 1.265 0.580 0.049 1.618 1.464 1.268 0.529 0.035 
NAMPT;R
P11-
92J19.4 1.047 0.934 1.428 0.160 0.474 1.010 1.174 1.248 0.189 0.173 0.960 1.297 0.677 -0.082 0.791 
AGFG1 0.998 0.985 1.217 0.086 0.476 1.450 1.089 1.166 0.294 0.143 1.292 1.102 0.852 0.093 0.648 
POLR2E 1.148 0.933 1.101 0.079 0.476 1.235 2.319 2.416 0.930 0.097 1.074 2.321 0.918 0.398 0.438 
PSMC5 1.177 2.009 0.826 0.322 0.479 1.596 1.955 0.226 -0.169 0.881 1.327 0.992 1.301 0.259 0.196 
LSM1 1.080 1.012 0.983 0.034 0.480 0.617 0.617 0.647 -0.674 0.001 0.548 0.603 0.564 -0.807 0.003 
CHORDC
1 1.002 0.799 1.020 -0.097 0.481 1.201 1.059 1.320 0.249 0.113 1.415 1.259 1.174 0.355 0.046 
258 
 
DNAJC1 1.189 1.271 0.882 0.138 0.484 2.203 1.700 1.570 0.852 0.029 1.793 1.164 1.492 0.546 0.094 
SRP9 1.026 1.057 0.977 0.028 0.487 1.048 0.966 0.923 -0.032 0.607 0.912 0.864 0.875 -0.179 0.016 
THYN1 1.046 0.961 0.864 -0.067 0.488 0.994 0.758 0.835 -0.222 0.191 0.993 0.889 0.906 -0.108 0.162 
MRPS34 0.991 0.666 1.053 -0.175 0.488 1.462 1.259 1.308 0.423 0.023 1.564 1.905 1.305 0.653 0.054 











1H2BL 0.955 0.912 1.041 -0.047 0.490 1.456 1.463 1.598 0.589 0.005 1.456 1.597 1.451 0.585 0.006 
259 
 
BANF1 0.747 0.816 1.166 -0.164 0.491 1.965 2.463 1.899 1.067 0.012 2.170 2.316 1.536 0.983 0.033 
TFCP2 1.090 0.999 0.991 0.037 0.492 1.125 1.055 1.049 0.105 0.084 0.965 1.006 0.939 -0.044 0.265 
RALY 0.992 0.906 1.019 -0.042 0.496 1.065 1.330 1.262 0.279 0.102 0.944 1.266 1.333 0.224 0.285 
TRIM23 0.952 1.110 1.058 0.054 0.497 1.072 1.215 0.963 0.109 0.379 1.117 1.151 0.883 0.061 0.666 
ATP6V1C
1 0.885 1.209 1.204 0.122 0.500 0.963 1.113 0.838 -0.051 0.706 1.102 0.823 0.865 -0.117 0.465 
ARCN1 1.008 1.214 0.969 0.082 0.500 0.776 0.831 0.761 -0.342 0.012 0.799 0.691 0.718 -0.445 0.019 
MAPRE2 1.022 0.952 1.274 0.103 0.500 0.990 1.014 0.941 -0.027 0.482 0.923 0.905 0.719 -0.245 0.168 
NIPSNAP
1 1.506 0.785 1.399 0.242 0.501 1.496 1.058 1.397 0.381 0.130 1.077 1.288 0.927 0.121 0.473 
PUM1 0.873 1.013 1.005 -0.057 0.502 0.904 1.079 1.346 0.131 0.514 1.113 1.121 1.133 0.166 0.002 
GPI 0.941 0.955 1.035 -0.035 0.503 1.149 1.229 1.152 0.234 0.018 1.144 1.272 1.077 0.216 0.092 
RPP30;RP
11-










B 0.941 0.868 1.066 -0.067 0.521 1.532 1.503 1.498 0.596 0.000 1.510 1.573 1.408 0.581 0.006 
C3orf26 1.042 0.907 1.486 0.163 0.522 1.532 2.087 1.556 0.771 0.034 1.417 1.931 0.990 0.480 0.227 
RPL35 0.962 1.051 0.879 -0.057 0.523 1.238 1.161 1.297 0.299 0.023 1.146 1.172 1.454 0.322 0.099 
SEC31A 0.976 1.078 0.716 -0.136 0.523 0.888 1.006 0.356 -0.551 0.364 0.778 0.857 0.732 -0.346 0.035 
URM1 0.994 0.825 1.038 -0.078 0.523 0.733 0.762 0.780 -0.400 0.004 0.602 0.753 0.717 -0.541 0.031 
EML4 0.966 1.059 1.044 0.032 0.524 1.009 0.930 0.940 -0.061 0.242 0.996 0.883 0.817 -0.159 0.197 
FLNC 1.023 1.000 0.869 -0.056 0.525 0.598 0.602 0.553 -0.776 0.003 0.614 0.591 0.669 -0.681 0.006 
FAM82B 0.923 1.135 1.108 0.072 0.525 0.721 0.946 1.213 -0.091 0.716 1.023 0.975 1.101 0.045 0.467 
261 
 
NONO 0.859 0.950 1.064 -0.068 0.526 1.772 1.712 1.748 0.802 0.000 1.970 1.710 1.543 0.793 0.016 
DAZAP1 0.826 0.813 1.150 -0.124 0.526 1.603 1.180 1.037 0.324 0.224 1.901 1.487 0.863 0.429 0.331 
CAND1 0.952 1.029 0.968 -0.026 0.528 0.900 0.915 0.905 -0.141 0.003 0.893 0.891 0.916 -0.152 0.007 
TMEM109 0.959 0.876 1.054 -0.058 0.529 0.668 0.672 0.716 -0.545 0.003 0.586 0.679 0.596 -0.692 0.009 
RPS6KA3 1.021 0.968 0.973 -0.019 0.530 1.039 0.986 0.735 -0.137 0.472 0.961 1.000 0.720 -0.177 0.358 
COPB1 1.032 0.948 0.964 -0.028 0.532 0.850 0.990 0.730 -0.234 0.206 0.859 0.962 0.762 -0.222 0.149 
XRN1 0.466 1.198 0.947 -0.307 0.532 0.518 1.469 0.803 -0.237 0.641 1.085 1.300 0.935 0.133 0.435 
RNH1 1.055 0.935 1.176 0.072 0.533 0.643 0.621 0.799 -0.550 0.040 0.668 0.719 0.674 -0.543 0.004 
LRPPRC 0.836 1.228 1.332 0.150 0.543 0.921 1.478 1.668 0.395 0.270 0.962 1.298 1.275 0.223 0.251 
CCDC124 0.719 1.041 1.028 -0.126 0.545 0.794 0.633 0.753 -0.468 0.042 1.024 0.989 0.651 -0.200 0.441 
RRP9 0.741 0.741 1.249 -0.181 0.546 1.277 1.297 1.324 0.378 0.002 1.695 1.517 1.410 0.620 0.015 
EIF5A;EIF
5AL1 1.031 1.035 0.976 0.020 0.549 0.953 0.966 0.970 -0.055 0.019 0.871 0.919 0.940 -0.137 0.052 
262 
 
ACTR3 0.905 1.012 1.009 -0.038 0.549 1.091 1.153 1.065 0.141 0.053 1.125 1.051 1.019 0.090 0.167 
RBM4B;R
BM4 0.976 1.078 0.764 -0.106 0.549 1.101 1.397 0.998 0.206 0.290 1.202 1.304 1.262 0.328 0.011 
MOB1B;M
OB1A 1.046 0.973 0.891 -0.047 0.553 0.882 0.855 1.140 -0.073 0.637 0.837 0.836 1.057 -0.145 0.325 
SMC2 0.949 0.946 1.042 -0.032 0.553 1.297 1.271 1.151 0.308 0.029 1.383 1.382 1.224 0.409 0.020 
CTSL2 1.004 0.862 1.028 -0.056 0.554 0.880 0.679 0.697 -0.421 0.071 0.680 0.643 0.622 -0.626 0.004 
ADAR 1.045 1.192 0.932 0.072 0.555 1.302 1.260 2.025 0.577 0.120 1.175 1.113 2.074 0.480 0.237 
GAPDH 1.008 0.995 0.980 -0.008 0.557 0.922 0.901 0.856 -0.165 0.035 0.912 0.890 0.871 -0.167 0.013 
TRNT1 1.024 0.921 0.992 -0.032 0.558 0.745 0.855 0.901 -0.267 0.082 0.738 0.861 0.864 -0.289 0.062 
SEC23A 0.979 0.997 1.007 -0.008 0.559 1.037 1.024 0.930 -0.006 0.912 0.922 0.955 0.908 -0.107 0.038 
PHYH 0.964 1.240 0.989 0.080 0.559 0.941 1.049 0.870 -0.073 0.448 0.883 1.345 0.869 0.015 0.948 
GNG12 1.043 0.907 1.343 0.115 0.560 0.858 0.861 0.611 -0.382 0.146 0.751 0.965 0.469 -0.518 0.231 
263 
 
FAM98B 1.019 1.104 0.964 0.039 0.561 0.965 1.004 0.915 -0.058 0.278 0.878 0.978 0.967 -0.089 0.212 
HEATR5A 1.207 0.785 0.787 -0.141 0.565 0.732 0.408 0.429 -0.988 0.067 0.467 0.479 0.632 -0.940 0.021 
LSM2 1.101 1.016 0.966 0.037 0.566 0.538 0.604 0.559 -0.821 0.004 0.487 0.580 0.554 -0.892 0.007 
CROCC 0.963 1.023 1.094 0.036 0.569 1.019 0.939 0.944 -0.049 0.328 0.938 0.915 0.852 -0.151 0.069 
USP9X 1.052 0.936 0.941 -0.037 0.574 0.731 0.706 0.642 -0.532 0.011 0.755 0.788 0.722 -0.407 0.008 
KATNAL2 0.976 1.054 0.876 -0.050 0.583 0.459 0.637 0.507 -0.919 0.022 0.431 0.593 0.572 -0.925 0.024 
SUB1 1.001 0.954 1.195 0.063 0.588 0.595 0.721 1.337 -0.268 0.527 0.620 0.713 0.921 -0.432 0.123 
FTSJ1 1.083 0.969 1.013 0.029 0.594 0.706 0.791 0.814 -0.379 0.026 0.654 0.749 0.805 -0.448 0.036 
HBS1L 0.986 1.116 0.983 0.038 0.594 1.080 1.065 0.993 0.064 0.233 1.064 0.984 0.996 0.020 0.622 
USMG5 0.745 1.250 1.682 0.216 0.594 0.942 1.047 0.874 -0.072 0.443 0.897 0.815 0.393 -0.600 0.252 
RPL14 0.989 1.031 0.926 -0.028 0.598 1.961 1.733 1.650 0.829 0.008 1.722 1.652 1.497 0.697 0.007 
SNX9 1.078 0.899 0.931 -0.049 0.602 1.118 1.025 1.018 0.074 0.230 1.150 1.086 1.100 0.153 0.026 




L10L 1.311 1.127 0.852 0.111 0.605 1.515 0.814 1.114 0.153 0.614 1.106 0.859 1.425 0.146 0.561 
GEMIN5 0.828 1.109 0.935 -0.073 0.610 0.737 0.977 0.814 -0.257 0.164 0.838 0.889 0.815 -0.240 0.023 
PPP2R1A 0.869 1.164 1.183 0.086 0.610 0.730 0.799 0.842 -0.342 0.029 0.842 0.737 0.707 -0.396 0.035 
NEMF 1.308 0.795 1.285 0.139 0.614 0.717 0.320 0.823 -0.802 0.200 0.511 0.474 0.622 -0.910 0.016 
NAA38 1.145 0.918 1.067 0.055 0.616 0.509 0.596 0.669 -0.767 0.022 0.457 0.652 0.564 -0.857 0.029 
PTBP1 0.998 1.050 0.987 0.016 0.617 0.925 1.108 1.213 0.105 0.457 0.975 1.040 1.093 0.049 0.410 
PKN2 0.985 0.920 1.039 -0.029 0.621 0.537 0.500 0.624 -0.859 0.012 0.486 0.553 0.563 -0.909 0.005 
RPRD1B 1.015 0.909 1.017 -0.031 0.625 1.868 1.707 2.001 0.891 0.005 1.821 1.655 1.919 0.844 0.005 
SHMT1 1.410 0.906 0.986 0.111 0.628 1.921 0.760 1.116 0.235 0.607 1.312 0.861 1.090 0.100 0.627 
TNIK;MIN
K1 1.062 1.016 0.800 -0.071 0.634 1.041 1.012 0.911 -0.020 0.764 1.133 1.164 1.051 0.157 0.071 
CRAT 1.209 0.974 0.961 0.059 0.634 1.217 1.091 0.920 0.096 0.498 0.979 1.154 0.946 0.032 0.753 
265 
 
ANKHD1 0.940 1.101 1.043 0.037 0.635 0.941 0.884 0.904 -0.137 0.036 0.864 0.931 0.984 -0.113 0.174 
PTPN11 0.946 1.012 1.150 0.046 0.636 0.852 0.699 1.153 -0.181 0.479 0.800 0.695 0.950 -0.307 0.143 
CCT7 1.009 0.990 1.012 0.005 0.640 1.246 1.280 1.258 0.335 0.001 1.230 1.272 1.205 0.305 0.006 
PRIM2 0.845 0.937 1.110 -0.063 0.640 1.028 1.224 1.178 0.189 0.132 1.195 1.232 1.054 0.211 0.092 
CRYZ 0.967 1.094 0.829 -0.063 0.641 1.055 1.091 0.933 0.034 0.666 1.133 1.121 1.072 0.148 0.025 
PSPC1 0.879 0.925 1.101 -0.053 0.643 1.535 1.715 1.889 0.771 0.012 1.966 1.767 1.723 0.861 0.005 
FAM136A 1.055 0.957 0.934 -0.029 0.648 0.974 0.985 1.143 0.044 0.617 0.954 0.953 1.046 -0.024 0.643 
EEF2 0.985 1.042 1.001 0.013 0.655 0.856 0.779 0.786 -0.310 0.019 0.956 0.861 0.801 -0.200 0.114 
GTPBP1 0.961 0.960 1.040 -0.020 0.656 0.637 0.531 1.583 -0.300 0.600 0.537 0.539 1.091 -0.554 0.245 
TRMT11 0.864 1.045 1.012 -0.043 0.661 0.784 0.801 0.919 -0.265 0.066 0.863 0.850 1.003 -0.147 0.193 
MRPL46 1.013 1.666 0.816 0.154 0.664 2.369 3.373 0.890 0.943 0.243 1.806 1.716 0.593 0.293 0.632 
EPRS 1.021 1.002 0.946 -0.016 0.673 1.043 0.989 1.024 0.027 0.357 0.954 0.913 1.054 -0.041 0.569 
SRP54 1.040 1.074 0.947 0.027 0.673 1.008 0.994 1.154 0.070 0.419 0.928 0.906 1.131 -0.024 0.832 
266 
 
PDIA3 0.928 1.064 0.954 -0.029 0.675 1.016 1.039 1.005 0.028 0.178 1.059 1.015 1.033 0.050 0.106 
C7orf50 1.178 0.732 0.949 -0.096 0.676 1.277 1.621 2.676 0.823 0.120 0.983 2.324 2.487 0.835 0.192 
ACP1 1.066 0.958 0.917 -0.031 0.678 0.816 0.777 0.828 -0.310 0.008 0.794 0.797 0.861 -0.292 0.016 
GFPT1 0.937 1.015 1.144 0.040 0.679 1.040 0.934 1.055 0.012 0.847 1.058 0.911 0.864 -0.088 0.421 
LRPAP1 0.989 1.108 0.967 0.028 0.688 0.494 0.555 0.479 -0.976 0.004 0.523 0.522 0.484 -0.973 0.001 
WASF1 1.149 1.316 0.809 0.097 0.690 0.941 1.808 1.324 0.391 0.288 0.864 1.311 1.249 0.167 0.472 
COPE 1.033 1.117 0.931 0.035 0.694 1.040 1.018 0.931 -0.007 0.898 0.974 0.904 0.844 -0.143 0.140 
TPR 1.280 0.919 0.976 0.066 0.696 0.654 0.812 0.772 -0.429 0.045 0.681 0.742 0.839 -0.412 0.042 
TXLNA 0.856 0.966 1.097 -0.046 0.697 0.823 0.727 1.644 -0.008 0.984 0.993 0.896 1.307 0.073 0.699 
ANXA2;A
NXA2P2 0.937 1.046 1.080 0.028 0.697 0.625 0.626 0.653 -0.656 0.001 0.698 0.595 0.597 -0.671 0.012 
MYH9 0.967 0.986 1.113 0.028 0.699 0.947 1.152 0.938 0.011 0.923 1.083 1.152 0.892 0.051 0.689 





C3B 0.912 1.123 0.885 -0.047 0.703 0.752 0.758 0.631 -0.492 0.030 0.678 0.602 0.656 -0.634 0.006 
GGH 1.007 0.969 1.060 0.016 0.705 0.856 0.884 0.852 -0.212 0.006 0.831 0.813 0.777 -0.309 0.008 
RBM42 0.721 0.929 1.223 -0.096 0.705 1.206 1.255 1.211 0.291 0.004 1.607 1.398 1.065 0.419 0.138 
PTK2 1.120 0.904 0.899 -0.046 0.705 1.693 1.448 0.956 0.409 0.238 1.406 1.369 1.217 0.409 0.024 
MLLT4 0.754 0.782 1.333 -0.116 0.705 0.128 0.461 0.776 -1.481 0.195 0.168 0.762 0.620 -1.219 0.216 
CCDC25 1.243 0.738 0.894 -0.096 0.706 0.863 0.747 0.554 -0.495 0.119 0.727 0.931 0.651 -0.394 0.123 
FTSJ3 0.908 1.157 0.841 -0.060 0.709 2.531 2.528 1.923 1.207 0.012 2.729 2.694 2.264 1.352 0.004 
RAB3GAP
2 0.889 0.918 1.540 0.110 0.711 2.339 2.592 2.143 1.233 0.004 2.372 2.726 1.311 1.028 0.087 
PDIA3 0.971 1.062 1.002 0.016 0.717 1.056 1.098 0.820 -0.025 0.868 1.037 1.059 0.802 -0.061 0.682 
EDC4 0.901 1.311 0.661 -0.118 0.719 0.327 0.903 0.131 -1.564 0.192 0.321 0.679 0.170 -1.583 0.111 
MAGED2 0.974 1.077 0.891 -0.033 0.721 0.946 0.960 0.811 -0.147 0.199 0.977 1.007 0.881 -0.069 0.360 
268 
 
CHMP5 0.962 1.042 1.028 0.014 0.725 0.952 0.967 0.980 -0.049 0.057 0.904 0.956 0.870 -0.137 0.073 
SNRPD2 0.983 0.981 1.021 -0.008 0.726 1.430 1.586 1.858 0.692 0.024 1.349 1.486 1.679 0.583 0.024 
SBDS 1.013 1.027 0.923 -0.019 0.727 1.074 1.012 0.981 0.031 0.505 1.106 0.970 0.913 -0.010 0.917 
TRPT1 1.106 1.083 0.901 0.037 0.733 1.206 1.079 0.673 -0.064 0.827 1.043 0.959 0.677 -0.188 0.428 
GIGYF2 1.091 0.954 0.898 -0.032 0.736 0.612 0.493 0.684 -0.758 0.032 0.569 0.576 0.638 -0.753 0.005 
ERC1;ER
C2 0.848 1.205 1.104 0.058 0.739 0.870 1.676 0.918 0.140 0.689 0.987 1.724 0.826 0.164 0.660 
PPIB 1.032 1.007 0.978 0.008 0.746 0.890 0.966 0.970 -0.087 0.166 0.831 0.918 0.903 -0.179 0.056 
BRIX1 0.722 1.019 1.162 -0.076 0.748 1.540 1.777 1.101 0.530 0.122 2.070 1.784 0.885 0.570 0.271 
SNUPN 0.908 0.836 1.177 -0.054 0.750 0.763 0.931 0.688 -0.344 0.115 0.934 0.947 0.887 -0.117 0.055 
HGD 0.981 1.054 0.990 0.012 0.753 0.985 1.015 0.948 -0.026 0.456 1.064 0.922 0.916 -0.051 0.544 
PICALM 0.999 1.089 0.958 0.020 0.753 1.106 1.093 0.925 0.054 0.587 1.045 1.030 1.078 0.071 0.067 
UBE2D3;




PSMD11 0.876 1.056 1.190 0.046 0.755 1.096 1.263 1.637 0.393 0.146 1.173 1.042 1.231 0.196 0.111 
UGDH 1.021 1.007 0.951 -0.011 0.760 0.991 1.106 0.973 0.031 0.646 0.910 1.103 1.032 0.017 0.851 
SF3B3 1.035 0.965 1.024 0.011 0.765 1.625 1.648 1.772 0.749 0.003 1.635 1.700 1.704 0.748 0.001 
SMC1A 0.676 1.303 1.449 0.117 0.766 0.808 0.896 1.042 -0.135 0.332 1.068 0.646 0.760 -0.311 0.283 
PUS3 0.954 1.213 0.751 -0.067 0.768 0.721 0.802 3.624 0.356 0.683 0.838 0.637 4.802 0.452 0.669 
SLK 0.930 0.979 1.181 0.035 0.770 1.636 1.477 1.715 0.684 0.009 1.544 1.444 1.343 0.528 0.012 
EPS8L2 0.904 1.132 1.044 0.032 0.771 0.718 1.031 1.774 0.131 0.762 0.993 0.914 1.316 0.085 0.646 
GSPT1 1.042 0.935 1.069 0.020 0.772 0.699 0.553 1.330 -0.320 0.487 0.688 0.686 1.025 -0.349 0.211 
ATP6V1B
2 0.901 1.014 1.046 -0.022 0.774 0.969 0.908 0.773 -0.186 0.195 0.957 0.797 0.706 -0.297 0.145 





B6B 0.969 1.021 1.029 0.009 0.777 1.000 1.211 1.121 0.147 0.209 1.022 1.170 0.860 0.013 0.926 
CDC5L 1.187 0.665 1.072 -0.080 0.784 0.849 0.948 1.865 0.195 0.638 0.879 1.893 1.672 0.492 0.288 
PUS7 1.008 0.889 1.064 -0.023 0.791 0.689 0.730 0.683 -0.513 0.003 0.709 0.908 0.759 -0.345 0.084 
NAA15 0.982 1.004 1.025 0.005 0.793 1.207 1.095 1.010 0.139 0.203 1.197 1.026 0.960 0.080 0.487 
HSPA6 1.059 0.901 1.004 -0.020 0.795 0.724 0.796 0.763 -0.395 0.010 0.639 0.850 0.813 -0.393 0.092 
BUD31 0.984 0.968 1.084 0.015 0.795 0.568 0.605 0.584 -0.772 0.001 0.561 0.597 0.501 -0.859 0.007 
DIS3 0.975 1.194 0.768 -0.054 0.797 1.238 0.905 0.884 -0.005 0.980 1.503 0.700 1.275 0.141 0.715 
SRSF1 1.248 0.910 0.780 -0.058 0.799 2.727 2.961 3.439 1.598 0.004 2.411 3.366 4.173 1.694 0.018 
GANAB 1.092 0.893 0.975 -0.024 0.800 0.440 0.529 0.490 -1.044 0.005 0.387 0.632 0.531 -0.981 0.042 
TUBB8;R
P11-
631M21.2 0.855 1.208 1.054 0.041 0.806 1.059 1.384 1.113 0.235 0.186 0.980 1.206 1.041 0.099 0.381 
271 
 
CAD 1.149 0.934 0.869 -0.033 0.808 0.759 0.683 0.696 -0.490 0.009 0.844 0.817 0.828 -0.269 0.003 
LLGL2 1.119 0.808 1.022 -0.038 0.811 0.743 0.504 0.575 -0.739 0.046 0.752 0.631 0.625 -0.585 0.021 
STAU1 0.999 1.057 0.966 0.010 0.817 0.807 1.623 1.241 0.234 0.510 0.959 1.407 1.056 0.170 0.413 
HARS2;H
ARSL 0.898 1.075 1.088 0.024 0.817 1.035 1.136 1.180 0.157 0.107 1.062 1.077 0.987 0.058 0.277 
TROVE2 1.066 0.868 1.029 -0.023 0.823 0.882 0.955 0.992 -0.087 0.226 0.830 1.072 0.924 -0.095 0.470 
SEC24B 0.775 1.091 1.088 -0.041 0.828 1.187 1.017 0.810 -0.011 0.952 1.551 1.118 0.746 0.124 0.724 
EHD4 0.962 0.992 1.073 0.011 0.830 1.946 0.927 2.000 0.617 0.231 2.189 0.959 1.838 0.649 0.215 
TRMT112 1.061 0.969 0.948 -0.012 0.831 0.630 0.750 0.785 -0.477 0.039 0.532 0.782 0.737 -0.568 0.081 
LMNA 1.271 1.191 0.745 0.058 0.833 1.870 1.738 1.113 0.618 0.118 1.419 1.377 1.338 0.462 0.003 
OGFR 0.895 1.349 0.912 0.046 0.834 1.456 1.780 1.781 0.735 0.017 1.643 1.548 1.799 0.731 0.007 
PARD6B 1.088 0.928 1.024 0.016 0.837 1.255 1.035 1.477 0.313 0.169 1.001 1.033 0.961 -0.003 0.922 
PPP6R3 1.195 0.765 0.999 -0.044 0.837 0.540 0.509 1.067 -0.590 0.228 0.697 0.667 0.884 -0.428 0.077 
272 
 
UXT 1.147 1.267 0.765 0.051 0.839 1.417 1.784 0.766 0.318 0.475 1.241 1.323 0.823 0.145 0.569 
TMEM62 1.280 0.907 0.778 -0.048 0.841 1.901 0.841 0.876 0.162 0.713 1.592 0.962 1.004 0.206 0.469 
PKP2 0.695 1.125 1.490 0.073 0.841 1.086 1.465 1.747 0.492 0.133 1.313 1.306 1.366 0.409 0.002 
SEPHS1 1.184 0.947 0.939 0.025 0.843 1.267 1.352 1.162 0.331 0.035 1.082 1.543 1.213 0.340 0.153 
HTATIP2 1.103 0.721 1.430 0.062 0.849 0.769 0.859 1.206 -0.109 0.633 0.688 0.725 0.745 -0.476 0.005 
OSTF1 1.028 0.988 0.975 -0.005 0.854 0.779 0.941 0.831 -0.238 0.097 0.667 0.842 0.724 -0.433 0.048 
CCNH 0.870 1.252 0.848 -0.038 0.854 0.948 1.657 0.905 0.169 0.608 1.119 1.264 1.177 0.245 0.041 
CSE1L 1.034 0.985 0.991 0.004 0.858 1.000 1.078 1.071 0.069 0.183 1.050 1.095 1.086 0.107 0.029 
KIF21A 1.118 0.909 0.948 -0.018 0.859 0.458 0.443 0.311 -1.329 0.018 0.536 0.516 0.361 -1.108 0.026 
COPS3 0.866 0.999 1.109 -0.020 0.865 0.573 0.742 0.674 -0.601 0.031 0.597 0.758 0.751 -0.519 0.044 
NXF1 1.020 1.057 0.946 0.009 0.866 0.589 0.986 1.138 -0.199 0.562 0.817 0.908 1.201 -0.055 0.770 
MYL6 0.862 1.022 1.197 0.026 0.869 0.773 1.039 0.832 -0.194 0.269 0.811 1.015 0.683 -0.277 0.236 
41884 0.852 0.861 1.267 -0.035 0.869 1.761 1.777 2.237 0.936 0.014 1.945 2.388 1.751 1.008 0.017 
273 
 
USP19 0.894 0.996 1.088 -0.015 0.871 1.656 1.955 1.389 0.723 0.037 1.488 1.995 1.357 0.670 0.057 
ARPC2 0.856 1.128 0.995 -0.019 0.883 1.153 1.160 1.014 0.146 0.146 1.181 1.054 1.071 0.138 0.114 
FUBP1 1.056 1.022 0.943 0.008 0.885 0.937 0.989 0.887 -0.094 0.174 0.852 0.960 0.894 -0.150 0.094 
LSM4 0.987 1.002 1.015 0.002 0.887 0.545 0.619 0.652 -0.728 0.011 0.514 0.634 0.662 -0.737 0.022 
ARL1 1.122 1.009 0.910 0.014 0.887 0.909 0.983 0.871 -0.121 0.143 0.771 1.024 1.009 -0.109 0.497 
MICU1 1.145 0.953 0.883 -0.018 0.888 1.405 0.855 0.940 0.058 0.816 1.200 0.918 1.078 0.083 0.537 
BAIAP2L1 0.905 1.392 0.725 -0.043 0.890 0.859 1.614 0.484 -0.192 0.739 0.847 1.144 0.620 -0.245 0.438 
UGP2 1.020 0.955 1.016 -0.005 0.891 0.622 0.646 0.615 -0.672 0.001 0.643 0.677 0.553 -0.685 0.016 
IKBKAP 1.076 0.862 1.045 -0.016 0.891 0.996 1.012 0.876 -0.060 0.458 0.771 1.650 0.896 0.063 0.868 
OXSR1 0.964 1.049 0.977 -0.006 0.892 0.830 0.711 0.818 -0.351 0.039 0.863 0.833 0.837 -0.245 0.004 
EIF3J 0.908 1.032 1.093 0.012 0.896 0.504 0.867 1.634 -0.162 0.772 0.753 0.894 1.205 -0.101 0.662 
VPS33B 0.987 1.188 0.813 -0.023 0.897 0.332 0.324 1.608 -0.845 0.385 0.328 0.266 1.984 -0.843 0.456 
CACYBP 0.997 1.143 0.904 0.014 0.899 0.877 0.812 0.961 -0.182 0.122 0.908 0.875 0.882 -0.171 0.009 
274 
 
IQGAP2 0.942 1.014 1.063 0.007 0.902 0.389 0.776 0.665 -0.772 0.125 0.563 0.791 0.643 -0.601 0.052 
DTD1 1.259 0.900 0.840 -0.024 0.908 1.243 1.117 0.685 -0.024 0.935 0.876 0.869 0.732 -0.281 0.079 
DNASE2 0.900 1.046 1.045 -0.008 0.923 0.810 0.920 0.916 -0.183 0.093 0.771 0.837 0.782 -0.329 0.012 
CCT5 0.978 0.973 1.043 -0.003 0.928 1.364 1.297 1.260 0.386 0.007 1.336 1.287 1.208 0.351 0.014 
THUMPD1 1.054 0.928 1.034 0.006 0.931 0.807 0.840 0.916 -0.229 0.052 0.729 0.839 0.924 -0.274 0.110 
TNS3;TNS
1;TENC1 0.738 1.230 1.057 -0.020 0.935 0.758 1.011 0.965 -0.145 0.376 1.001 0.928 0.928 -0.072 0.187 
RAB21 1.252 0.896 0.866 -0.014 0.941 1.691 1.176 1.106 0.379 0.185 1.361 1.243 1.244 0.358 0.015 
TBCE 0.879 1.081 1.069 0.008 0.943 0.926 1.088 0.992 -0.001 0.994 0.649 0.956 0.888 -0.287 0.236 
HSPA14 1.001 1.092 0.925 0.005 0.944 0.741 0.634 0.582 -0.624 0.026 0.686 0.695 0.644 -0.567 0.003 
CSNK1A1 1.038 1.077 0.906 0.006 0.946 1.438 1.298 1.043 0.320 0.144 1.296 1.326 1.121 0.315 0.053 
PA2G4 1.015 0.983 1.000 -0.001 0.950 1.176 1.025 1.133 0.150 0.127 1.152 1.004 1.114 0.122 0.178 




RS2 0.988 1.046 0.964 -0.002 0.953 1.184 1.364 1.362 0.379 0.030 1.187 1.273 1.214 0.292 0.010 
GTF2F1 1.140 0.674 1.356 0.020 0.954 0.735 0.627 0.977 -0.384 0.176 0.598 0.672 0.887 -0.496 0.098 
SPATS2 0.930 1.051 1.018 -0.003 0.964 1.202 1.134 1.023 0.160 0.144 1.148 1.025 0.930 0.043 0.670 
OVCA2 1.216 0.926 0.875 -0.007 0.965 0.959 0.877 0.936 -0.115 0.095 0.705 0.845 0.944 -0.277 0.153 
FGA 1.212 0.832 0.976 -0.008 0.965 1.062 1.183 1.001 0.110 0.259 1.004 1.060 0.892 -0.026 0.761 
ZNFX1 1.161 0.980 0.889 0.005 0.966 0.500 0.586 0.572 -0.859 0.007 0.525 0.571 0.531 -0.884 0.002 
CYCS 0.960 1.041 0.997 -0.002 0.966 0.939 0.951 0.959 -0.075 0.014 0.908 0.818 0.919 -0.184 0.075 
NRD1 1.073 0.802 1.147 -0.007 0.970 0.371 0.487 0.522 -1.135 0.017 0.323 0.612 0.482 -1.130 0.052 
WASL 0.985 1.074 0.949 0.002 0.971 0.841 0.955 0.836 -0.192 0.092 0.826 0.938 0.859 -0.196 0.069 
RAB8B;R
AB13 1.105 0.915 0.982 -0.003 0.971 0.584 0.638 0.727 -0.628 0.021 0.577 0.664 0.769 -0.587 0.039 




1 1.056 0.935 1.009 -0.002 0.972 1.080 1.103 1.081 0.122 0.006 1.109 1.054 1.091 0.117 0.033 
MPG 1.145 0.818 1.079 0.005 0.977 1.573 1.560 1.933 0.749 0.018 1.358 1.769 1.697 0.676 0.029 
ILKAP 1.216 0.936 0.871 -0.005 0.978 2.703 1.999 1.976 1.139 0.016 1.611 1.758 2.021 0.839 0.013 
CSK 0.729 0.986 1.373 -0.006 0.983 1.068 0.956 1.383 0.166 0.404 1.220 0.887 1.005 0.040 0.791 
OPA1 0.920 1.132 0.956 -0.002 0.985 0.996 1.126 1.011 0.060 0.393 0.984 0.850 0.924 -0.124 0.181 
HK1 1.125 0.858 1.041 0.002 0.985 1.465 0.840 0.808 -0.003 0.992 1.120 1.024 0.881 0.005 0.966 
SMG8 1.176 1.110 0.771 0.003 0.988 2.377 2.297 0.852 0.739 0.267 1.933 2.687 1.150 0.859 0.137 
SEC24D 0.912 0.989 1.111 0.001 0.989 1.070 1.006 1.145 0.101 0.202 1.105 1.047 1.016 0.077 0.160 
DECR1 1.109 1.159 0.773 -0.003 0.989 1.204 1.106 1.114 0.190 0.040 1.158 1.137 1.366 0.282 0.078 
NTPCR;C
1orf57 0.987 1.001 1.013 0.000 0.992 0.797 0.808 0.849 -0.290 0.009 0.821 0.777 0.738 -0.362 0.015 
TOMM34 1.401 0.973 0.733 0.000 1.000 1.990 1.615 1.231 0.662 0.081 1.224 1.626 1.205 0.420 0.096 
 
